Document:

First Amendment to Executive Agreement

 EXHIBIT 10.1 
 First Amendment to Executive Agreement 
 The Brink’s Company (the “Company”), Brink’s,
Incorporated (“Brink’s”) and Michael T. Dan (the “Executive”), agree to extend the term of the Executive Agreement dated as of May 4, 1998, among the Company, Brink’s and the Executive (the “Agreement”)
and to amend the heading of such Agreement and the provisions of Sections 12 and 13(b) of the Agreement as follows: 
  

	 	1.	The heading of the Agreement is hereby amended by replacing the name “Pittston” with the name “Brink’s”. 

  

	 	2.	Section 12 of the Agreement is hereby amended by replacing the name and address of the Company with the following: 

 The Brink’s Company 
 1801 Bayberry Court, Suite 400 
 P.O. Box 18100 
 Richmond, VA 23226 
 Attention of Corporate Secretary 
  

	 	3.	Section 13(b) is hereby amended by replacing the phrase “on the tenth anniversary of the date of this Agreement” with the phrase “on April 23, 2010”
and by replacing the phrase “to such tenth anniversary date” with the phrase “to such date”. 

 The parties
expressly agree that the none of the rights or obligations of the Company, Brink’s or the Executive under an Employment Agreement among such parties, dated as of May 4, 1998, as thereafter and hereafter amended (the “Employment
Agreement”), shall be amended or otherwise modified in any way by the execution or implementation of this First Amendment to the Agreement, and that all such rights and obligations shall remain in full force and effect in accordance with the
terms of the Employment Agreement. 
 *            *            *            * 

 IN WITNESS WHEREOF, the parties have caused this
Amendment to be executed and delivered as of the 28th day of March, 2007. 
  

			
	THE BRINK’S COMPANY,
		
	 by
	 	 /s/ Frank T. Lennon

		 	Frank T. Lennon
		 	Vice President and Chief Administrative Officer
	
	BRINK’S, INCORPORATED,
		
	 by
	 	 /s/ Frank T. Lennon

		 	Frank T. Lennon
		 	Vice President
		
		 	 /s/ Michael T. Dan

		 	Michael T. Dan

  

 2Form of First Amendment to Executive Agreement

 EXHIBIT 10.2 
 First Amendment to Executive Agreement 
 The Brink’s Company (the “Company”) and
                                     (the
“Executive”), agree to extend the term of the Executive Agreement dated as of                     
        , between the Company and the Executive (the “Agreement”) and to amend the heading of such Agreement and the provisions of Sections 2, 12, and 13(b) of the Agreement as follows:

  

	 	1.	The heading of the Agreement is hereby amended by replacing the name “Pittston” with the name “Brink’s”. 

  

	 	2.	Section 2 of the Agreement is hereby amended and restated as follows: 

 Employment Period. The Company hereby agrees to continue the Executive in its employ, and the Executive hereby agrees to remain in the employ of the Company subject to the terms and conditions of this
Agreement, for the period commencing on the Operative Date and ending on the third anniversary of such date (the “Employment Period”); provided, however, that, effective after the first anniversary of the Operative Date, the Executive
shall have the right to terminate his employment for any reason, or for no reason at all, whereupon the Employment Period shall terminate effective as of the date of such termination of employment; and, provided further, that, notwithstanding the
foregoing, the Executive’s right to terminate employment for Good Reason pursuant to Section 4 hereunder shall apply at any time during the Employment Period. 
  

	 	3.	Section 12 of the Agreement is hereby amended by replacing the name and address of the Company with the following: 

 The Brink’s Company 
 1801 Bayberry Court, Suite 400 
 P.O. Box 18100 
 Richmond, VA 23226 
 Attention of Corporate Secretary 
  

	 	4.	Section 13(b) is hereby amended by replacing the phrase “on the tenth anniversary of the date of this Agreement” with the phrase “on April 23, 2010”
and by replacing the phrase “to such tenth anniversary date” with the phrase “to such date”. 

 The parties
expressly agree that the none of the rights or obligations of the Company or the Executive under a Severance Agreement between such parties, dated as of
                             , as thereafter and hereafter amended (the “Severance
Agreement”), shall be amended or otherwise modified in any way by the execution or implementation of this First Amendment to the Agreement, and that all such rights and obligations shall remain in full force and effect in accordance with the
terms of the Severance Agreement. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed and delivered as of the ____
day of March, 2007. 
  

			
	THE BRINK’S COMPANY,
		
	by	 	  

		
		 	  

		 	(Executive)

  

 2Material Contract: Share Purchase Agreement and Appendices Dated 12 March 2007

 Exhibit 4 (a) (ii) 
  
 Execution Copy 
  
 Share Purchase Agreement 
  
 dated as of March 12, 2007 
  
 by and between 
  

	1.	Hyos Invest Holding AG, Weinplatz 10, 8022 Zurich, Switzerland (Seller 1) 

  

	2.	Dr. Ulrich Sigg, * Switzerland (Seller 2) 

  

	3.	Dr. Robert Riedweg, * Switzerland (Seller 3) 

  

	4.	Active Investor AG, Zugerstrasse 76B, 6340 Baar, Switzerland (Seller 4) 

  
 (hereinafter each a Seller, and, collectively, Sellers) 
  
 and 
  
 Smith & Nephew International B.V., Kruisweg 637, 2132 NB Hoofddorp, The Netherlands 
  
 (hereinafter Buyer) 
  
 and 
  
 Smith & Nephew plc, 15 Adam Street, London
WC2N 6LA, U.K. 
  
 (hereinafter Guarantor) 
  
 regarding 
  
 Plus Orthopedics Holding AG 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Contents 
  

							
	 1.
	  	Definitions	  	5
			
	 2.
	  	Sale and Purchase of Shares	  	5
	 	  	2.1	  	Object of Sale and Repayment of Shareholder Loans	  	5
	 	  	2.2	  	Consideration	  	5
	 	  	 	  	 2.2.1     Calculation of Purchase Price for the Shares
	  	5
	 	  	 	  	 2.2.2     Set-off Rights
	  	6
	 	  	2.3	  	Closing Accounts	  	6
	 	  	2.4	  	Net Working Capital Adjustment and Net Debt Adjustment	  	6
	 	  	 	  	 2.4.1     Net Working Capital Adjustment
	  	6
	 	  	 	  	 2.4.2     Net Debt Adjustment
	  	6
	 	  	 	  	 2.4.3     Payment of Net Working Capital Adjustment and Net Debt Adjustment
	  	6
	 	  	2.5	  	Escrow	  	7
			
	 3.
	  	Actions Prior to Closing	  	8
	 	  	3.1	  	General	  	8
	 	  	3.2	  	Filings and Submissions	  	8
	 	  	3.3	  	Third Party Consents	  	8
	 	  	3.4	  	Escrow of Data Room Documentation	  	8
	 	  	3.5	  	Closing Memorandum	  	8
	 	  	3.6	  	Estimated Net Working Capital | Estimated Net Debt	  	8
	 	  	3.7	  	Shareholder Loans	  	9
			
	 4.
	  	Closing	  	9
	 	  	4.1	  	Date and Place	  	9
	 	  	4.2	  	Conditions Precedent to Closing	  	9
	 	  	 	  	 4.2.1     Conditions to Obligations of Sellers and Buyer
	  	9
	 	  	 	  	 4.2.2     Conditions to Obligations of Buyer
	  	9
	 	  	 	  	 4.2.3     Condition to Obligations of Sellers
	  	10
	 	  	 	  	 4.2.4     Waiver of Nonfulfilled Conditions
	  	10
	 	  	 	  	 4.2.5     Right of Termination
	  	10
	 	  	4.3	  	Closing Actions	  	10
	 	  	 	  	 4.3.1     Joint Actions by Sellers and Buyer
	  	10
	 	  	 	  	 4.3.2     Actions by Sellers
	  	10
	 	  	 	  	 4.3.3     Actions by Buyer
	  	11
			
	 5.
	  	Representations and Warranties	  	12
	 	  	5.1	  	Representations and Warranties of Sellers	  	12
	 	  	5.2	  	Representations and Warranties of Buyer	  	12
	 	  	5.3	  	Exclusive Representation and Warranties	  	12
			
	 6.
	  	Remedies	  	12
	 	  	6.1	  	Remedy of Buyer	  	12
	 	  	 	  	 6.1.1     Sellers’ Right to Cure and Sellers’ Liability
	  	12
	 	  	 	  	 6.1.2     Notice of Misrepresentation or Breach of Warranty (Rüge)
	  	12
	 	  	 	  	 6.1.3     Time Limitations on Claims for Misrepresentations, Breach of Warranty or Breach of Tax Indemnity in
Article 8.2 (Verjährung)
	  	13
	 	  	 	  	 6.1.4     Limitations on Liability
	  	13
	 	  	 	  	 6.1.5     Third Party Claims
	  	14
	 	  	6.2	  	Remedies of Sellers	  	15
	 	  	6.3	  	Remedies Exclusive	  	15
	 	  	6.4	  	Treatment of Payments	  	15
			
	 7.
	  	Conduct of Business Between Signing and Closing	  	15
	 	  	7.1	  	Conduct of Business	  	15
	 	  	7.2	  	Access to the Group	  	15
	 	  	7.3	  	Restricted Actions	  	15

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 2 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

							
	 8.
	  	Other Covenants	  	16
	 	  	8.1	  	Tax Indemnity Provided by Buyer	  	16
	 	  	8.2	  	Tax Indemnity Provided by Sellers	  	16
	 	  	8.3	  	Indemnity for Incentive Payments	  	17
	 	  	8.4	  	Press Releases and Other Public Announcements	  	17
	 	  	8.5	  	No Claims Against Directors	  	17
	 	  	8.6	  	Document Retention and Access	  	18
	 	  	8.7	  	Non-Competition	  	18
	 	  	8.8	  	Confidentiality	  	19
	 	  	8.9	  	Further Assurance	  	19
			
	 9.
	  	Taxes, Costs, Expenses and Interest	  	20
	 	  	9.1	  	Taxes	  	20
	 	  	9.2	  	Costs and Expenses	  	20
	 	  	9.3	  	Interest	  	20
			
	 10.
	  	General Provisions	  	20
	 	  	10.1	  	Effect on Third Parties	  	20
	 	  	10.2	  	Notices	  	20
	 	  	10.3	  	Entire Agreement	  	21
	 	  	10.4	  	Amendments and Waivers	  	21
	 	  	10.5	  	No Assignment	  	21
	 	  	10.6	  	Severability; Good Faith	  	21
	 	  	10.7	  	Relationship Between Sellers and Buyer	  	21
	 	  	10.8	  	Representative of Sellers	  	22
	 	  	10.9	  	Guarantee	  	22
			
	 11.
	  	Governing Law and Arbitration	  	22
	 	  	11.1	  	Governing Law	  	22
	 	  	11.2	  	Arbitration	  	22

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 3 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Annexes 
  

					
	N° of Annex	  	Name of Annex	  	 
			
	B	  	Structure of Group	  	 
			
	1	  	Definitions	  	 
			
	2.1(a)(i)	  	Shares Owned by Sellers	  	 
			
	2.1(a)(ii)	  	Shareholder Loans	  	 
			
	2.2.1(a)	  	Computation of Fixed Amount	  	 
			
	2.3(a)	  	Proposed Closing Accounts and Final Closing Accounts	  	 
			
	2.3(b)	  	Dispute Resolution Regarding Proposed Closing Accounts	  	 
			
	2.4	  	Calculation of Net Debt and Net Working Capital	  	 
			
	2.5	  	Escrow Agreement	  	 
			
	3.3	  	Consents of Third Parties	  	 
			
	3.4	  	Data Room Escrow Agreement (agreed form)	  	 
			
	4.2.1(a)	  	Governmental Approvals and Merger Control Laws	  	 
			
	5.1	  	Sellers’ Representations and Warranties	  	 
			
	5.2	  	Buyer’s Representations and Warranties	  	 
			
	6.1.4(d)(ii)	  	Dataroom Indices	  	 
			
	6.1.4(d)(iii)	  	Disclosure Letter	  	 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 4 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
  
 This Share
Purchase Agreement (the Agreement) is made as of March 12, 2007 by and between Sellers, Buyer and Guarantor (each a Party and together the Parties). 
  
 Whereas 
  

	A.	Plus Orthopedics Holding AG (the Company) is a corporation organized and existing under the laws of Switzerland with its registered office at Erlenstrasse 4, CH-6343
Rotkreuz, with a nominal share capital of CHF 20,000,000 divided into 20,000 bearer shares with a nominal value of CHF 1,000 each (collectively, the Shares, and each a Share). 

  

	B.	As of the date of this Agreement, the Company directly and|or indirectly owns the shares in the subsidiaries and associated companies as set forth in Annex B (the
Company together with such subsidiaries and associated companies, the Group, each of them a PO Company and together the PO Companies). 

  

	C.	As of the date of this Agreement, Sellers are the owners of 100 % of the Shares. 

  

	D.	Sellers intend to sell the Shares to Buyer and Buyer intends to buy the Shares from Sellers pursuant to the terms and conditions of this Agreement. 

  

	E.	Prior to executing this Agreement, Buyer conducted a due diligence investigation and reviewed, inter alia, the Disclosure Information (as hereinafter defined).

  
 Now, therefore, the
Parties hereto agree as follows: 
  

	1.	Definitions 

  
 Capitalized terms used in this Agreement shall have the meaning assigned to them in Annex 1. 
  

	2.	Sale and Purchase of Shares 

  

	2.1	Object of Sale and Repayment of Shareholder Loans 

  

	 	(a)	Subject to the terms and conditions of this Agreement: 

  

	 	(i)	Sellers hereby agree to sell and, at the Closing, to transfer to Buyer, and Buyer hereby agrees to buy from Sellers, the full legal and beneficial ownership, free and clear from any
Liens, of the Shares as set forth in Annex 2.1(a)(i); 

  

	 	(ii)	Buyer hereby agrees to repay at the Closing, on its own behalf or on behalf of the Company, the Shareholder Loans set forth in Annex 2.1(a)(ii) with all accrued interest
thereon in accordance with the interest rate set forth in that Annex up to the Closing Date (the Shareholder Loans). 

  

	 	(b)	Buyer may elect that any of its obligations under this Agreement are performed by one or more of its Affiliates in accordance with this Agreement provided that
(i) notwithstanding such election, Buyer shall be and remain fully liable for all of its and its Affiliates obligations under or in connection with this Agreement, and (ii) Sellers are not adversely affected in any manner by such election.

  

	2.2	Consideration 

  

	2.2.1	Calculation of Purchase Price for the Shares 

  
 The consideration for the Shares (the Purchase Price) payable by Buyer to Sellers shall consist of: 
  

	 	(a)	a fixed amount of CHF 939,445,000 (in words: Swiss francs nine hundred thirty nine million four hundred forty five thousand) for the Shares as set forth in Annex 2.2.1(a);

  

	 	(b)	plus the Estimated Net Working Capital determined in accordance with Article 3.6; 

  

	 	(c)	minus the Estimated Net Debt determined in accordance with Article 3.6; 

  

	 	(d)	plus or minus the Net Working Capital Adjustment determined in accordance with Article 2.4.1; 

  

	 	(e)	plus or minus the Net Debt Adjustment determined in accordance with Article 2.4.2; 

  
 the aggregate of (a), (b) and (c) above being the preliminary purchase price (the Preliminary Purchase
Price). 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 5 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	2.2.2	Set-off Rights 

  
 Buyer shall not be entitled to set-off any of its claims it may have against any of the Sellers against, or otherwise withhold the proper payment of, any
amount payable by Buyer to Sellers under or pursuant to this Agreement, regardless if such claim of Buyer against Sellers has arisen under or in connection with this Agreement or otherwise. 
  

	2.3	Closing Accounts 

  

	 	(a)	No later than 60 (sixty) Business Days following the Closing Date, Sellers shall prepare, or cause to be prepared, and deliver to Buyer the consolidated financial statements of the
Group as at the Adjustment Date, audited by PricewaterhouseCoopers AG and established in accordance with the principles set forth in Annex 2.3(a) (the Proposed Closing Accounts), and the proposed purchase price adjustment pursuant
to Articles 2.4.1 and 2.4.2 and Annex 2.4 (the Proposed Adjustment). Buyer shall procure that Sellers and their advisors are promptly given full and unfettered access (during ordinary business hours) to the books, records and
personnel of the Group as Sellers may request for the purposes of preparing and establishing the Proposed Closing Accounts and the Proposed Adjustment. 

  

	 	(b)	The Proposed Closing Accounts and the Proposed Adjustment shall be deemed final and binding for the Parties for all purposes, unless Buyer gives notice to Sellers within 20 (twenty)
Business Days following receipt of the Proposed Closing Accounts and the Proposed Adjustment that it disagrees with any specific item of the Proposed Closing Accounts or the Proposed Adjustment (such notice, the Notice of Objection), stating in
writing and in reasonable detail the reasons for Buyer’s objections, in which case the procedures set forth in Annex 2.3(b) shall apply. 

  

	2.4	Net Working Capital Adjustment and Net Debt Adjustment 

  

	2.4.1	Net Working Capital Adjustment 

  

	 	(a)	If the Net Working Capital as per the Adjustment Date, as determined on the basis of the Final Closing Accounts and in accordance with Annex 2.4, exceeds the Estimated
Net Working Capital, then Buyer shall, subject to Article 2.4.3, pay to Sellers on a CHF-for-CHF basis a cash amount equal to any surplus. 

  

	 	(b)	If the Net Working Capital as per the Adjustment Date, as determined on the basis of the Final Closing Accounts and in accordance with Annex 2.4, is less than the
Estimated Net Working Capital, then Sellers shall, subject to Article 2.4.3, pay to Buyer on a CHF-for-CHF basis a cash amount equal to any deficiency. 

  

	2.4.2	Net Debt Adjustment 

  

	 	(a)	If the Net Debt as per the Adjustment Date, as determined on the basis of the Final Closing Accounts and in accordance with Annex 2.4, is less than the Estimated Net
Debt, then Buyer shall, subject to Article 2.4.3, pay to Sellers on a CHF-for-CHF basis a cash amount equal to any deficiency. 

  

	 	(b)	If the Net Debt as per the Adjustment Date, as determined on the basis of the Final Closing Accounts and in accordance with Annex 2.4, exceeds the Estimated Net Debt,
then Sellers shall, subject to Article 2.4.3, pay to Buyer on a CHF-for-CHF basis a cash amount equal to any surplus. 

  

	2.4.3	Payment of Net Working Capital Adjustment and Net Debt Adjustment 

  

	 	(a)	All amounts required to be paid pursuant to Articles 2.4.1 and 2.4.2 shall be aggregated or offset against each other, as the case may be. 

  

	 	(b)	The balance determined pursuant to Article 2.4.3(a) shall be paid in immediately available funds in CHF for value within 10 (ten) Business Days (with interest from the Closing
Date to payment at the interest rate determined in accordance with Article 9.3) of the earlier of (i) either the Proposed Adjustment becoming final and binding pursuant to Article 2.3(b), or (ii) the determination of the Final
Adjustment being delivered by the Appraiser to Sellers and Buyer pursuant to Annex 2.3(b), by wire transfer or, as the case may be, by way of release 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 6 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
from the Escrow Account, to the bank account or accounts designated in writing by the Party or Parties entitled to receive the payment or as provided for in
the Escrow Agreement, respectively. For the avoidance of doubt, the limitations provided for in Article 6.1.4(a) and (b) do not apply with respect to the Final Adjustment. 

  

	2.5	Escrow 

  

	 	(a)	At Closing, Buyer shall pay a portion of the Preliminary Purchase Price in the amount of CHF * (in words: Swiss francs *) (the Initial Escrow Amount) to an account in the
name of the Escrow Agent to be opened with Credit Suisse (the Escrow Account). 

  

	 	(b)	The Escrow Account shall serve as a payment fund for claims which Buyer may have against any of the Sellers under this Agreement, including, but not limited to, claims for price
adjustments pursuant to Articles 2.4.1 or 2.4.2 or possible misrepresentations or breach of warranties pursuant to Article 5.1 and Annex 5.1. The amounts in the Escrow Account shall be released in accordance with the terms and conditions
set forth below and in the escrow agreement among the parties and the Escrow Agent (to be entered into as of Closing substantially in the form set forth in Annex 2.5, the Escrow Agreement): 

  

	 	(i)	if the Final Adjustment is payable to Buyer, Sellers and Buyer shall instruct the Escrow Agent to release the Final Adjustment to Buyer; 

  

	 	(ii)	10 (ten) Business Days following the determination of the Final Adjustment, Sellers and Buyer shall instruct the Escrow Agent to release CHF * (in words: Swiss francs *) (less
a Final Adjustment if payable to Buyer in accordance with Article 2.4) to Sellers, unless and to the extent Buyer on or before the last Business Day prior to the expiration of the 10 (ten) Business Day period has delivered to Sellers one or more
Notices of Breach; 

  

	 	(iii)	10 (ten) Business Days following the receipt of a final tax assessment from the * tax authorities with respect to the tax audit for *, Sellers and Buyer shall instruct the Escrow
Agent to release CHF * (in words: Swiss francs *) to Sellers, unless and to the extent Buyer on or before the last Business Day prior to the expiration of the 10 (ten) Business Day period has delivered to Sellers one or more Notices of Breach;

  

	 	(iv)	* months after the Closing Date, Sellers and Buyer shall instruct the Escrow Agent to release CHF * (in words: Swiss francs *) to Sellers, unless and to the extent Buyer has on
or before the last Business Day prior to the expiration of the * months period after the Closing Date delivered to Sellers one or more Notices of Breach; and 

  

	 	(v)	* years after the Closing Date, Sellers and Buyer shall instruct the Escrow Agent to release CHF * (in words: Swiss francs *) plus any remaining balance held in the Escrow
Account including any proceeds and interests accrued on the Escrow Account to Sellers, unless and to the extent Buyer has on or before the last Business Day prior to the expiration of the * year period after the Closing Date delivered to Sellers one
or more Notices of Breach. 

  

	 	(c)	In the event that any Notice(s) of Breach that are validly served prior to the relevant escrow release dates set forth in Article 2.5(b) show an amount of reasonably anticipated
Damage (in accordance with Article 6.1.2(a)) which is less than the portion of the Escrow Amount to be released on such date, Sellers and Buyer shall instruct the Escrow Agent to release such difference to Buyer. 

  

	 	(d)	If and to the extent Buyer has delivered to Sellers one or more Notices of Breach and did not timely initiate arbitral proceedings as set forth in Article 6.1.3, last paragraph in
respect of such relevant Notice of Breach (the Repealed Notice(s)), Sellers and Buyer shall, upon expiration of the * period stated in Article 6.1.3, last paragraph, instruct the Escrow Agent to release the amount claimed under such Repealed
Notices from any relevant amounts set forth in Article 2.5(b)(ii), (iii), (iv) and (v), respectively, to the extent such amounts are releasable by virtue of the release dates set forth in those paragraphs and subject always to any relevant
amount not being subject to any other valid Notice(s) of Breach. 

  

	 	(e)	As long as the Escrow Account is not depleted, Buyer shall not be entitled to enforce payment from Sellers in connection with this Agreement other than from the Escrow Account.

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 7 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	3.	Actions Prior to Closing 

  

	3.1	General 

  
 Unless specifically otherwise provided herein, Sellers and Buyer undertake to use their commercially reasonable best efforts to procure that: 

 

	 	(a)	the conditions precedent set forth in Article 4.2 shall be satisfied on or by the Closing Date; 

  

	 	(b)	all their Affiliates will do all acts and things as are reasonably necessary (and within their power) to implement the transactions contemplated by this Agreement.

  
 Sellers and Buyer shall fully cooperate and
promptly inform each other of any relevant actions taken prior to Closing. 
  

	3.2	Filings and Submissions 

  
 No later than 20 (twenty) Business Days following the date of this Agreement, Buyer and, if requested, Sellers shall make (if permitted under applicable
law) all filings and submissions required pursuant to Article 4.2.1(a). 
  
 Sellers shall provide Buyer and Buyer shall provide Sellers with all the information necessary for the filings and submissions. No Party shall make any filings or submissions without the prior consent of the other
Party (such consent not to be unreasonably withheld or delayed). 
  

	3.3	Third Party Consents 

  
 Sellers and Buyer shall use their commercially reasonable best efforts to obtain the consents from third parties which are listed in Annex 3.3
and such other consents as any Party may reasonably request. 
  

	3.4	Escrow of Data Room Documentation 

  

	 	(a)	Promptly following the date of this Agreement, Sellers shall deliver the originals of the documentation disclosed to Buyer in connection with the due diligence review as reflected
in the Disclosure Information to the Data Room Escrow Agent, who shall keep such documentation in escrow on behalf of Sellers and Buyer in accordance with the terms of the data room escrow agreement set forth in Annex 3.4, it being
understood that each of Sellers retains a copy of such documentation. Sellers shall represent in such data room escrow agreement the identity of such documentation with the documentation made available to Buyer during its due diligence review. Buyer
shall be given sufficient opportunity to verify the identity of the documentation made available to Buyer during its due diligence review with the documentation to be given into escrow prior to such documentation being given into escrow.

  

	 	(b)	Sellers shall further deliver a copy of such documentation to Buyer, save for the documentation provided to Ernst & Young on a adviser-to-adviser basis and the documents
listed in the Data Room Indices under the heading “Giftschrank” and certain other documents that Sellers may reasonably identify, provided, however, that Buyer shall use the data room documentation solely for purposes of integration
planning and/or the transactions contemplated under this Agreement. 

  

	3.5	Closing Memorandum 

  
 No later than 10 (ten) Business Days prior to the Closing Date, Sellers’ legal counsel shall prepare, in cooperation with Buyer’s legal counsel,
a closing memorandum which describes the closing actions pursuant to Article 4.3 and which shall serve as evidence for the closing of the transactions contemplated under this Agreement. 
  

	3.6	Estimated Net Working Capital | Estimated Net Debt 

  

	 	(a)	No later than 5 (five) Business Days prior to Closing, Sellers shall deliver to Buyer a written statement of their reasonable good faith estimate of the Net Working Capital as at
the Adjustment Date (the Estimated Net Working Capital), together with a reasonably detailed explanation of the calculation thereof. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 8 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(b)	No later than 5 (five) Business Days prior to Closing, Sellers shall deliver to Buyer a written statement of their reasonable good faith estimate of the Net Debt as at the
Adjustment Date (the Estimated Net Debt), together with a reasonably detailed explanation of the calculation thereof (which, for the avoidance of doubt, will conform, so far as the Shareholder Loans are concerned, with the amount to be
provided under Article 3.7). 

  

	3.7	Shareholder Loans 

  
 No later than 5 (five) Business Days prior to the Closing Date, Sellers shall deliver to Buyer written confirmation of the total amount of the Shareholder
Loans including accrued interest thereon as of the Closing Date, together with excerpts from the account records of the Group. 
  

	4.	Closing 

  

	4.1	Date and Place 

  
 The Closing shall take place at the last day of the month (or, if such day is not a Business Day, on the first Business Day thereafter) which occurs first
after the lapse of 5 (five) Business Days after the day on which all conditions precedent to Closing set forth in Article 4.2 have been satisfied or waived (where permitted) or, subject to Article 4.2.5(a) and (b), on such other date as
Sellers and Buyer may agree, but in no event later than * (the Long Stop Date). 
  
 Closing shall take place at the offices of Homburger, Weinbergstrasse 56/58, CH-8006 Zurich, Switzerland, or at such other location as Sellers and Buyer may agree. 
  

	4.2	Conditions Precedent to Closing 

  

	4.2.1	Conditions to Obligations of Sellers and Buyer 

  
 The respective obligations of Sellers and Buyer to effect the transactions contemplated under this Agreement shall be subject to the satisfaction or
waiver (where permitted) by Sellers and Buyer of the following conditions: 
  

	 	(a)	(i) All governmental approvals as set forth in Annex 4.2.1(a) shall have been obtained, or (ii) any waiting period under the Merger Control Laws set forth in
Annex 4.2.1(a) shall have expired or been terminated by the competent authorities, provided in both cases that the applicable Merger Control Laws require the Parties to suspend the completion of the transactions contemplated herein until
the approval under the Merger Control Laws is obtained or the respective waiting period has expired or been terminated by the competent authority. 

  

	 	(b)	No action shall be pending or threatened in writing and no order, injunction or decree of any court, administrative body or arbitration tribunal exists which seeks to enjoin the
consummation of the transactions contemplated hereunder. 

  

	 	(c)	There shall not have been a change in the assets, liabilities or financial position of the Group taken as a whole which fundamentally and sustainably adversely impairs the value of
the Group as a whole, and which was not already known and was and could not reasonably be expected to have been taken into account by Sellers and Buyer at the date of this Agreement, and which is not (a) the result of a general economic decline
at large or in the conditions of the medical technology industry, the securities markets or the currency exchange rates developments, (b) the result of the announcement or the consummation of the transaction contemplated by this Agreement, or
(c) the result of changes in laws, regulations or governmental policies. 

  

	4.2.2	Conditions to Obligations of Buyer 

  
 The respective obligations of Buyer to effect the transactions contemplated under this Agreement shall be subject to the satisfaction or waiver of the
condition that: 
  

	 	(a)	Sellers shall have performed in all material respects all of their obligations pursuant to this Agreement that are to be performed prior to or on the Closing Date.

  

	 	(b)	All representations and warranties of Sellers pursuant to Article 5.1 and Annex 5.1 shall be true and correct as of the Closing Date (except that those
representations and warranties 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 9 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
which are explicitly made as of a specific date shall be true and correct only as of such date) to the extent that any misrepresentation or breach of
warranty for itself or taken together does not constitute a Material Adverse Effect. 

  

	4.2.3	Condition to Obligations of Sellers 

  
 The respective obligations of Sellers to effect the transactions contemplated under this Agreement shall be subject to the satisfaction or waiver of the
condition that: 
  

	 	(a)	Buyer shall have performed in all material respects all of its obligations pursuant to this Agreement that are to be performed prior to or on the Closing Date.

  

	 	(b)	All representations and warranties of Buyer pursuant to Article 5.2 and Annex 5.2 shall be true and correct as of the Closing Date. 

  

	4.2.4	Waiver of Nonfulfilled Conditions 

  
 Sellers and Buyer shall inform each other forthwith upon becoming aware of any fact or matter which could reasonably be expected to constitute a breach or
could prevent or hinder the satisfaction of any of the conditions set forth in Articles 4.2.1, 4.2.2 or 4.2.3 and Sellers and Buyer shall enter into good faith negotiations on how to resolve the issue and, without prejudice to any other
provision of this Agreement, Sellers and Buyer each shall be entitled to seek to cure at its own expense any breach or non-satisfaction. At any time prior to Closing, (i) Sellers and Buyer may jointly waive the conditions to Closing set forth
in Article 4.2.1 (in their entirety or portions thereof), (ii) Buyer may waive the conditions to Closing set forth in Article 4.2.2 (in their entirety or portions thereof), and (iii) Sellers may waive the conditions to Closing
set forth in Article 4.2.3 (in their entirety or portions thereof). 
  

	4.2.5	Right of Termination 

  

	 	(a)	Should the conditions precedent to Closing set forth in Articles 4.2.1 or 4.2.2 not be met on or before the Long Stop Date, Buyer may at the latest 20 (twenty) Business
Days from the Long Stop Date terminate this Agreement unless Buyer failed to use all commercially reasonable best efforts to procure the satisfaction of any such condition. 

  

	 	(b)	Should the conditions precedent to Closing set forth in Articles 4.2.1 or 4.2.3 not be met on or by the Long Stop Date, Sellers may within 20 (twenty) Business Days from
the Long Stop terminate this Agreement, unless Sellers failed to use all commercially reasonable best efforts to procure the satisfaction of any such condition. 

  

	 	(c)	If this Agreement is terminated according to Article 4.2.5(a) or (b), such termination shall be without liability of any Party to the other Parties; provided that if such
termination shall result from the breach by any Party of its obligations under this Agreement, such Party shall be fully liable for all damages suffered by the other Parties as a result of such breach. The right to request specific performance shall
be preserved. 

  

	 	(d)	If this Agreement is terminated, all provisions of this Agreement shall cease to be effective except for Article 4.2.5(c), Article 4.2.5(d), Article 8.4 (Press
Releases and Other Public Announcements), Article 9.2 (Costs and Expenses), Article 10 (General Provisions) and Article 11 (Governing Law and Arbitration). 

  

	4.3	Closing Actions 

  

	4.3.1	Joint Actions by Sellers and Buyer 

  
 At the Closing, Sellers and Buyer shall execute the Escrow Agreement substantially in the form attached hereto as Annex 2.5 duly signed by the
Escrow Agent. 
  

	4.3.2	Actions by Sellers 

  
 At the Closing, Sellers shall: 
  

	 	(a)	deliver to Buyer certificates representing the Shares; 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 10 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(b)	deliver to Buyer (i) to the extent issued, the share certificates or equivalent documents in the relevant jurisdiction in respect of each of the shares held, directly or
indirectly, by the Company in each of the PO Companies and (ii), in respect of each PO Company (other than Plus Orthopedics GmbH (Austria), Intraplant GmbH (Austria) and Intercus GmbH (Germany)), the certificate of incorporation, share register or
ledger and share certificate book (with any unissued share certificates) and all minute books and other statutory books (which shall be written up to but not including Closing) or such equivalent items in the relevant jurisdiction which the laws of
the jurisdiction of incorporation of the PO Company requires it to keep or are kept by the relevant PO Company, including, in each case, evidence of ownership of the relevant shares together with an uninterrupted and verifiable chain of transfer
documents to prove ownership; 

  

	 	(c)	deliver to Buyer resignation letters of (i) the Sellers as members of the boards of directors of each relevant PO Company as notified by Buyer to Sellers no later than 5 (five)
Business Days prior to the Closing Date, and (ii) to the extent reasonable under the circumstances, of any other member of the boards of directors of each relevant PO Company as notified by Buyer to Sellers no later than 5 (five) Business Days
prior to the Closing Date, in each case declaring their resignation as of the Closing and confirming to Buyer and the relevant PO Company that the relevant board member has no claims against the Company arising out of or in connection with such
board membership; 

  

	 	(d)	to the extent legally possible, ensure that resolutions of the boards of directors of each relevant PO Company (or if required by the law of its jurisdiction or its constitutional
documents, of its shareholders) are passed at which such persons as Buyer may notify to Sellers no later than 5 (five) Business Days prior to the Closing Date, are appointed as directors of the relevant PO Company, subject to completion of Closing;

  

	 	(e)	deliver to Buyer waivers of Sellers in relation to rights under existing shareholders agreement; 

  

	 	(f)	deliver to Buyer a waiver of Seller 4 in connection with its rights of first refusal in relation to private equity transaction with respect to the transactions contemplated under
this Agreement; 

  

	 	(g)	deliver to Buyer a certified copy of any power of attorney under which any of the actions referred to in this Article 4.3.2 are executed, including evidence reasonably
satisfactory to Buyer of the authority of any person signing on behalf of Sellers; and 

  

	 	(h)	confirm to Buyer in writing that the conditions set forth in Articles 4.2.1 and 4.2.2 are satisfied as of the Closing Date. 

  

	4.3.3	Actions by Buyer 

  
 At Closing, Buyer shall: 
  

	 	(a)	pay the Preliminary Purchase Price as follows: 

  

	 	(i)	an amount equal to the Preliminary Purchase Price minus the Initial Escrow Amount to the account or accounts as designated by Sellers in writing no later than 10 (ten) Business Days
before the Closing Date; and 

  

	 	(ii)	the Initial Escrow Amount of CHF * (in words: Swiss francs *) to the Escrow Account; 

  

	 	(b)	repay the Shareholder Loans including accrued interest thereon pursuant to Article 2.1(a)(ii) and as determined in accordance with Article 3.7 to the account or accounts
as designated by Sellers in writing no later than 10 (ten) Business Days before the Closing Date; 

  

	 	(c)	deliver to Sellers a certified copy of any power of attorney under which any of the actions referred to in this Article 4.3.3 are executed, including evidence reasonably
satisfactory to Sellers of the authority of any person signing on behalf of Buyer; and 

  

	 	(d)	confirm to Sellers in writing that the conditions set forth in Articles 4.2.1(a) and (b) and 4.2.3 are satisfied as of the Closing Date. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 11 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	5.	Representations and Warranties 

  

	5.1	Representations and Warranties of Sellers 

  
 Subject to the limitations set forth in Article 6, Sellers hereby represent and warrant to Buyer that the representations and warranties as set forth
in Annex 5.1 are true and accurate on both the date of this Agreement and the Closing Date, except that those representations and warranties which are explicitly made as of a specific date shall be true and correct only as of such date,
and all representations and warranties shall be limited by the Fair Disclosure made to Buyer in the Disclosure Information. 
  

	5.2	Representations and Warranties of Buyer 

  
 Subject to the limitations set forth in Article 6, Buyer hereby represents and warrants to Sellers that the representations and warranties as set
forth in Annex 5.2 are true and accurate on both the date of this Agreement and the Closing Date, except that those representations and warranties which are explicitly made as of a specific date shall be true and correct only as of such
date. 
  

	5.3	Exclusive Representation and Warranties 

  
 Sellers acknowledge that, other than as expressly provided in this Agreement, Buyer has not made and does not make, and Sellers have not relied and do not
rely on, any representation or warranty, express or implied, pertaining to the subject matter of this Agreement. Buyer acknowledges that, other than as expressly provided in this Agreement, Sellers have not made and do not make, and Buyer has not
relied and does not rely on, any representation or warranty, express or implied, pertaining to the subject matter of this Agreement. In particular, and without limitation to the foregoing, Buyer acknowledges that Sellers are not making any
representations as to budgets, business plans, forward-looking statements and other projections of a financial, technical or business nature relating to the business of the Group or any PO Company. 
  

	6.	Remedies 

  

	6.1	Remedy of Buyer 

  

	6.1.1	Sellers’ Right to Cure and Sellers’ Liability 

  

	 	(a)	With respect to all of its obligations under this Agreement, including, but not limited to, any misrepresentation or breach of warranty notified by Buyer to Sellers pursuant to
Article 6.1.2, Sellers shall have the right, within a reasonable period of time not exceeding 40 (forty) Business Days after the receipt of the Notice of Breach or a similar notice regarding other breaches of this Agreement, to put Buyer in the
same position in which it would have been if the obligations or as the case may be the representation or warranty had been complied with. 

  

	 	(b)	If, and to the extent, such cure cannot be effected, or is not effected within such a time period, Sellers shall be liable to Buyer, irrespective of any fault of Sellers, subject to
the exclusions and limitations set forth in this Article 6, for any loss, damage, out of pocket cost or expense, including reasonable attorney’s fees, of Buyer and any PO Company (the Damage) caused by such breach of obligation,
warranty or misrepresentation. 

  

	6.1.2	Notice of Misrepresentation or Breach of Warranty (Rüge) 

  

	 	(a)	Buyer shall deliver to Sellers a notice in writing describing the underlying facts of a claim for misrepresentation or breach of warranty in reasonable detail to the extent then
known referring to the specific representation or warranty allegedly breached and stating the amount of reasonably anticipated Damage relating to such claim as well as disclosing to Sellers such documents and information supporting its claim as is
reasonable (the Notice of Breach) at the earlier of: 

  

	 	(i)	within 40 (forty) Business Days after Buyer having obtained knowledge (x) of a misrepresentation or breach of warranty pursuant to Article 5.1 or (y) receipt by Buyer
of notice of any claim made or threatened in writing to be made by any third party which Buyer believes is reasonably likely to give rise to a claim for misrepresentation or breach of warranty; or 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 12 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(ii)	in case of a submission to, or a decision or order by, any court, arbitral tribunal or governmental or administrative body (including, without limitation tax authorities) which
Buyer believes is reasonably likely to give rise to a claim for misrepresentation or breach of warranty, promptly upon Buyer receiving any such submission, decision or order but in any event within such period as will afford Sellers reasonable
opportunity to respond, or to require Buyer to procure that the relevant PO Company respond, to such submission or to lodge, or to require Buyer to procure the relevant PO Company to lodge, a timely appeal or other challenge against such decision or
order. 

  

	 	(b)	Failure to give Notice of Breach within the time periods set forth above shall not exclude Sellers liability hereunder; provided, however, that Sellers shall not be liable
for any damage, loss or expense to the extent that the same is caused by Buyer’s failure to give duly and timely notice within the time period set forth in this Article 6.1.2. 

  

	 	(c)	The regime provided for in this Article 6.1.2 shall be in lieu of, not in addition to, Buyer’s duty to immediately inspect and notify Sellers in accordance with
Article 201 CO. 

  

	6.1.3	Time Limitations on Claims for Misrepresentations, Breach of Warranty or Breach of Tax Indemnity in Article 8.2 (Verjährung)

  
 Claims by Buyer against Sellers for
misrepresentation, breach of warranty or breach of the Tax indemnity provided by Sellers in Article 8.2 shall be time-barred unless and to the extent Buyer delivers to Sellers Notices of Breach in accordance with Article 6.1.2(a) or
similar notices regarding breaches of the Tax indemnity in Article 8.2: 
  

	 	(a)	unless otherwise set forth in this Article 6.1.3, on or before * months after the Closing Date; 

  

	 	(b)	with regard to the representations and warranties in paragraph 4 (Taxes) of Annex 5.1, and the Tax indemnity in Article 8.2, * years after the Closing Date;

  

	 	(c)	with regard to the representations and warranties in paragraphs 1 and 2 of Annex 5.1 (Ownership and Qualifications on the one hand and Due Authorization on the
other hand), on or before * years after the Closing Date. 

  
 It is understood and agreed that any Notice of Breach or a similar notice regarding any breach of the Tax indemnity in Article 8.2 shall be served to Sellers on or by the date set forth in the preceding
paragraph, in which case the resolution of such claims may also be effected after such date; provided, however, notwithstanding the foregoing, Buyer’s claim shall be time-barred (verjährt) unless Buyer initiates arbitral
proceedings against Sellers in accordance with Article 11.2 within * of the date of Buyer’s Notice of Breach or similar notice regarding any breach of the Tax indemnity in Article 8.2. Sellers and Buyer explicitly waive the
application of Article 210 paragraph 1 CO. 
  

	6.1.4	Limitations on Liability 

  

	 	(a)	Buyer shall not be entitled to be paid any sum in respect of a claim to recover Damage under this Agreement unless (i) such claim exceeds on a stand-alone basis the amount of
CHF * (the Qualifying Claim), and (ii) the liability of Sellers to Buyer in respect of such Qualifying Claim exceeds, or will exceed, when aggregated with the aggregated liability of Sellers hereunder in respect of all other
Qualifying Claims, the sum of CHF * (the Threshold) whereupon Buyer shall be entitled to recover all Qualifying Claims. 

  

	 	(b)	Notwithstanding anything in this Agreement to the contrary (other than as set forth in Article 6.1.4(c)), Sellers’ liability under this Agreement shall not exceed an
amount of CHF * (the Cap); it being understood that, in accordance with Article 10.7 of this Agreement, the liability of each of Sellers is limited to the overall amount corresponding to the Cap times the percentage of the
shareholding of each Seller in the Company as set forth in Annex 2.1(a)(i). 

  

	 	(c)	Any limitation of Sellers’ liability under Article 6.1.4(a) and (b) shall not apply to Sellers’ representations and warranties set forth in paragraphs 1 and
2 of Annex 5.1. 

  

	 	(d)	All matters and information which have been Fairly Disclosed in this Agreement or in: 

  

	 	(i)	the Confidential Information Memorandum as delivered to Buyer; 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 13 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(ii)	the documents listed in the data room indices attached hereto as Annex 6.1.4(d)(ii) (the Data Room Indices) and put into escrow in accordance with Article 3.4;
and 

  

	 	(iii)	the Disclosure Letter delivered to Buyer prior to the execution of this Agreement, including any documents attached to the Disclosure Letter, all as set forth in
Annex 6.1.4(d)(iii); 

  
 all such
documents, matters and information referred to in this Article 6.1.4(d) collectively, the Disclosure Information, shall to the extent Fairly Disclosed operate as an exclusion of, or a limitation to, Sellers’ representations and
warranties and Buyer’s rights under this Agreement, and Sellers shall be under no liability to the extent that any matter or information being the basis of a claim for Damage has been Fairly Disclosed to Buyer in the Disclosure Information,
provided, however, that any limitation under this Article 6.1.4(d) shall not apply to the Tax indemnity provided by Sellers set forth in Article 8.2 and Sellers’ representation and warranty set forth in paragraph 16 of
Annex 5.1. 
  

	 	(e)	Sellers shall, and shall have the right to, update the disclosure between the date hereof and the Closing with respect to those representations and warranties that must be true and
accurate at and as of the Closing Date, provided, however, that it shall be agreed and understood that any disclosure made after the date hereof shall not operate as an exclusion of, or limitation to, Sellers’ representations and
warranties and Buyer’s rights to make claims under any provision of this Agreement. 

  

	 	(f)	Sellers’ liability shall be excluded or reduced, as the case may be, if and to the extent that: 

  

	 	(i)	Buyer or, following Closing, the Group shall have failed to use their commercially reasonable best efforts to mitigate their Damage in respect thereof; 

  

	 	(ii)	Buyer or the Group have recovered or, by applying their commercially reasonable best efforts, could recover or could have reasonably recovered, as the case may be, from any third
person, including but not limited to an insurer, any sum in respect of any matter to which a claim made relates, after deduction of all duly documented costs and expenses incurred in making such recovery (including reasonable attorney’s fees);

  

	 	(iii)	a specific provision, reserve or valuation allowance has been or is made or included in the Final Closing Accounts; 

  

	 	(iv)	such liability is attributable to any act, omission, transaction or arrangement of Buyer (other than one to which Sellers consented, or one which is required under the provisions of
this Agreement, or in order to comply with applicable law under an enforceable court order) after the signing of this Agreement; 

  

	 	(v)	the matter giving rise to a claim has been taken into account in the purchase price adjustments according to Article 2.4; 

  

	 	(vi)	any Tax payable by any entity of the Group or by Buyer or its Affiliates is reduced as a result of a matter giving rise to a claim; and 

  

	 	(vii)	such claim arises or is increased as a result of any legislation, regulation or rule of law not in force at the Closing or the withdrawal after Closing of any concession previously
made by any relevant authority or as a result of any change made or introduced on or after the date of this Agreement in any legislation, regulation or rule of law of any relevant authority, whether or not such change or withdrawal purports to be
effective retrospectively in whole or part. 

  

	6.1.5	Third Party Claims 

  
 After the Closing, in case of any third party claim, including, but not limited to, claims brought by tax or other governmental authorities, Buyer shall
be entitled to oppose, or to cause the relevant PO Company to oppose, such claim, and Sellers shall use their commercially reasonable best efforts in assisting Buyer or the relevant PO Company in the defense of such claim at Sellers’ own costs.
Subject to the provisions of this Agreement, Sellers shall bear all reasonable attorney’s fees incurred by Buyer or the PO Companies in the defense of such claims (to the extent such fees cannot be recovered from 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 14 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 
the third party). Buyer shall procure that no such claim is settled without the prior written consent of Sellers, which consent shall not be unreasonably
withheld or delayed. 
  

	6.2	Remedies of Sellers 

  
 The provisions of Article 6.1 shall apply by analogy with respect to any misrepresentation or breach of warranty by Buyer. 
  

	6.3	Remedies Exclusive 

  
 The remedies in this Article 6 and in Article 4.2.5 for breach of representations and warranties shall be in lieu of, and not in addition to,
the remedies provided for under statutory law. All other remedies including, without limitation, the right to rescind this Agreement shall not apply and are expressly waived. In particular, and without limitation to the foregoing, Sellers and Buyer
hereby explicitly waive the right of contract rescission under Articles 23 et seq. and 205 CO. 
  

	6.4	Treatment of Payments 

  
 Sellers and Buyer agree to treat all payments made under this Agreement, including, without limitation, the payments made under this Article 6, as
adjustments to the Purchase Price. 
  

	7.	Conduct of Business Between Signing and Closing 

  

	7.1	Conduct of Business 

  
 Unless Fairly Disclosed in the Disclosure Information, at all times from the date of this Agreement to the Closing Date, Sellers shall procure that the
Group continues to operate its business as a going concern, in the ordinary course of business and consistent with prior practice and in compliance with applicable laws and regulations, including but not limited to the AdvaMed Code of Ethics in the
United States of America and the Eucomed Code of Business Practice in other countries in which the PO Companies do business. 
  
 Sellers undertake to procure that the Group continues to incur and pay for capital expenditure from the date of this Agreement to the Closing Date in
accordance with the 2007 budget as approved by the competent corporate body of the Group and contained in the Disclosure Information. 
  

	7.2	Access to the Group 

  
 Subject to any constraints under applicable law, Sellers shall procure that Buyer is given reasonable access during ordinary business hours to the
management, legal and financial advisors and auditors and documents of the Group to the extent this is necessary for Buyer or its advisors to perform the obligations pursuant to Article 3, provided, however, that such access shall not
unreasonably interfere with the business and operations of the Group. 
  

	7.3	Restricted Actions 

  
 Unless either specifically provided for in this Agreement, or Fairly Disclosed in the Disclosure Information, or contemplated in the 2007 budget as
approved by the competent corporate body of the Group and contained in the Disclosed Information, or otherwise within the ordinary course of the Group’s business, Sellers shall not, and shall procure that the PO Companies shall not, without
prior consent of Buyer (or, if applicable Merger Control Laws do not so permit, prior consultation of Buyer) do or agree to do any of the following from the date of this Agreement through to the Closing Date: 
  

	 	(a)	do anything or omit to do anything that could materially interfere with the consummation of the transactions contemplated under this Agreement; 

  

	 	(b)	do or omit to do anything which would have a Material Adverse Effect; 

  

	 	(c)	make any material change in the terms of employment of any director, officer or employee of the PO Companies other than in accordance with past practice or existing commitments (in
relation to executive employees as Fairly Disclosed) as well as existing collective bargaining arrangements as Fairly Disclosed; 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 15 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(d)	form, enter into, vary, terminate or withdraw from any material partnership, consortium, joint venture or other incorporated association; 

  

	 	(e)	make material amendments to the articles of incorporation or organizational regulations of the PO Companies which are not in the interest of the Company; 

 

	 	(f)	transfer any shares that are directly or indirectly held by any PO Company to a third party or transfer any material assets of the Group to a third party; 

 

	 	(g)	increase or reduce or otherwise change the share capital, or grant any option or conversion rights on the equity of any PO Company; 

  

	 	(h)	enter into, increase or extend any liability under any guarantee or indemnity in favor of any third party in excess of CHF * per item; 

  

	 	(i)	make, increase or extend any loan or advance or grant any credit to any third party in excess of CHF * per item; 

  

	 	(j)	grant, create or allow to be created any Lien over any of its assets other than charges arising by operation of law; 

  

	 	(k)	borrow any money or incur any indebtedness or other liability as against a third party in excess of CHF * in the aggregate; 

  

	 	(l)	declare, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of the Shares or to any of the PO Companies’ capital
stock, except for dividends to another wholly owned PO Company; 

  

	 	(m)	enter into, amend, modify or give notice of, or consent to the, termination of any material license, distribution or supply agreement, or amend, waive, modify, terminate or consent
to the termination of any of the PO Companies’ rights thereunder; 

  

	 	(n)	change the accounting procedures, principles or practice of the PO Companies in effect at the date of this Agreement; 

  

	 	(o)	incur, or agree to incur, a commitment or commitments involving individual items of capital expenditure exceeding in total CHF *; 

  

	 	(p)	enter into any transaction between Sellers and their Affiliates (other than PO Companies (on the one hand) and any of the PO Companies on the other; 

  

	 	(q)	institute or settle any litigation where the amount claimed together with any costs incurred or likely to be incurred exceeds CHF *; and/or 

  

	 	(r)	materially change the payment and collection policy as to the accounts payable and accounts receivable respectively. 

  

	8.	Other Covenants 

  

	8.1	Tax Indemnity Provided by Buyer 

  
 Buyer shall indemnify and hold harmless Sellers from any Swiss income tax and additional net wealth tax that becomes payable due to dividend distribution
(and all interest payment obligations and legal and tax advisory expenses arising in connection therewith) up to a maximum amount of CHF * which become payable if Buyer, directly or indirectly, causes or permits any of the PO Companies, during
the * year period following the Closing, to take any action that could cause the transactions contemplated under this Agreement to be characterized by the Federal Tax Administration and|or any competent cantonal or communal Tax authority, with
respect to any of the Sellers as a direct or indirect partial liquidation of the Company or its subsidiaries, under Article 20a paragraph 1 letter a of the Federal Direct Tax Act, as adopted by the Federal Parliament on June 23, 2006,
and|or under the cantonal laws. 
  

	8.2	Tax Indemnity Provided by Sellers 

  

	 	(a)	Sellers shall indemnify and hold harmless Buyer against any Tax payable by any of the PO Companies arising in respect of or in consequence of (a) income, profit or gain earned,

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 16 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
accrued or received (or deemed to be earned, accrued or received) on or before the Closing Date, or (b) any event, transaction, sale or service which
occurred (or is deemed to occur) on or before the Closing Date, in each case which was not: (i) fully paid on or before the Closing Date, or (ii) fully provided for in the Final Closing Accounts. 

  

	 	(b)	For the purposes of Article 8.2(a) there shall be treated as Tax payable by any of the PO Companies an amount equal to any Tax which would have been so payable but for the use
or set-off of any deduction, credit, allowance, repayment or other exemption in respect of Tax (each a “Relief”) arising either (i) to the relevant PO Company in respect of an event occurring after the Closing Date, or (ii) to
Buyer or any other member of Buyer’s group (and provided that for the avoidance of doubt “Relief” shall not include any deduction, credit, allowance, repayment or other exemption in respect of Tax which on the Closing Date was already
available to the relevant PO Company or Sellers to use or set-off against Tax in respect of current or future tax periods). 

  

	 	(c)	Sellers shall pay to Buyer any amount payable under this Article 8.2 on or before the date which is the later of the date 10 (ten) Business Days after demand is made therefore by
Buyer and 2 (two) Business Days before the first date on which the Tax in question becomes payable (or, in the case of an amount payable under Article 8.2(b), would have become payable were it not for the use or set off of the relevant losses) by
the relevant PO Company. 

  

	 	(d)	For the avoidance of doubt, Buyer shall be solely responsible for all Tax affairs of each of the PO Companies with effect from the Closing Date. 

  

	8.3	Indemnity for Incentive Payments 

  
 Sellers shall indemnify and hold harmless the PO Companies for any Tax arising as a result of incentive payments that may be made to certain members of
the top management of the Group in relation with the transactions contemplated by this Agreement. For purposes of this Article 8.3, the limitations provided for in Article 6.1.4(a) and (d) shall not apply. 
  

	8.4	Press Releases and Other Public Announcements 

  
 Following the date of this Agreement, all public announcements or press releases issued in connection with the transactions contemplated by this Agreement
shall only be published after Buyer and Sellers shall have consulted and agreed on the contents of such public announcements or press releases. Nothing in this Agreement shall restrict or prohibit: 
  

	 	(a)	any announcement or disclosure required by statutory law or by any competent judicial or regulatory authority or by any competent securities exchange (in which case Sellers and
Buyer shall, to the extent reasonably practicable, cooperate in good faith in order to agree on the content of any such announcement prior to it being made); 

  

	 	(b)	Buyer or the Group from informing customers or suppliers of the acquisition of the Group by Buyer after Closing; or 

  

	 	(c)	Buyer from making any disclosure to any of its directors, officers, employees, agents or advisors who are required to receive such information to carry out their duties (conditional
upon any such person agreeing to keep such information confidential for so long as Buyer is obligated to do so in accordance with this clause or applicable law). 

  

	8.5	No Claims Against Directors 

  

	 	(a)	Save in case of unlawful intent and gross negligence, Buyer shall not make, and procure that the PO Companies shall not make, any claim (a) against any director or manager of
the PO Companies in connection with their acts or omissions as directors or managers of the PO Companies in the period prior to Closing; and (b), without prejudice to the Buyer’s right to bring a claim against Sellers under this Agreement,
against Sellers in connection with the Sellers’ position as direct or indirect shareholder, director or manager of any of the PO Companies. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 17 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(b)	Promptly following the Closing, Buyer shall procure that (a) shareholder’s meetings or equivalent meetings of all PO Companies are held; and (b) such meetings grant
unconditional discharge to the directors and managers of the PO Companies in connection with their acts or omissions as directors and managers of the PO Companies in the period prior to Closing in the terms set forth in Article 8.5(a).

  

	 	(c)	Save in case of unlawful intent and gross negligence, Sellers shall not make, and procure that the PO Companies shall not make, any claim against any director or manager of the PO
Companies in connection with their acts or omissions as directors or managers of the PO Companies in the period prior to Closing. 

  

	8.6	Document Retention and Access 

  

	 	(a)	Buyer shall procure that the Group preserve all books and records relating to the period prior to the Closing Date for a period of 10 (ten) years commencing on the date when the
books and records were drawn-up but no longer than 10 (ten) years from the Closing Date (or in the case of books and records relating to Tax, employment and employee matters, and matters relating to Environmental Laws for so long as required by
applicable law). 

  

	 	 (b)
	 Until the 5th (fifth) anniversary of the Closing Date, Buyer shall procure that the Group afford Sellers and their advisors reasonable access, upon prior notice during normal business hours, to the books and records of the Group and
provide copies of such information as Sellers may reasonably request in connection with any judicial, administrative, Tax, audit, or arbitration procedure involving Sellers which relate to or involve the Group or its business and affairs.

  

	8.7	Non-Competition 

  

	 	(a)	Seller *, without additional compensation, will not, for a period of * from the Closing, directly or indirectly acquire, own, participate or engage within Europe (including,
but not limited to the countries of the EU, EEC and EFTA), USA, Japan and China, in the design, development, manufacture or marketing of products competitive with those designed, developed, manufactured, marketed or under development by the Group
prior to the Closing in the field of joint replacements (such design, development, manufacture or marketing of products referred to herein as the Protected Activity). 

  

	 	(b)	Notwithstanding the foregoing, Seller *, without additional compensation, shall not be prohibited from, or restricted in: 

  

	 	(i)	continuing to be active in the Group; 

  

	 	 (ii)
	 holding or taking (whether directly or indirectly) a financial interest in securities of an entity with Protected
Activity which are held for investment purposes only, if (x) such interest amounts to less than 10% (ten percent) of the issued securities of a company which is listed on a stock exchange or less than 33 1/3% (thirty three and one third percent) of the issued securities of a privately held company; (y) such interest
carries less than 10% (ten percent) and 33 1/3% (thirty three and
one third percent) respectively, of the voting rights (if any) attaching to such securities; and (z) Seller * is not involved in the management of the issuer of the securities or of any person connected with the issuer other than by the
exercise of voting rights attaching to the securities. 

  

	 	(c)	Sellers, without additional compensation, undertake, for the benefit of Buyer and the Group, that they shall not, and that none of their Affiliates shall: 

 

	 	(i)	induce, or attempt to induce, any supplier, distributor, or customer of Group to cease to supply, distribute or purchase, or to restrict or vary the terms of supply, distribution or
purchase, to the Group, Buyer or any of their Affiliates; 

  

	 	(ii)	for a period of * after the Closing Date hire or attempt to hire any Key Person for employment with Sellers or any of their Affiliates; provided, however, that the foregoing
shall not apply (x) to responses to or follow-up hiring in respect of general solicitations or advertisements for job position not specifically directed to the Key Persons; (y) to any Key Person who is terminated by Buyer or the Group or
terminates 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 18 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
his or her employment of the Group without any solicitation from Sellers or any of their Affiliates; or (z) to hiring with prior consent of Buyer; and

  

	 	(iii)	for a period of * after the Closing Date induce, or attempt to induce, any employee of the Group to enter into employment with Sellers or any of their Affiliates; provided,
however, that the foregoing shall not apply (x) to responses to or follow up hiring in respect of general solicitations or advertisements for job positions not specifically directed to the employees; (y) to any employee who is
terminated by Buyer or the Group or terminates his or her employment with Buyer of the Group without any solicitation from Sellers or any of their Affiliates; or (z) to employment with prior written consent of Buyer. 

 

	8.8	Confidentiality 

  

	 	(a)	The confidentiality agreement executed by the Guarantor and Credit Suisse Securities (Europe) Limited in the name and on behalf of Sellers and the Group on December 14, 2006
(Confidentiality Agreement) shall remain in full force and effect until the Closing. After the Closing, Sellers and Buyer shall continue to keep confidential the contents of this Agreement and other confidential information concerning the
Group and Sellers and shall not inform any third party about its content unless required to do so by law or regulation or mutually agreed upon by Sellers and Buyer. It is understood and agreed that neither the Confidentiality Agreement nor the
foregoing confidentiality undertaking shall (i) restrict the Buyer to provide information to providers of financing for the purpose of financing the transactions contemplated by this Agreement, (ii) restrict Buyer or Sellers from
disclosing this Agreement or details on the transactions contemplated hereby for the purposes of procuring the satisfaction of the conditions precedent to Closing, (iii) restrict Buyer or Sellers from pursuing its rights and exercising its
remedies under this Agreement, or (iv) restrict Buyer and the Group in the conduct of the business of the Group. 

  

	 	(b)	If, after the Closing, a Party is required by applicable law, governmental or other regulation (including stock exchange regulations) or by court decision or governmental order to
make a disclosure, it shall inform, to the extent reasonably practicable, the other Parties that such disclosure is required, and the Parties shall use their reasonable efforts to agree in good faith on the content of such disclosure prior to it
being made. 

  

	 	(c)	Sellers shall keep and shall procure that their Affiliates, directors, employees and advisors shall keep all confidential information in respect of the Group in confidence, and
further undertake not to disclose any such information to third parties, and shall not use for their own or any other person’s benefit or to the detriment of Buyer, its Affiliates or the Group any confidential information, except as may be
required by law or applicable regulations and save to the extent that such confidential information comes into the public domain other than by a breach of this Article. 

  

	 	(d)	In the event the transactions contemplated by this Agreement are not consummated, upon the request of one Party, each Party hereto will, and will cause its Affiliates and their
respective directors, employees and advisors to, promptly (and in no event later than 5 (five) Business Days after such request) return or cause to be returned all documents and information, including, but not limited to the Disclosure Information
furnished by the other Parties in connection with this Agreement or the transactions contemplated hereby, except for 1 (one) copy that may be retained by each advisor to either Party for the files which they are required to keep in their capacity as
professional advisors and which shall be kept confidential. 

  

	8.9	Further Assurance 

  
 Sellers and Buyer shall perform (or procure the performance of) all further acts and things and execute and deliver (or procure the execution and delivery
of) such further documents as may be required by law or as may be necessary or reasonably required by Buyer to implement and give effect to this Agreement. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 19 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	9.	Taxes, Costs, Expenses and Interest 

  

	9.1	Taxes 

  
 Except as otherwise provided for in this Agreement, each of Sellers and Buyer shall bear all Taxes incurred by or levied on it in connection with the
transactions contemplated under this Agreement. 
  

	9.2	Costs and Expenses 

  
 Except as expressly provided otherwise herein, each Party shall bear its own costs and expenses (including advisory fees like, in Sellers’ case, the
fees of Homburger and Credit Suisse) incurred in the negotiation, preparation and completion of this Agreement. 
  

	9.3	Interest 

  
 If a Party defaults in the payment when due of any sum payable under this Agreement (howsoever determined), the liability of such Party shall be increased
to include interest on that sum from the date when the payment is due until the date of actual payment (as well after as before judgment) at a rate of 3 (three) months CHF-LIBOR (as per Financial Times page «Money Rates» as at the date
the payment is due) plus * basis points per annum. 
  

	10.	General Provisions 

  

	10.1	Effect on Third Parties 

  
 Except with respect to the PO Companies pursuant to Article 8.3 and the directors and managers of the PO Companies pursuant to Article 8.5, no
person other than the Parties shall have any rights or benefits under this Agreement, and nothing in this Agreement is intended to confer on any person other than the Parties any rights, benefits or remedies. 
  

	10.2	Notices 

  
 All notices or other communications to be given under or in connection with the Agreement shall be made in writing and shall be delivered by personal
deliveries, by registered mail (return receipt requested), by an internationally recognized courier, such as Federal Express, DHL or UPS, or by telefax to the following addresses: 
  

			
	if to Sellers:	  	 Dr. Heinz Schärer
 Homburger
 Weinbergstrasse 56|58
 8006 Zürich, Switzerland
 fax: +41 43 222 15 00

			
		
	if to Buyer:	  	 Smith & Nephew International B.V.
 c/o Smith &
Nephew plc
 15 Adam Street
 London WC2N 6LA
 Attention: Company Secretary
 Fax: +44 207 960 2357

		
	 If to Guarantor:
	  	 Smith & Nephew plc
 15 Adam Street
 London WC2N 6LA
 Attention: Company Secretary
 Fax: +44 207 960 2357

		
	 with a copy to
	  	 Freshfields Bruckhaus Deringer
 65 Fleet Street
 London
 EC4Y 1HS
 United Kingdom
 Attention: Ben Spiers
 Fax: + 44 20 7108 7155

  
 or such other address
as any of the Parties may notify to the other Parties in accordance with the above. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 20 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Any notice to be given hereunder shall be given prior to the expiry of a term
or deadline (if any) set forth in this Agreement or by applicable law. All notices, communications, documents or other information shall be effective only if received by the Party to whom it is addressed irrespective of whether received prior to or
after the expiry of such term or deadline (provided that the notice was timely and duly given in accordance with this Article 10.2). 
  

	10.3	Entire Agreement 

  
 Subject to the Confidentiality Agreement which shall survive as stated in Article 8.8(a), this Agreement, including the Annexes and any other
documents referred to herein, constitutes the entire agreement and understanding among the Parties with respect to the subject matter hereof, and shall supersede all prior oral and written agreements or understandings of the Parties relating hereto.
All references to this Agreement shall be deemed to include the Annexes hereto. 
  

	10.4	Amendments and Waivers 

  
 This Agreement may only be modified or amended by a document signed by all Parties. Any provision contained in this Agreement may only be waived by a
document signed by the Party waiving such provision. Subject to Article 10.8 a waiver by any of the Sellers is effective only with respect to the specific Seller having signed such waiver. 
  

	10.5	No Assignment 

  

	 	(a)	Except as provided below the Parties shall not assign this Agreement or any rights or obligations hereunder, including, but not limited to, by way of a business transfer
(Vermögensübertragung) or demerger (Abspaltung), to any third party without the prior written consent of Sellers (if the assignment is proposed to be undertaken by Buyer) or Buyer (if the assignment is proposed to be
undertaken by Sellers). 

  

	 	(b)	Buyer may assign this Agreement in whole or in part to an Affiliate (the Permitted Assignee), provided that Sellers’ liability shall not be increased by such an
assignment. Following such assignment this Agreement may be enforced by such Permitted Assignee as if it were the Buyer under this Agreement. Any Permitted Assignee to whom an assignment is made in accordance with this Article 10.5 may itself
make an assignment as if it were the Buyer under this Article 10.5. 

  

	10.6	Severability; Good Faith 

  

	 	(a)	Should any part or provision of this Agreement be held to be invalid or unenforceable by any competent arbitral tribunal, court, governmental or administrative authority having
jurisdiction, the other provisions of this Agreement shall nonetheless remain valid. In this case, the Parties shall endeavor to negotiate a substitute provision that best reflects the economic intentions of the Parties without being unenforceable,
and shall execute all agreements and documents required in this connection. 

  

	 	(b)	If a Party to this Agreement (the Failing Party) should fail to take any action to be taken or to deliver any document to be delivered as of a specified date, the other Party
shall not resort to any contractual remedies under this Agreement if such failure is promptly and fully cured in good faith by the Failing Party. 

  

	10.7	Relationship Between Sellers and Buyer 

  
 Each Seller shall severally, and not jointly with the other Sellers, be liable for all obligations under this Agreement. Subject to the limitations set
forth in Article 6.1.4, each Seller shall be liable under this Agreement as against Buyer in proportion to its shareholding in the Company as set forth in Annex 2.1(a)(i). For the avoidance of doubt, no Seller shall become liable
for claims for specific performance or for Damage with respect to Shares held by another Seller or for misrepresentation or breach of warranty set forth in paragraphs 1(a) and 2 of Annex 5.1 by another Seller. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 21 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	10.8	Representative of Sellers 

  
 Each of Sellers hereby empowers Dr. Heinz Schärer as his|its authorised representative and general attorney in fact under this Agreement with
the right of substitution. This power of attorney includes in particular the exercise of any rights, the giving and receiving of notices and the making or receiving of any other form of statement or communication on behalf of Sellers under this
Agreement. The power of attorney is deemed to be in force as long as it has not been revoked or substituted by a notice according to Article 10.2. 
  

	10.9	Guarantee 

  
 Guarantor guarantees all the obligations of Buyer under this Agreement as Guarantor pursuant to Article 111 CO. 
  

	11.	Governing Law and Arbitration 

  

	11.1	Governing Law 

  
 This Agreement shall be governed by and construed in accordance with the substantive laws of Switzerland. 
  

	11.2	Arbitration 

  
 Any dispute, controversy or claim arising out of, or in relation to, this Agreement, including the validity, invalidity, breach or termination thereof,
shall be resolved, to the exclusion of the ordinary courts, by a three-person arbitral tribunal in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers of Commerce in force on the date on which Notice of Arbitration is
submitted in accordance with such rules, with claimant or group of claimants on the one hand and respondent or group of respondents on the other hand each appointing one arbitrator and the two arbitrators thus appointed designating the third
arbitrator who shall be the chairperson of the arbitral tribunal. The appointing authority shall be the Zurich Chamber of Commerce. The proceedings shall be conducted and any award shall be rendered in English. The seat of arbitration shall be
Zurich, Switzerland. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 22 | 100 

 Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Sellers: 
  

					
	  Hyos Invest Holding AG	 	 	 	 
			
	  

	 	 	 	 
	  By:  Carolina Müller-Möhl	 	 	 	 
			
	  Dr. Ulrich Sigg	 	 	 	 
	  

	 	 	 	 
			
	  Dr. Robert Riedweg	 	 	 	 
			
	  

	 	 	 	 
			
	  Active Investor AG	 	 	 	 
			
	  

	 	 	 	

	  By:  Michael Theurillat	 	 	 	By:  Martin Staub

  

			
	Buyer:	 	 
		
	Smith & Nephew International B.V.	 	 
		
	  

	 	 
	By:	 	 
		
	Guarantor:	 	 
		
	Smith & Nephew plc	 	 
		
	  

	 	 
	By:	 	 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 23 | 100 

 Annex B to the Share and Loan Purchase Agreement regarding Plus Orthopedics Holding AG 
  
  
 Annex B: 
  
 Structure of the Group 
  

							
	 Plus Orthopedics Holding AG

			
	 %

	  	 Company

	  	 Capital Structure

			
	 100%
	  	 Plus Orthopedics AG
 (Rotkreuz, Switzerland)
	  	 •        share capital: CHF 6,000,000
 •        6,000 registered shares with a nominal value of CHF 1,000
each

			
	 49%
	  	 Intraplant GmbH (Mödling, Austria)
	  	 •        capital: EUR 36,000

			
	 90%
	  	 Plus Orthopedics S.r.l. (Agregate Brianza, Italy)
	  	 •        capital: EUR 2,777,750
 •        EUR 2,777,750 quotas with a nominal value of EUR 1

				
	 	  	 100%
	  	 Xmedica S.r.l. (Milan, Italy)                    
	  	 •        capital: EUR 51,000
 •        51,000 quotas with a nominal value of EUR 1

			
	 100%
	  	 Plus Orthopedics (UK) Limited (Swindon, UK)
	  	 •        share capital: GBP 1,000,100
 •        1,000,100 registered shares with a nominal value of GBP
1

			
	 49%
	  	 Plus Orthopedics GmbH (Mödling, Austria)
	  	 •        capital: EUR 36,400

			
	 100%
	  	 Plus Orthopedics France S.A.R.L. (Courbevoie, France)
	  	 •        capital EUR 2,000,035
 •        43,244 quotas with a nominal value of EUR 46,25

			
	 100%
	  	 Ortho-I.D. S.A.S. (Bron, France)
	  	 •        share capital: EUR 64,000
 •        4,000 registered shares with a nominal value of EUR 16

			
	 51%
	  	 Plus Orthopedics B.V. (Zoetermeer, Netherlands)
	  	 •        paid-in capital: NLG 150,000 (EUR 68,067.03)
 •        1,500 equity shares with a nominal value of NLG 100

			
	 95.52%1
	  	 Plus Orthopedics GmbH (Marl, Germany)
	  	 •        capital: EUR 785,310

				
	 	  	 80%
	  	Endocare Produktions- und Vertriebsges. mbH (Rudolstadt, Germany)	  	 •        capital: EUR 200,000

				
	 	  	 20%
	  	 Intercus GmbH (Rudolstadt, Germany)
	  	 •        capital: EUR 25,000

				
	 	  	 95.24%2
	  	 Endoplant GmbH (Marl, Germany)
	  	 •        capital: EUR 126,000

	 1
	 not taking into account 11,900 treasury shares held by Plus Orthopedics GmbH (Germany)

	 2
	 2.86% held by Plus Orthopedics
Holding AG 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 24 | 100 

 Annex B to the Share and Loan Purchase Agreement regarding Plus Orthopedics Holding AG 
  

									
	%

	  	 Company

	  	 Capital Structure

	100%	  	 Plus Orthopedics España SA
 (Madrid, Spain)
	  	 •        share capital: EUR 450,000
 •        20,000 registered shares with a nominal value of EUR
22.50

			
	100%	  	 Plus Orthopedics, Inc.
 (San Diego, USA)
	  	 •        share capital: USD 4,000,000
 •        4,000,000 registered shares with a nominal value of
USD 1

			
	100%	  	 Plus Orthopedics Schweiz AG (Rotkreuz, Switzerland)
	  	 •        share capital: CHF 100,000
 •        100 registered shares with a nominal value of CHF
1,000

			
	90%	  	 Plus Orthopedics Hellas S.A. (Helioupolis,
Hellas|Greece)
	  	 •        share capital: EUR 1,394,125
 •        47,500 registered shares with a nominal value of EUR 29.35
 •        no share certificates issued

			
	100%	  	 Plus Orthopedics K.K. (Tokyo, Japan)
	  	 •        share capital: JPY 350,000,000
 •        7,000 registered shares with a nominal value of JPY 50,000
each.

			
	100%	  	 Plus Orthopedics (Beijing) Co.,
Ltd.                
 (Beijing,
China)
	  	 •        share capital: USD 3,400,000

			
	100%	  	 Endoplant AG
 (Rotkreuz, Switzerland)
	  	 •        share capital: CHF 100,000
 •        100 registered shares with a nominal value of CHF
1,000

				
	 	  	 90%
	  	 LifeTek LLC
 (Gainesville, Florida, USA)
	  	 •        capital contributions: USD 8,025

					
	 	  	 	  	 97.4%
	  	 Biograft de Mexico SA de CV
 (Distritto Federal, Mexico)
	  	 •        share capital: MXN: 250,000
 •        5,000 registered shares with a nominal value of MXN 50

			
	100%	  	 Plus Orthopedics Belgium SPRL
 (Nivelles, Belgium)
	  	 •        share capital: EUR 150,000
 •        300 shares (“sans valeur minimale”)

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 25 | 100 

 Annex 1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 1 
  
 Definitions 
  
 As used in this Agreement in capitalized form, the following terms shall
have the following meaning: 
  
 Adjustment Date shall mean
the Closing Date or, if the Closing Date does not occur on the last day of a month, then the Adjustment Date shall mean the last day of the month ending before the Closing Date. 
  
 Affiliate shall mean a physical person or legal entity which exercises control over a second person or legal entity,
or is under control by it, or is under common control by the same person or legal entity. 
  
 For purposes of this definition, “control” shall be deemed to exist if a person or legal entity (either alone or with its Affiliates) owns more than half of the voting rights of a legal entity, or is
otherwise able to exercise a controlling influence over another person or legal entity. 
  
 Agreement shall mean this Share Purchase Agreement including all of its Annexes and related documents. 
  
 Appraiser shall have the meaning set forth in Section (a) of Annex 2.3(b). 
  
 Benefit Plans shall have the meaning set forth in paragraph 19
of Annex 5.1. 
  
 Business Day shall mean any
day on which the commercial banks in Zurich, Zug, New York and London are open for normal business transactions. 
  
 Buyer shall mean the legal entity defined as Buyer on the cover page to this Agreement. 
  
 Cap shall have the meaning set forth in Article 6.1.4(b).

  
 CHF shall mean Swiss Francs, being the lawful currency
of Switzerland. 
  
 Closing shall mean the consummation of
the transactions as described in Article 4.3. 
  
 Closing
Date shall mean the date on which the Closing actually occurs, as provided for in Article 4.1. 
  
 CO shall mean the Swiss Code of Obligations (OR). 
  

Company shall have the meaning set forth in Recital A. 
  
 Confidentiality Agreement shall have the meaning set forth in Article 8.8(a). 
  
 Consolidated Financial Statements shall mean the consolidated
financial statements of the Group as at December 31, 2006 attached hereto as Annex 5.1.3. 
  
 Damage shall have the meaning set forth in Article 6.1.1(b). 
  
 Data Room Escrow Agent shall mean Dr. * and Dr. *. 
  
 Data Room Indices shall have the meaning set forth in Article 6.1.4(d)(ii). 
  
 Disclosure Letter shall mean the letter delivered by the Sellers to
Buyer at the signing of this Agreement relating to the representations and warranties given by Sellers in Annex 5.1. 
  
 Disclosure Information shall have the meaning set forth in Article 6.1.4(d). 
  
 Environmental Laws shall have the meaning set forth in paragraph 17 of Annex 5.1. 
  
 Escrow Account shall have the meaning as set forth in Article 2.5(a).

  
 Escrow Agent shall mean Credit Suisse Solution
Partners AG, Talacker 16, 8001 Zurich, Switzerland. 
  
 Escrow
Agreement shall have the meaning as set forth in Article 2.5(b). 
  
 Estimated Net Debt shall have the meaning set forth in Article 3.6. 
  
 Estimated Net Working Capital shall have the meaning set forth in Article 3.6. 
  
 Failing Party shall have the meaning set forth in Article 10.6. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 26 | 100 

 Annex 1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Fairly Disclosed shall mean a disclosure of a fact in a manner which
allowed Buyer and its advisers to fairly and reasonably identify and assess the impact of such fact on the business operations and prospects of the Group. The concept of Fair Disclosure as defined herein shall supersede article 200 CO.

  
 Final Adjustment shall mean the Net Debt Adjustment
and Net Working Capital Adjustment becoming final and binding on Sellers and Buyer pursuant to Article 2.3. 
  
 Final Closing Accounts shall mean the consolidated financial balance sheet of the Group (supported by the consolidated financial statements
produced in accordance with Article 2.3) as at the Adjustment Date becoming final and binding on Sellers and Buyer pursuant to Article 2.3. 
  
 Guarantor shall mean the legal entity defined as Guarantor on the cover page to this Agreement. 
  
 Group shall have the meaning as set forth in Recital B. 

 
 IFRS shall mean the International Financial Reporting Standards as
promulgated by the International Accounting Standards Board. 
  
 Initial Escrow Amount shall have the meaning set forth in Article 2.5(a). 
  
 Intellectual Property Rights shall have the meaning set forth in paragraph 8 of Annex 5.1. 
  
 Key Persons shall mean any of * and the members of the Board of Directors of the Company in office at the date of this Agreement. 
  
 Lien shall mean any lien, charge, encumbrance, security interest
including but not limited to interests arising from options, pledges, mortgages, indentures, security agreements, rights of first refusal or rights of preemption, irrespective of whether such Lien arises under any agreement, covenant, other
instrument, the mere operation of statutory or other laws or by means of a judgment, order or decree of any court, judicial or administrative authority, and shall also mean any approval or consent required from a third party to the exercise or full
vesting of a right or title. 
  
 Litigation shall have the
meaning set forth in paragraph 13 of Annex 5.1. 
  
 Long Stop Date shall have the meaning set forth in Article 4.1. 
  
 Material Adverse Effect shall have occurred where after the date of this Agreement a change in the assets, liabilities or financial position of the Group taken as a whole has occurred which fundamentally and
sustainably adversely impairs the value of the Group as a whole, and which was not already known and was and could not reasonably be expected to have been taken into account by Sellers and Buyer at the date of this Agreement. 
  
 Material Contract shall have the meaning set forth in
paragraph 11 of Annex 5.1. 
  
 Merger
Control Laws shall mean the laws applicable on Buyer or Sellers relating to the consummation of the transactions set forth in Annex 4.2.1(a). 
  

Net Debt shall mean the aggregate of the financial assets and financial liabilities line items set forth in Annex 2.4 
  
 Net Debt Adjustment shall mean the adjustment to reflect the
difference between the Estimated Net Debt and the Net Debt as at the Adjustment Date as determined on the basis of the Final Closing Accounts, all as set forth in Article 2.4 and Annex 2.4. 
  
 Net Working Capital shall mean the aggregate of the current assets
and current liabilities line items set forth in Annex 2.4. 
  
 Net Working Capital Adjustment shall mean the adjustment to reflect the difference between the Estimated Net Working Capital and the Net Working Capital as at the Adjustment Date as determined on the basis of the Final Closing
Accounts, all as set forth in Article 2.4 and Annex 2.4. 
  
 Notice of Breach shall have the meaning set forth in Article 6.1.2(a). 
  
 Notice of Objection shall have the meaning set forth in Article 2.3(b). 
  
 Party(ies) shall mean Sellers and|or Buyer and|or the Guarantor, as the context may require. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 27 | 100 

 Annex 1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Permitted Assignee shall have the meaning set forth in
Article 10.5. 
  
 Permits shall mean governmental and
administrative licenses and permits that are necessary for the carrying out of the business and operations of the Group. 
  
 PO Company(ies) shall have the meaning set forth in Recital B. 
  
 Policies shall have the meaning set forth in paragraph 12 of Annex 5.1. 
  
 Preliminary Purchase Price shall have the meaning set forth in
Article 2.2.1. 
  
 Proposed Adjustment shall have the
meaning set forth in Article 2.3(a). 
  
 Proposed Closing
Accounts shall have the meaning set forth in Article 2.3(a). 
  
 Protected Activity shall have the meaning set forth in Article 8.7(a). 
  
 Purchase Price shall have the meaning set forth in Article 2.2.1. 
  
 Qualifying Claim shall have the meaning set forth in Article 6.1.4(a). 
  
 Repealed Notice(s) shall have the meaning set forth in Article 2.5(d). 
  
 Sellers shall mean the legal entities and persons defined as Sellers
on the cover page to this Agreement. 
  
 Shareholder Loans
shall mean the loans from the Sellers to the Company as set forth in Annex 2.1(a)(ii), including all accrued interest thereon in accordance with the interest rate set forth in that Annex up to the Closing Date. 
  
 Shares shall have the meaning set forth in Recital A.

  
 Tax or Taxes includes, without limitation,
(a) taxes on gross or net income, profits and gains, and (b) all other taxes, levies, duties, imposts, charges and withholdings of any nature, including any excise, property, value added, sales, use, occupation, transfer, franchise and
payroll taxes and any national insurance or social security contributions, and any payment whatsoever which the relevant person may be or become bound to make to any person as a result of the discharge by that person of any tax which the relevant
person has failed to discharge, together with all penalties, charges and interest relating to any of the foregoing or to any late or incorrect return in respect of any of them, in each case payable in any jurisdiction whatsoever and regardless of
whether such taxes, levies, duties, imposts, charges, withholdings, penalties and interest are chargeable directly or primarily against or attributable directly or primarily to the relevant person or any other person and of whether any amount in
respect of them is recoverable from any other person. 
  
 Tax
Authority means any taxing or other authority in any jurisdiction whatsoever competent to impose any tax liability, or assess or collect any tax. 
  
 Threshold shall have the meaning set forth in Article 6.1.4(a). 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 28 | 100 

 Annex 2.1(a)(i) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.1(a)(i) 
  
 Shares owned by Sellers 
  

					
	 Legal Owner of Shares

	  	No. of Shares

	  	  in %  

	 Hyos Invest Holding AG
	  	*	  	*
	 Dr. Ulrich Sigg
	  	*	  	*
	 Dr. Robert Riedweg
	  	*	  	*
	 Active Investor AG
	  	    *	  	    *
	 	  	
	  	

	 Total
	  	*	  	*
	 	  	
	  	

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 29 | 100 

 Annex 2.1(a)(ii) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.1(a)(ii) 
  
 Shareholder Loans 
  
 Amount of Shareholder Loans as at December 31, 2006 
  

					
	 Lender

	  	 Borrower

	  	Amount

	 Hyos Invest Holding AG
	  	Plus Orthopedics Holding AG	  	*
			
	 Dr. Ulrich Sigg
	  	Plus Orthopedics Holding AG	  	*
			
	 Dr. Robert Riedweg
 (including loan granted by Neovation AG)
	  	Plus Orthopedics Holding AG	  	    *
			
	 Active Investor AG
	  	Plus Orthopedics Holding AG	  	*
	 	  	 	  	

	 Total
	  	 	  	*
	 	  	 	  	

  
 The interest rate for
each of the Shareholder Loans corresponds to the interest rate as published each calendar year by the Federal Tax Administration for related party loans (Zinssätze für die Berechnung der geldwerten Leistungen), i.e., for the
calendar year 2007 4.50 % per annum. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 30 | 100 

 Annex 2.2.1(a) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.2.1(a) 
  
 Computation of Fixed Amount 
  

					
	 	  	Enterprise Value	  	*
	 minus
	  	 	  	 
	 	  	Ortho ID Deferred Payment	  	*
	 minus
	  	 	  	 
	 	  	Projected Net Working Capital	  	*
	 minus
	  	 	  	 
	 	  	Value for Minority Interests	  	*
	 minus
	  	 	  	 
	 	  	Pension Liabilities	  	*
	 equals
	  	 	  	 
	 	  	Fixed Amount	  	939,445,000

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 31 | 100 

 Annex 2.3(a) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.3(a) 
  
 Proposed Closing Accounts and Final Closing Accounts 
  

	 	1.	The Proposed Closing Accounts and the Final Closing Accounts shall be drawn up: 

  

	 	(a)	in accordance with this Annex; and 

  

	 	(b)	so far as not inconsistent therewith, in accordance with IFRS, as such Standards are applied pursuant to the Plus Orthopedics IFRS Accounting Manual Version 2.0 |
October 2005 as disclosed in the Disclosure Information, applied on a consistent basis, in the same format as the Consolidated Financial Statements. 

  

	 	2.	The Proposed Closing Accounts and the Final Closing Accounts shall be drawn up as per the Adjustment Date. 

  

	 	3.	The Proposed Closing Accounts and the Final Closing Accounts shall be expressed in CHF and amounts in other currencies shall be translated into CHF at the exchange rates prevailing
on the close on the Adjustment Date, or, if the Adjustment Date is not a Business Day, on the last Business Day before the Adjustment Date. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 32 | 100 

 Annex 2.3(b) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.3(b) 
  
 Dispute Resolution Regarding Proposed Closing Accounts 
  

	 	(a)	Sellers and Buyer shall endeavor in good faith to resolve any objection of Buyer within 20 (twenty) Business Days after Sellers’ receipt of Buyer’s Notice of Objection. If
Sellers and Buyer are unable to do so, either Sellers or Buyer may submit such disagreement for final and binding resolution to Deloitte AG, who shall select an experienced partner of its accounting department, or, if Deloitte AG is for any reason
whatsoever not in a position to act, to an experienced partner of the accounting department of another internationally recognized accounting firm domiciled in Switzerland (other than PricewaterhouseCoopers and Ernst & Young) agreed upon by
Sellers and Buyer, or, if such agreement has not occurred within further 10 (ten) Business Days, to the person nominated by the ICC International Center for Expertise of the International Chamber of Commerce (ICC) in accordance with the
provisions regarding the appointment of experts contained in the ICC’s Rules of Expertise upon application of either Sellers or Buyer (each of Deloitte AG or the person agreed upon by Sellers and Buyer or nominated by the ICC International
Center for Expertise in accordance with this paragraph hereinafter an Appraiser). 

  

	 	(b)	If the Sellers, Buyer and the Appraiser, within 10 (ten) Business Days after referral of their disagreement or his or her nomination by the ICC, cannot reach an agreement on the
terms of engagement of the Appraiser, either Sellers or Buyer may submit such matter to the International Center for Expertise of the ICC for final resolution in accordance with the provisions regarding the administration of expert proceedings
contained in the ICC’s Rules of Expertise. 

  

	 	(c)	The Appraiser shall establish independently, on the terms set forth in Articles 2.3(a), 2.4.1 and 2.4.2 and Annex 2.3(a) and Annex 2.4, the Final
Closing Accounts and the Final Adjustment. In so doing, the Appraiser shall act as an expert, and not as an arbitrator, and his determination of any subject matter falling within the scope of his mandate shall be final and binding on the Sellers and
Buyer, except in the event of manifest error on the part of the Appraiser (when the relevant part of its determination shall be void and the matter be remitted to the Appraiser for correction). 

  

	 	(d)	Sellers and Buyer shall procure that the Appraiser will be furnished with all documents and information relating to the establishment of the Final Closing Accounts and the Final
Adjustment as the Appraiser may request. Except to the extent that Sellers and Buyer agree otherwise, the Appraiser shall determine his own procedure but: 

  

	 	(i)	apart from procedural matters and as otherwise set forth in this Agreement shall determine only: 

  

	 	(1)	whether the specific items of the Proposed Closing Accounts which are disputed by Buyer in Buyer’ Notice of Objection are correct and in accordance with Article 2.3(a) and
Annex 2.3(a); and if not so, what alterations should be made to the Proposed Closing Accounts in order to correct the relevant inaccuracy of such specific items; and 

  

	 	(2)	based on the Final Closing Accounts established by the Appraiser, the Final Adjustment in accordance with Articles 2.4.1 and 2.4.2 and Annex 2.4;

  

	 	(ii)	shall make his determination pursuant to Section (d)(i) of this Annex 2.3(b) as soon as is reasonably practicable but not later than 45 (forty five) Business Days
from the date of his appointment; 

  

	 	(iii)	the procedure of the Appraiser shall comply with the principles of due process and shall in particular: 

  

	 	(1)	give the Sellers and Buyer a reasonable opportunity to make written and oral representations to him; 

  

	 	(2)	require that Sellers supply Buyer and Buyer supplies Sellers with a copy of any written representations at the same time as they are made to the Appraiser; 

 

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 33 | 100 

 Annex 2.3(b) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	(3)	permit Sellers and Buyer to be present while oral submissions are being made by either Buyer or Sellers respectively; and 

  

	 	(4)	be conducted in English. 

  

	 	(e)	Sellers, Buyer and the Appraiser shall, and shall procure that its accountants, assistants and other advisors shall, keep all information and documents provided to them pursuant to
this Annex 2.3(b) confidential and shall not use the same for any purpose, except for disclosure or use in connection with the preparation of the Final Closing Accounts, the proceedings before the Appraiser or otherwise in connection
with the determination of the Final Adjustment. 

  

	 	(f)	The costs and expenses (including VAT) of the Appraiser shall be allocated between Sellers and Buyer in proportion to Sellers’ or Buyer’s relative success or defeat in the
proceedings before the Appraiser (measured against Sellers’ and Buyer’s position in their initial submissions to the Appraiser). 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 34 | 100 

 Annex 2.4 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.4 
  
 Calculation of Net Debt and Net Working Capital 
  

	1.	Net Debt 

  
 The Net Debt shall be calculated by reference to the aggregate of the following financial assets and financial liabilities line items shown on the Final
Closing Accounts established in accordance with the Agreement: 
  

							
	 	  	Account-No.

	  	 Account Name

	  	Net Debt as of
Dec. 31, 2006*
(TCHF)

	 	  	200900	  	Bank overdrafts and current debt	  	*
	 plus
	  	 	  	 	  	 
	 	  	260010	  	Non-current bank loans	  	*
	 plus
	  	 	  	 	  	 
	 	  	260023	  	Loans from related parties (shareholders)	  	*
	 plus
	  	 	  	 	  	 
	 	  	260021	  	Loans from third parties	  	*
	 plus
	  	 	  	 	  	 
	 	  	232900	  	Current leasing liabilities	  	*
	 plus
	  	 	  	 	  	 
	 	  	200950	  	Financial Liabilities	  	*
	 plus
	  	 	  	 	  	 
	 	  	250900	  	Non-current leasing liabilities	  	*
	 less
	  	 	  	 	  	 
	 	  	100900	  	Cash and cash equivalents	  	*
	 less
	  	 	  	 	  	 
	 	  	110900	  	Financial assets	  	*
	 	  	 	  	 	  	

	 equals
	  	 	  	Net Debt	  	185,852
	 	  	 	  	 	  	

	*	Draft YE2006 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 35 | 100 

 Annex 2.4 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	2.	Net Working Capital 

  
 Net Working Capital shall be calculated by reference to the aggregate of the following current assets and current liabilities line items shown in the
Final Closing Accounts established in accordance with the Agreement: 
  

							
	 	  	Account No.

	  	 Account Name

	  	Amount as of
Dec. 31, 2006*
(TCHF)

	 	  	120900	  	Trade accounts receivable	  	*
	 plus
	  	 	  	 	  	 
	 	  	130900	  	Inventories	  	*
	 plus
	  	 	  	 	  	 
	 	  	150900	  	Other current assets	  	*
	 plus
	  	 	  	 	  	 
	 	  	159590	  	Current income tax receivables	  	*
	 plus
	  	 	  	 	  	 
	 	  	180010	  	Non current receivables	  	*
	 less
	  	 	  	 	  	 
	 	  	210900	  	Trade payables	  	*
	 less
	  	 	  	 	  	 
	 	  	230900	  	Other liabilities and accruals	  	*
	 less
	  	 	  	 	  	 
	 	  	231900	  	Current income tax liabilities	  	*
	 less
	  	 	  	 	  	 
	 	  	233900	  	Current provisions	  	*
	 	  	 	  	 	  	

	 equals
	  	 	  	Net Working Capital	  	*
	 	  	 	  	 	  	

	*	Draft FY2006 

  
 Notes: 
  

	(1)	The calculation of the Net Working Capital as at the Adjustment Date shall exclude items which are a direct consequence of the transactions contemplated by this Agreement,
including, without limitation, provisions or liabilities for Taxes arising as a result of the Closing. 

  

	(2)	The Net Working Capital shall be calculated so as to avoid double counting with Net Debt and, for the avoidance of doubt, any adjustments made to the Proposed Closing Accounts in
arriving at the Final Closing Accounts shall be applied in a mutually consistent manner in the calculation of Net Debt and Net Working Capital. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 36 | 100 

 Annex 2.5 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 2.5 
  
 Escrow Agreement 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 37 | 100 

 Annex 2.5 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Execution Copy 
  
 Escrow Agreement 
  
 dated as of March 12, 2007 
  
 by and between 
  

	1.	Hyos Invest Holding AG, Weinplatz 10, 8022 Zürich, Switzerland (Seller 1) 

  

	2.	Dr. Ulrich Sigg, * Switzerland (Seller 2) 

  

	3.	Dr. Robert Riedweg, * Switzerland (Seller 3) 

  

	4.	Active Investor AG, Zugerstrasse 76B, 6340 Baar, Switzerland (Seller 4) 

  
 (hereinafter each a Seller, and, collectively, Sellers) 
  
 and 
  
 Smith & Nephew International B.V., Kruisweg 637, 2132 NB Hoofddorp, The Netherlands 
  
 (hereinafter Buyer) 
  
 and 
  
 Credit Suisse Solution Partners AG, Talacker 16,
CH-8001 Zurich, Switzerland 
  
 (hereinafter Escrow Agent)

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 38 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Contents 
  

							
	 1.
	  	Definitions	  	41
			
	 2.
	  	Appointment of the Escrow Agent	  	42
			
	 3.
	  	Deposit Into Escrow	  	42
	 	  	3.1	  	Opening of the Escrow Account	  	42
	 	  	3.2	  	Transfer of Initial Escrow Amount to the Escrow Account	  	42
	 	  	3.3	  	Management of the Escrow Amount	  	42
	 	  	3.4	  	Investment of the Escrow Amount	  	42
	 	  	3.5	  	Instructions Given to the Escrow Agent	  	43
	 	  	3.6	  	Acknowledgement With Respect to Lien, Retention Right or Other Charge Relating to the Escrow Account	  	43
			
	 4.
	  	Fees of the Escrow Agent	  	43
			
	 5.
	  	Release of Escrow Amount	  	43
	 	  	5.1	  	General remarks	  	43
	 	  	5.2	  	Release Based on Joint or Corresponding Instructions	  	44
	 	  	5.3	  	According to an Arbitral Award or Court Decision	  	44
	 	  	5.4	  	Payment	  	44
			
	 6.
	  	Indemnity	  	44
			
	 7.
	  	Limitations	  	44
	 	  	7.1	  	Measures Taken by a Court of Authority	  	44
	 	  	7.2	  	Acting of Escrow Agent	  	44
			
	 8.
	  	Warranties	  	45
			
	 9.
	  	General Provisions	  	45
	 	  	9.1	  	Notices	  	45
	 	  	9.2	  	Signatures	  	46
	 	  	9.3	  	General Conditions and Safe Custody Regulations of Escrow Agent	  	46
	 	  	9.4	  	Entire Agreement	  	46
	 	  	9.5	  	Severability	  	46
	 	  	9.6	  	Assignment	  	46
	 	  	9.7	  	Costs and Expenses; Taxes	  	46
	 	  	9.8	  	Entry Into Force	  	46
	 	  	9.9	  	Amendments and Waivers	  	46
	 	  	9.10	  	Representative of Sellers	  	46
			
	 10.
	  	Termination	  	47
	 	  	10.1	  	In General	  	47
	 	  	10.2	  	Termination by the Principals	  	47
	 	  	10.3	  	Termination by the Escrow Agent	  	47
			
	 11.
	  	Governing law and Jurisdiction	  	47
	 	  	11.1	  	Governing law	  	47
	 	  	11.2	  	Jurisdiction	  	47

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 39 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Schedules 
  

			
	Number of Schedule	  	Description
		
	Schedule A	  	SPA
		
	Schedule B	  	Authorization of Fiduciary Deposits
		
	Schedule C	  	List of Signatories
		
	Schedule D	  	General Conditions and Safe Custody Regulations

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 40 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 This escrow agreement (the Escrow Agreement) is made as of
[month] [day], 2007 by and among the Sellers of the shares in Plus Orthopedics Holding AG, a corporation organized under the laws of Switzerland, with its registered office at Erlenstrasse 4, CH-6343
Rotkreuz (the Company), the Buyer and Credit Suisse Solution Partners AG as escrow agent (the Escrow Agent); Sellers and Buyer hereinafter jointly referred to as the Principals, and together with the Escrow Agent, the
Parties and, individually, a Party. 
  
 Whereas 

 

	A.	Principals have executed a share purchase agreement dated March, 12, 2007 as attached hereto in Schedule A (SPA) regarding the purchase and sale of all the shares in
the Company (the Shares); 

  

	B.	Principals have agreed under the SPA to enter into this Escrow Agreement and to deposit with the Escrow Agent a portion of the Preliminary Purchase Price to be paid for the Shares
under the SPA in the amount of CHF * (in words: Swiss Francs *) (the Initial Escrow Amount) to serve as payment fund for claims Buyer may have as against any of the Sellers under the SPA; 

  

	C.	Principals desire that the Escrow Agent serve as an escrow agent to hold the Escrow Amount (as defined hereinafter) pursuant to the terms of this Escrow Agreement for release as set
forth herein, and the Escrow Agent is willing to accept the appointment and to hold and release the Escrow Amount (as defined hereinafter), all upon the terms and conditions set forth herein; 

  

	D.	The relationship between the Escrow Agent and the Principals shall be solely and exclusively governed by this Escrow Agreement and neither of the Principals may assert any claims
whatsoever against the Escrow Agent in connection with the SPA or any other agreement. This Escrow Agreement shall remain fully valid even if the SPA or any other agreement will become void or unenforceable for whatever reason.

  
 Now, therefore, the Parties agree as follows: 

 

	1.	Definitions 

  
 For the purpose of this Escrow Agreement, capitalized terms used herein shall have the following meanings: 
  

			
	 Agreement:
	  	means this Escrow Agreement together with any attachments, schedules, appendixes or supplements.
		
	 Buyer:
	  	means Smith & Nephew International B.V., Kruisweg 637, 2132 NB Hoofddorp, The Netherlands.
		
	 Buyer’s Account:
	  	 means the account of the Buyer as indicated in Article 5.4(a).

		
	 Company:
	  	means Plus Orthopedics Holding AG, a Swiss company having its registered office at Erlenstrasse 4, 6343 Rotkreuz, Switzerland.
		
	 Escrow Account:
	  	means Swiss Francs current account no [...], clearing [...] (remittance instructions: SWIFT: CRESCHZZ80A), opened in the name of the Escrow Agent and the designation “Escrow
PO-Group” with Credit Suisse, Zurich, Switzerland.
		
	 Escrow Agent:
	  	means Credit Suisse Solution Partners AG, Talacker 16, 8001 Zurich, Switzerland.
		
	 Initial Escrow Amount:
	  	means the cash amount of CHF * (in words: Swiss Francs *) being placed into the Escrow Account.
		
	 Escrow Amount:
	  	means the Initial Escrow Amount plus the proceeds and interests thereon and minus the charges and releases debited to the Escrow Account in accordance with the terms hereof.
		
	 Party/Parties:
	  	means individually either Sellers, Buyer or the Escrow Agent, or collectively Sellers, Buyer and the Escrow Agent (as the context requires).
		
	 Principals:
	  	means jointly the Sellers and Buyer.

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 41 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  

			
	 SPA:
	  	means the share purchase agreement dated as of [...], 2007 signed between Sellers and Buyer with regards to the purchase and sale of all shares of the Company and attached hereto in Schedule
A.
		
	 Sellers:
	  	means (1) Hyos Invest Holding AG, Weinplatz 10, 8022 Zurich, Switzerland; (2) Dr. Ulrich Sigg, * Switzerland; (3) Dr. Robert Riedweg, * Switzerland; and (4) Active Investor AG, Zugerstrasse
76B, 6340 Baar, Switzerland.
		
	 Sellers’ Accounts:
	  	means the accounts of the Sellers as indicated in Article 5.4(b).

  

	 	1.2	Unless the context otherwise requires, words in the singular shall be construed as including references to such words in the plural, and vice versa. 

  

	 	1.3	The headings in this Agreement are for convenience and reference purposes only and do not affect its interpretation. 

  

	 	1.4	All appendices and schedules to this Agreement, including any exhibits to the appendices and schedules form integral parts of this Agreement. 

  

	 	1.5	For the computation of periods of time defined in days or Business Days, both the first and the last day shall be included. 

  
 Unless otherwise defined herein, the terms used in this Escrow Agreement in
capitalized form shall have the meaning assigned to them in the SPA. 
  

	2.	Appointment of the Escrow Agent 

  
 The Principals hereby appoint the Escrow Agent as escrow agent according to the terms and conditions set forth herein. The Escrow Agent herewith declares
that he assumes all rights and duties as escrow agent according to the terms and conditions set forth herein. 
  

	3.	Deposit Into Escrow 

  

	3.1	Opening of the Escrow Account 

  
 Upon signing of this Escrow Agreement, the Escrow Agent shall open in its name with Credit Suisse, Bleicherweg 33, p.o. box 527, CH-8070 Zurich (IBAN
CHn; SWIFT code: n) a CHF current account under the number n. The Escrow Account shall bear the designation “Escrow PO-Group”.

  

	3.2	Transfer of Initial Escrow Amount to the Escrow Account 

  
 On the date hereof, Buyer shall transfer to the Escrow Account the Initial Escrow Amount of CHF * (in words: Swiss Francs *) (such Initial Escrow
Amount plus the proceeds and interests thereon and minus the charges and releases debited to the Escrow Account in accordance with the terms hereof, the Escrow Amount) including an amount in CHF corresponding to the fees payable at such time
as set forth in Article 4. 
  

	3.3	Management of the Escrow Amount 

  
 The Escrow Agent shall not use or manage the Escrow Amount in any way other than as set forth herein. The Escrow Agent shall provide the Principals with
bank statements regarding the Escrow Account per the end of each calendar quarter or upon specific request by either of the Principals. The Escrow Agent shall issue such confirmations and certifications as the Principals may jointly and reasonably
request. Pursuant to common instructions in writing by the Principals, the Escrow Agent shall grant the Principals access to information about the Escrow Account. 
  

	3.4	Investment of the Escrow Amount 

  

	 	(i)	The Escrow Agent shall hold and maintain the Escrow Amount, and shall invest such Escrow Amount as instructed by the Principals in (a) fiduciary call deposits (callable at 48
hours-notice) or (b) fiduciary time deposits with foreign branches or subsidiaries of Credit Suisse not subject to withholding taxes on interest earned except to the extent that the Escrow Agent is required by law to make payment subject to any
taxes. The Authorisation for Fiduciary Deposits contained in Schedule B, which forms an integral part of this Agreement, shall 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 42 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
govern such fiduciary investments. The Principals take note, however, that due to US tax regulations any investments in US securities will be precluded.
Without any instructions from the Principals, the Escrow Amount will be invested in fiduciary call deposits (callable at 48 hours-notice). 

  

	 	(ii)	All such investments shall (a) have a maturity of no longer than six (6) months from date of investment, and (b) shall be denominated in CHF. If the Sellers at their
discretion decide for a longer maturity of parts of the Escrow Amount, the Sellers shall bear all additional costs of the early cancellation of the investments. Other investments shall only be made by the Escrow Agent in accordance with joint
written instructions given by the Principals. Such joint written instructions can be given by way of facsimile (as an exception to Article 9.1 of this Agreement). 

  

	 	(iii)	The usual banking commissions and charges with respect to the investments to be effected by the Escrow Agent in accordance with this Agreement commonly charged by Credit Suisse for
such investments will be charged by the Escrow Agent from time to time by debiting the Escrow Account. 

  

	3.5	Instructions Given to the Escrow Agent 

  
 Subject to the provisions set forth herein, the right to give instructions to the Escrow Agent with respect to the Escrow Account shall be limited to
joint or corresponding instructions by the Principals, provided that information of purely informative character (such as, for example, change of addresses) shall be given individually by the Party concerned. 
  

	3.6	Acknowledgement With Respect to Lien, Retention Right or Other Charge Relating to the Escrow Account 

  
 The Escrow Agent hereby acknowledges that it shall not have and waives, as
the case may be, any lien, retention right or other charge for whatever reason on the Escrow Amount, provided however, that the Escrow Agent shall have a pledge on the Escrow Amount as security for the payment of any fees, costs, expenses,
all taxes, duties and/or charges that the Escrow Agent may incur or become liable to pay in connection with this Escrow Agreement. 
  

	4.	Fees of the Escrow Agent 

  
 All fees and expenses payable to the Escrow Agent shall be borne by Buyer. 
  
 The fees of the Escrow Agent shall consist of: 
  

	 	(a)	a flat upfront fee covering the period until 12 (twelve) months after Closing in the amount of CHF * (in words: Swiss francs *), plus VAT (if applicable) to be paid on the date
hereof as set forth in Article 3.2; plus 

  

	 	(b)	a flat fee of CHF * (in words: Swiss francs *), plus VAT (if applicable) for each period of twelve (12) months after the initial 12 (twelve) months period after Closing
payable at the beginning of each 12 (twelve) months period; plus, 

  

	 	(c)	if this Escrow Agreement has not been terminated on or before 5 (five) years after Closing, a flat fee of CHF * (in words: Swiss francs *), plus VAT (if applicable) for
the then remaining term of this Escrow Agreement for each additional period of 12 (twelve) months. 

  
 Buyer acknowledges that no pro rata temporis reimbursement of Buyer by the Escrow Agent shall take place should, after the date hereof, the Escrow
Amount be released, for whatever reason, sometime one of the various the different periods stated above (and not rather at the end of any such period). 
  

	5.	Release of Escrow Amount 

  

	5.1	General remarks 

  
 The Escrow Agent shall under no circumstances be required to pay out any amount exceeding the Escrow Amount (less costs and fees) deposited at the time of
such payment. All payments out of the Escrow Account shall take into consideration the repayment dates of the investments effected in accordance with this Escrow Agreement and the value date for payments to be made by the Escrow Agent shall be
postponed to coincide with the maturity of the investments effected. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 43 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 In the event of a release in accordance with Article 5 of all or part of the
Escrow Amount shall be made prior to the maturity of the investments pursuant to Article 3.4 above, Sellers and Buyer shall each bear 50% of all the costs of the early cancellation of the investments. 
  
 Any release of funds of the Escrow Account in accordance with Article 5
shall be notified by the Escrow Agent to the Principals no later than 5 (five) Business Days prior to such release, except where jointly instructed by the Principals. 
  

	5.2	Release Based on Joint or Corresponding Instructions 

  
 The Escrow Agent shall release the Escrow Amount (less costs and fees), or part thereof, at any time in accordance with the joint or corresponding written
instructions of the Principals. 
  

	5.3	According to an Arbitral Award or Court Decision 

  
 To the extent not previously released based on joint or corresponding written instructions of the Principals, the Escrow Agent shall release the Escrow
Amount in accordance with a final and binding arbitral award or any other competent court instructing the Escrow Agent to release funds of the Escrow Account. 
  

	5.4	Payment 

  
 All payments by the Escrow Agent under this Escrow Agreement shall be effected 
  

	 	(a)	if to Buyer to the Account No. IBAN n with [Bank] (SWIFT code: n);

  

	 	(b)	if to Sellers to the Account No. IBAN n with [Bank] (SWIFT code: n) (the
Transaction Account). 

  
 A change of the
above accounts shall be notified in accordance with the provisions in Article 9.1. 
  

	6.	Indemnity 

  
 The Principals severally and not jointly indemnify the Escrow Agent and hold the Escrow Agent harmless from any and all losses, costs, expenses,
liabilities, claims, actions or demands including court and legal costs which it may incur as a result of or in connection with the performance of this Escrow Agreement, provided, however, that the Principals shall not be bound to release and
hold the Escrow Agent harmless in case of the Escrow Agent’s fraud, bad faith, willful misconduct, gross negligence or negligence with respect to the Escrow Agent’s essential obligations as set forth in Articles 3.3. 3.4 and 5 of this
Escrow Agreement. 
  
 The Principal’s obligation hereunder
shall include, but not be limited to, reimbursing or advancing the Escrow Agent all costs of proceedings reasonably incurred or expected, including reasonable attorneys, court and other fees once determined pursuant to a final, non-appealable and
enforceable judgment, order or award of a competent court or arbitral tribunal; provided, however, that any fees and expenses incurred by the Escrow Agent shall be substantiated by satisfactory documentary evidence. 
  
 The Principals shall assist the Escrow Agent in all legal proceedings and
shall on Escrow Agent’s first request take over such proceedings to the extent permitted by applicable procedural rules. 
  
 The indemnifications of the Escrow Agent provided in this Article shall survive termination of this Agreement, and any resignation or removal of the
Escrow Agent. 
  

	7.	Limitations 

  

	7.1	Measures Taken by a Court of Authority 

  
 The Parties acknowledge and agree that any measures taken by any court of authority having jurisdiction over the Escrow Agent which might result in
preventing the Escrow Agent from executing its obligations under this Escrow Agreement shall have to be taken into consideration and be a valuable excuse for the Escrow Agent for not being able to perform in due time so long as such measures are in
effect and reasonably thereafter. 
  

	7.2	Acting of Escrow Agent 

  
 The Escrow Agent shall not be required to perform any acts that may violate any law or applicable rules of any governmental agency. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 44 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 The Escrow Agent shall be protected in acting upon any written notice,
request, demand, waiver, consent, receipt or other paper or document furnished to it, irrespective of its means of communication (mail, courier or facsimile) to the Escrow Agent, not only as to its due execution and the validity and effectiveness of
its provisions but also as to the truth and acceptability of any information therein contained, which it believes in good faith to be genuine and what it purports to be. In addition, the Principals are aware that the banking secrecy is not
guaranteed with facsimile use. 
  
 Subject to mandatory
provisions of law, the Escrow Agent shall not be liable for any error of judgement, or for any act done or step taken or omitted by it in good faith, or for any mistake of fact or law, or for anything which it may do or refrain from doing in
connection with this Escrow Agreement. 
  
 The Escrow Agent is
not to be held responsible for any loss of principal or interest that may be incurred as a result of making investment of the Escrow Amount in the manner specified herein or of cancellation any such investments for the purpose of this Agreement.

  
 The Escrow Agent shall be under no obligation to institute,
appear in or defend any action, suit or legal or arbitration proceeding in connection with this Escrow Agreement or to take any other action likely to make it subject to liability, cost or expense, unless first indemnified to its satisfaction.

  

	8.	Warranties 

  
 Each of the Parties to this Agreement represents and warrants that it has full power, authority and legal right to assume the obligations set forth
herein, to execute and deliver, and to perform and observe the terms and provisions of this Agreement and that this Agreement constitutes its legally binding and valid obligations enforceable in accordance with its terms and does not conflict with
any law, regulation or instrument binding on or relating to it and that this Agreement is within its powers and has been duly authorised by it, that all necessary actions have been taken and all consents and approvals have been granted to authorise
the execution, delivery and performance of this Agreement and that the person signing this Agreement on behalf of each of them is authorised to do so. 
  

	9.	General Provisions 

  

	9.1	Notices 

  
 Any and all notices or other instruments or papers to be given or sent under or in connection with this Escrow Agreement shall be in writing, shall
specifically refer to this Escrow Agreement and shall be delivered by personal delivery, by registered mail (return receipt required), an internationally recognized courier (such as Federal Express, DHL or UPS) or by telefax to the following
addresses: 
  

			
	if to Sellers:	 	 Dr. Heinz Schärer
 Homburger
 Weinbergstrasse 56|58
 8006 Zürich, Switzerland
 fax: +41 43 222 15 00

		
	if to Buyer:	 	 Smith & Nephew International B.V.
 c|o Smith &
Nephew plc
 15 Adam Street
 London WC2N 6LA
 Attention: Company Secretary
 fax: +44 207 960 2357

		
	with a copy to	 	 Freshfields Bruckhaus Deringer
 65 Fleet
Street
 London EC4Y 1HS
 United Kingdom
 Attention: Ben Spiers
 fax: +44 207 108 7155

		
	if to Escrow Agent:	 	 Credit Suisse Solution Partners AG
 Patrik Tagni / Special Finance Group (SEGM)
 Talacker 16
 8001 Zürich, Switzerland
 fax: +41 44 333 09 10

		
	with a copy to	 	Sellers/Buyer

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 45 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 or such other addresses as any of the Parties may notify to the other Parties
in accordance with the above. All notices under this Escrow Agreement shall be effective upon receipt or if transmitted by facsimile, when sent. The Parties are obliged to provide for a valid facsimile number at all times. 
  
 A copy of any notice given under this Escrow Agreement by one Party to
another shall also be sent to the other Parties as set forth in this Article 9.1 for information purposes. 
  

	9.2	Signatures 

  
 Any and all notices or other instructions or papers to be sent to the Escrow Agent by any other Party shall be signed by the person(s) mentioned in
Schedule C, as amended from time to time by formal notice given in accordance with Article 9.1. The Escrow Agent is, nevertheless, free (but not obliged) to accept signatures of other persons authorised to represent the relevant Party.

  

	9.3	General Conditions and Safe Custody Regulations of Escrow Agent 

  
 The General Conditions and Safe Custody Regulations of the Escrow Agent as set forth in Schedule D shall be considered as an integral part of this
Escrow Agreement; provided, however, that the specific terms and conditions stated in this Escrow Agreement shall supersede any other terms and conditions set forth in Schedule D. 
  

	9.4	Entire Agreement 

  
 This Escrow Agreement contains the entire agreement among the Parties with respect to the specific subject matter covered hereby. It may not be modified
or discharged, nor may any of its terms be waived, except by a written amendment signed by all Parties. 
  

	9.5	Severability 

  
 Should any provision of this Escrow Agreement be prohibited or ineffective or otherwise unenforceable, in whole or in part for whatever reason, such
provision shall cease to have effect without prejudicing the validity of the other provisions herein. The Parties or the court having jurisdiction hereupon will replace such provision with another provision so that, to the extent possible, the
economic balance of this Escrow Agreement will be preserved. 
  

	9.6	Assignment 

  
 This Escrow Agreement shall be binding upon and inure to the benefit of the Parties. It is agreed, however, that no Party may assign any of its rights or
obligations hereunder without the written consent of the other Parties; provided, however, that Buyer may assign this Escrow Agreement or any of its rights hereunder to any of its Affiliates without the other Parties’ consent so long as
Buyer continues to be bound by all of its obligations under this Escrow Agreement, and further provided that Buyer informs the other Parties about such assignment in accordance with Article 9.1 above and complies with any and all documentation
requirements of the Escrow Agent. 
  

	9.7	Costs and Expenses; Taxes 

  
 Sellers and Buyer shall bear all cost, expenses and Taxes incurred by them under this Escrow Agreement. 
  

	9.8	Entry Into Force 

  
 This Escrow Agreement enters into force upon signing by all Parties. 
  

	9.9	Amendments and Waivers 

  
 This Escrow Agreement may only be modified or amended by a document signed by all parties. Any provision contained in this Escrow Agreement may only be
waived by a document signed by the party waiving such provision. 
  

	9.10	Representative of Sellers 

  
 Each Seller hereby empowers Dr. Heinz Schärer as his|its duly authorized representative and general attorney in fact under this Escrow Agreement
with the right of substitution. Accordingly, the Escrow 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 46 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 
Agent may rely on any notices or instructions, if given on behalf of any of the Sellers by Dr. Heinz Schärer or, as the case may be, his
substitute, such authorizations to remain valid until revoked in writing by any Seller. Sellers shall within 20 (twenty) days following receipt of such revocation by the Escrow Agent appoint a new representative in replacement of Dr. Heinz
Schärer, otherwise the Escrow Agent shall only accept joint instructions by all the Sellers. 
  

	10.	Termination 

  

	10.1	In General 

  
 This Escrow Agreement shall terminate, once the Escrow Amount has completely been released in accordance with this Escrow Agreement. 
  

	10.2	Termination by the Principals 

  
 Notwithstanding anything else set forth herein, the Principals may terminate this Escrow Agreement at any time by giving the Escrow Agent 5 (five)
Business Days’ prior joint or corresponding written notice. The Escrow shall be entitled to deduct Costs and fees from the Escrow Amount notwithstanding such termination. 
  

	10.3	Termination by the Escrow Agent 

  
 The Escrow Agent may terminate its appointment as escrow agent under this Escrow Agreement at any time in accordance with Article 476 par. 1 CO by giving
the Principals 6 (six) months’ prior written notice. 
  
 Notwithstanding anything else set forth herein, in the event the Escrow Amount is not completely released on December 31, 2017, the Escrow Agent may terminate its appointment as escrow agent under this Escrow Agreement at any time by
giving the Principals 3 (three) months’ prior written notice. 
  
 If the Escrow Agent terminates its appointment or becomes unable to perform his obligations hereunder, the Principals shall immediately and jointly nominate a successor to act as escrow agent (the Successor). In such a case, the
Escrow Agent shall immediately transfer the Escrow Account to the Successor, and the Successor shall then perform all duties which the Escrow Agent had under this Escrow Agreement. 
  
 If the Escrow Agent cannot be replaced in accordance with the preceding paragraph or the Principals cannot agree on a
Successor within 60 (sixty) Business Days following receipt of the Escrow Agent’s termination notice, any of the Parties shall be entitled to request the president of the Zurich Chamber of Commerce to appoint a Successor. Should such
appointment not occur within 30 (thirty) Business Days following such request, then the Escrow Agent shall continue to keep the Escrow Account. The Escrow Agent shall then only release the Escrow Amount in accordance with joint or corresponding
written instructions received by the Principals pursuant to Article 4.2. or in accordance with a final and binding arbitral award pursuant to Article 4.4. Any other obligation of the Escrow Agent to release the Escrow Amount under this
Escrow Agreement shall in such a case cease to be effective, it being understood by the Parties that all other provisions of this Escrow Agreement shall continue to be valid and binding. 
  

	11.	Governing law and Jurisdiction 

  

	11.1	Governing law 

  
 All legal relationship between the Parties in connection with this Escrow Agreement shall exclusively be governed by, and construed in accordance with,
Swiss law. 
  

	11.2	Jurisdiction 

  
 Any dispute, controversy or claim arising out of, or in connection with, this Escrow Agreement, including any dispute relating to its conclusion, binding
effect, amendment and termination, shall be resolved exclusively by the Commercial Court of Zurich (Handelsgericht des Kantons Zürich). 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 47 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Schedule A 
  
 Share Purchase Agreement dated as of n 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 48 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Schedule B 
  
 Authorization of Fiduciary Deposits 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 49 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Schedule C 
  
 List of Authorized Signatories 
  
 We hereby notify the Escrow Agent of the following persons with unlimited
authority to sign (with right of substitution), to carry out any legal acts and to assume other obligations vis-à-vis the Escrow Agent in connection and exclusively in accordance with the terms and conditions of the Escrow Agreement of
[date] among Sellers, Buyer and Escrow Agent. 
  
 For Buyer: 
  

							
	Name

	  	Nationality
Date of birth

	  	Signature

	  	Authority to sign

	 	  	 	  	 	  	[sole signature]
[jointly by two]
				
	 	  	 	  	 	  	[sole signature]
[jointly by two]
				
	For Sellers	  	 	  	 	  	 
				
	 	  	 	  	 	  	sole signature
				
	 	  	 	  	 	  	sole signature

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 50 | 100 

 Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Schedule D 
  
 General Conditions and Safe Custody Regulations as attached

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 51 | 100 

 Annex 3.3 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 3.3 
  
 Consents of Third Parties 
  
 * Senior Working Capital Facility Agreement between * dated August 20,
2003 and Amendments N° 1 - 7 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 52 | 100 

 Annex 3.4 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 3.4 
  
 Data Room Escrow Agreement (agreed form) 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 53 | 100 

 Annex 3.4 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Execution Copy 
  
 Data Room Escrow Agreement 
  
 dated as of March 12, 2007 
  
 by and between 
  

	1.	Hyos Invest Holding AG, Weinplatz 10, 8022 Zurich, Switzerland (Seller 1) 

  

	2.	Dr. Ulrich Sigg, * Switzerland (Seller 2) 

  

	3.	Dr. Robert Riedweg, * Switzerland (Seller 3) 

  

	4.	Active Investor AG, Zugerstrasse 76B, 6340 Baar, Switzerland (Seller 4) 

  
 (hereinafter each a Seller, and, collectively, Sellers) 
  
 and 
  
 Smith & Nephew International B.V., Kruisweg 637, 2132 NB Hoofddorp, The Netherlands 
  
 (hereinafter Buyer) 
  
 and 
  
 * Switzerland 
  
 (hereinafter Data Room Escrow Agent) 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 54 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Contents 
  

							
	 Number of Exhibit
	  	56
			
	 1.
	  	Definitions	  	57
			
	 2.
	  	Appointment of Data Room Escrow Agent | Storage of the Data Room Documentation	  	57
	 	  	2.1	  	Appointment	  	57
	 	  	2.2	  	Storage of the Data Room Documentation	  	57
	 	  	2.3	  	Fee	  	58
			
	 3.
	  	Effects of the Escrow	  	58
			
	 4.
	  	Access	  	58
			
	 5.
	  	Liability	  	59
			
	 6.
	  	Confidentiality	  	59
			
	 7.
	  	Term and Termination	  	60
	 	  	7.1	  	Term	  	60
	 	  	7.2	  	Joint Prolongation by Sellers and Buyer	  	60
	 	  	7.3	  	Joint Termination by Sellers and Buyer	  	60
	 	  	7.4	  	Termination by the Data Room Escrow Agent	  	60
	 	  	7.5	  	Collection of the Data Room at Termination	  	60
			
	 8.
	  	General Provisions	  	61
	 	  	8.1	  	Notices	  	61
	 	  	8.2	  	Entire Agreement	  	61
	 	  	8.3	  	Severability	  	61
	 	  	8.4	  	Assignment	  	61
	 	  	8.5	  	Amendments and Waivers	  	62
	 	  	8.6	  	Representative of Sellers	  	62
	 	  	8.7	  	Entry Into Force	  	62
			
	 9.
	  	Governing law and Jurisdiction	  	62
	 	  	9.1	  	Governing law	  	62
	 	  	9.2	  	Jurisdiction	  	62

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 55 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 Table of Exhibits 
  

			
	Number of Exhibit	  	Name
		
	1        	  	Data Room Indices

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 56 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 This data room escrow agreement (the Data Room Escrow Agreement) is made as of
March 12, 2007 by and among the Sellers of the shares in Plus Orthopedics Holding AG, a corporation organized under the laws of Switzerland, with its registered office at Erlenstrasse 4, CH-6343 Rotkreuz (the Company), the Buyer and * as
data room escrow agent and * as deputy data room escrow agent to act in lieu of * in case he is not in a position to act under this Data Room Escrow Agreement (the Data Room Escrow Agent); Sellers and Buyer hereinafter jointly referred to as
the Principals, and together with the Data Room Escrow Agent, the Parties and, individually, a Party. 
  
 Whereas 
  

	A.	As of the date hereof, Principals have executed the share purchase agreement (the SPA) regarding the purchase and sale of all the shares in the Company.

  

	B.	Sellers have stored in a data room at Homburger Rechtsanwälte, Weinbergstrasse 56|58, CH-8006 Zurich, binders containing the documentation referenced in the Data Room Indices
(the Data Room Documentation), to which Buyers and their representatives, advisers and consultants, prior to executing the SPA, have had access for purposes of conducting a due diligence of the the Company and its subsidiaries.

  

	C.	Sellers and Buyers have agreed in the SPA that the originals of the Data Room Documentation shall be stored with the Data Room Escrow Agent. 

  
 Now, therefore, the Parties hereto agree as follows:

  

	1.	Definitions 

  
 Unless otherwise defined herein, the terms used in this Data Room Escrow Agreement in capitalized form shall have the meaning assigned to them in the SPA.

  

	2.	Appointment of Data Room Escrow Agent | Storage of the Data Room Documentation 

  

	2.1	Appointment 

  
 The Principals hereby appoint the Data Room Escrow Agent as escrow agent according to the terms and conditions set forth herein. The Data Room Escrow
Agent herewith declares that he assumes all rights and duties as escrow agent according to the terms and conditions set forth herein. 
  

	2.2	Storage of the Data Room Documentation 

  

	 	(a)	Sellers undertake, as soon as reasonably practicable after the date hereof but in no event later than 15 (fifteen) Business Days after the date of the SPA, to cause Homburger to
seal the binders containing the Data Room Documentation and to deliver the Data Room Documentation so sealed to the Data Room Escrow Agent. 

  

	 	(b)	The Data Room Escrow Agent undertakes to store the Data Room Documentation in a locked, safe and secure area on its premises or on premises under its exclusive control, such storing
being, with respect to safety and security, at least equivalent to the storing used by the Data Room Escrow Agent for archiving its client files (access of other representatives of Bär & Karrer to the storage room may be possible). The
Data Room Escrow Agent shall exercise due care for the safekeeping of the Data Room Documentation. During the time of this Data Room Escrow Agreement, the Data Room Escrow Agent shall hold the Data Room Documentation on behalf of Sellers and Buyer,
and Sellers and Buyer shall together be joint owners of the Data Room Documentation contained therein. 

  

	 	(c)	Upon delivery of the Data Room Documentation, the Data Room Escrow Agent shall put – in cooperation with representatives of Sellers and Buyer – the binders containing the
Data Room Documentation delivered to it by Sellers in boxes which shall be sealed by the Data Room Escrow Agent in the presence of the Sellers’ and Buyer’s representatives. 

  

	 	(d)	Sellers represent that the Data Room Documentation put in escrow with the Data Room Escrow Agent under this Data Room Escrow Agreement is identical with the documentation made
available to Buyer during its due diligence review. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 57 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  

	2.3	Fee 

  

	 	(a)	The Data Room Escrow Agent shall receive an initial non-recurring set-up fee of CHF * (in words: Swiss francs *), plus VAT (if applicable) payable by Sellers and Buyer in equal
proportions upon receipt of the Data Room Documentation. The fee for the services rendered by the Data Room Escrow Agent as data room escrow agent hereunder shall be an annual fee of CHF *(in words: Swiss francs *), plus VAT (if applicable)
payable by Sellers and Buyer in advance in equal proportions as compensation for all of the Data Room Escrow Agent’s general obligations under this Data Room Escrow Agreement (other than the services to be rendered under Article 4 hereunder,
for which paragraph (b) hereof shall apply). If the Data Room Documentation is stored with the Data Room Escrow Agent for a period of less than an entire calendar year, the annual fee for such year shall be payable on a pro rata basis.

  

	 	(b)	For any services rendered under Article 4 of this Data Room Escrow Agreement (the Services), the Data Room Escrow Agent shall be compensated by the Requesting Party on a
“time reasonably spent plus expenses basis”, applying the hourly rates charged by the Data Room Escrow Agent or for a mid level associate. Sellers and Buyer acknowledge that (i), as of the date hereof, the base hourly rate for the Data
Room Escrow Agent is CHF * (in words: Swiss francs *), for a mid level associate is CHF * (in words: *), plus VAT (if applicable) (ii) the Data Room Escrow Agent may adjust such base hourly rate in accordance with applicable internal
procedures, and (iii) the Data Room Escrow Agent may, if the circumstances of the Services so require, delegate parts of its Services to a security company, e.g. Securitas or the like. Such Costs shall be borne by Seller and Buyer. The
Requesting Party shall pay the billed amount within one month after the date of the invoice. 

  

	 	(c)	In case the Data Room Escrow Agent is asked to render services not provided for in this Data Room Escrow Agreement, the Data Room Escrow Agent shall be compensated on a “time
reasonably spent plus expenses basis”, applying the hourly rates of the Data Room Escrow Agent (as further specified in paragraph (b) of this Article 2.3). The Data Room Escrow Agent has the right to deny services to be rendered if
not provided for in this Data Room Escrow Agreement. The Data Room Escrow Agent shall render such additional services only if being instructed to do so in a joint request of Sellers and Buyer, such request specifying the party paying the fees and
expenses for these services. The billed amount shall be payable within one month after the date of the invoice. 

  

	3.	Effects of the Escrow 

  

	 	(a)	In the event of a dispute or controversy as to whether a document has been part of the Data Room Documentation as of the date of the SPA, the Data Room Documentation delivered to,
and stored by, the Data Room Escrow Agent shall be controlling. 

  

	 	(b)	In the event of any other discrepancy between the copies of the Data Room Documentation being retained by Sellers and by Buyer, the Data Room Documentation delivered to, and stored
by, the Data Room Escrow Agent shall be controlling. 

  

	4.	Access 

  

	 	(a)	The Data Room Escrow Agent shall grant Sellers and/or Buyer (and their employees and advisers) access to the Data Room Documentation for the purpose of reviewing such documentation
during normal business hours upon (i) the written request of either party to the Data Room Escrow Agent (the Requesting Party) and (ii) receipt of a copy of a written notice by the Requesting Party notifying the other party (the
Receiving Party) of its intention to access and review the Data Room Documentation at a specified date and time. Such written request and notice, respectively, shall have been delivered by the Requesting Party to the Data Room Escrow Agent
and the Receiving Party, respectively, at least 3 (three) Business Days prior to the date for which access has been requested. 

  

	 	(b)	Upon granting the Requesting Party access to the Data Room Documentation, the Data Room Escrow Agent, in presence of the Requesting Party, shall unseal the sealed binder(s)
containing the document(s) requested by the Requesting Party, release the relevant sealed 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 58 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
binders to the Requesting Party for review, and, after such review and, if applicable, the photocopy procedure as described in section (c) of this
Article 4, place such document(s) back into, and reseal, the previously released boxes in the presence of the Requesting Party. The Data Room Escrow Agent shall certify to both Parties that (i) the document(s) released to the Requesting Party
have been placed back into the relevant boxes and (ii) the previously unsealed boxes have been properly resealed. Binders shall not be unsealed by the Requesting Party. 

  

	 	(c)	Following its review, the Requesting Party may request the Data Room Escrow Agent to produce photocopies of the relevant parts of the Data Room Documentation. The Data Room Escrow
Agent shall record the index number of the document of which the Requesting Party received a photocopy and have the Requesting Party confirm such record. 

  

	 	(d)	In no event shall the Data Room Escrow Agent remove, or allow any of the Parties or their employees or advisers to remove, any of the originals being part of the Data Room
Documentation from the area where they are stored. 

  

	5.	Liability 

  

	 	(a)	When accepting the sealed binders containing the Data Room Documentation as described in Article 2, the Data Room Escrow Agent shall not be under any obligation to verify whether
such sealed binders contain the Data Room Documentation and shall not accept any liability with respect thereto. 

  

	 	(b)	The Data Room Escrow Agent shall be liable in accordance with article 97 CO and subject to this Data Room Escrow Agreement to each of the other Parties hereto for any loss,
claim, cost or reasonable expense incurred or sustained by each of them as a result of any of the following: 

  

	 	(i)	the Data Room Documentation or a part thereof that has been delivered to, and is stored by, the Data Room Escrow Agent pursuant to Article 2.2 hereof has been destroyed,
damaged or is otherwise not collectable by Sellers and Buyer; 

  

	 	(ii)	a violation of any of the Data Room Escrow Agent’s other obligations hereunder, including its obligations under the confidentiality undertakings pursuant to Article 6
hereof. 

  
 The Data Room Escrow Agent is under no
circumstances liable to the other Parties for acts and willful misconduct by the Requesting Party. 
  

	 	(c)	Notwithstanding the foregoing, it shall be agreed and understood that the Data Room Escrow Agent shall not be bound in any way by any agreement (other than this Data Room Escrow
Agreement) between the other Parties hereto, including, but not limited to, the SPA. Without prejudice to the provisions in Article 8.2 of this Data Room Escrow Agreement, the Data Room Escrow Agent does not assume any liability or
responsibility for the sufficiency, form, manner or validity of any request or other notice delivered to him under this Data Room Escrow Agreement or for the identity of the persons executing such notices, which the Data Room Escrow Agent reasonably
believes to be genuine, correct and appropriately authorized. 

  

	6.	Confidentiality 

  
 The Data Room Escrow Agent shall, and shall procure that any of its employees shall, not grant access to the Data Room Documentation to any third party
(other than the Parties hereto or their employees and advisers) and not disclose any information that the Data Room Escrow Agent or any of its employees have come to know in connection with the performance of this Data Room Escrow Agreement. The
Data Room Escrow Agent’s obligations under this Article shall survive termination of this Data Room Escrow Agreement and continue to be in full force and effect thereafter. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 59 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  

	7.	Term and Termination 

  

	7.1	Term 

  
 This Data Room Escrow Agreement shall be concluded for a period of 6 (six) years, subject to the Parties’ right to extend the Data Room Escrow Agreement pursuant to Article 7.2 or to terminate the Data Room
Escrow Agreement pursuant to Articles 7.3 and 7.4; provided, however, that this Data Room Escrow Agreement shall not terminate as long as proceedings relating to the SPA among Sellers and Buyers remain pending. 
  

	7.2	Joint Prolongation by Sellers and Buyer 

  
 Sellers and Buyer may jointly extend the term of this Data Room Escrow Agreement for a supplementary term of up to 5 (five) years by giving the Data Room
Escrow Agent 30 (thirty) Business Days’ written notice prior to the expiry of the term of this Data Room Escrow Agreement. Appropriate fees shall be agreed between the Parties for the storage and services of the Data Room Escrow Agent.

  

	7.3	Joint Termination by Sellers and Buyer 

  
 Sellers and Buyer may jointly terminate this Data Room Escrow Agreement at any time by giving the Data Room Escrow Agent 10 (ten) Business Days’
prior written notice. In the event of such termination, or the expiry of the time period set forth in Article 7.1, the Data Room Escrow Agent shall be entitled to compensation to the extent provided for in article 475 para. 2 CO or agreed
in this Data Room Escrow Agreement. For the avoidance of doubt, the Data Room Escrow Agent shall be entitled to fees and/or other compensation as set out in this Data Room Escrow Agreement only for the period of time during which it effectively
acted as Data Room Escrow Agent and in connection with the collection of the Data Room Documents under Article 7.5. 
  

	7.4	Termination by the Data Room Escrow Agent 

  
 The Data Room Escrow Agent shall be entitled to terminate this Data Room Escrow Agreement prior to the expiry of the time period set forth in Article 7.1
for cause pursuant to article 476 CO or in case of non-payment of any fee or compensation (or part thereof) by Sellers and/or Buyer for more than 60 (sixty) Business Days; provided, however, that the Data Room Escrow Agent shall be
required to give 90 (ninety) calendar days’ prior written notice for such termination to be effective. 
  

	7.5	Collection of the Data Room at Termination 

  
 In case the termination of this Data Room Escrow Agreement pursuant to Article 7.3 or 7.4 occurs prior to Closing, Sellers shall collect, and the
Data Room Escrow Agent shall release, the Data Room Documentation within 10 (ten) Business Days of termination or expiry of the term of this Data Room Escrow Agreement. Upon collection, Sellers shall acknowledge in writing to the Data Room Escrow
Agent the number of binders that have been returned to them. If the Data Room Documentation or part thereof has not been collected within such time, the Data Room Escrow Agent shall be entitled to have the Data Room Documentation (or the remaining
part thereof) stored at a storage facility at its own discretion and at Sellers’ cost and risk. 
  
 In case of expiry of the term or termination of this Data Room Escrow Agreement pursuant to this Article 7 following the Closing, Buyer shall
collect, and the Data Room Escrow Agent shall release, the Data Room Documentation within 10 (ten) Business Days of termination or expiry of the term of this Data Room Escrow Agreement. Upon collection, Buyer shall acknowledge in writing to the Data
Room Escrow Agent the number of binders that have been returned to it. If the Data Room Documentation or part thereof has not been collected within such time, the Data Room Escrow Agent shall be entitled to have the Data Room Documentation (or the
remaining part thereof) stored at a storage facility at its own discretion and at Buyer’s cost and risk. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 60 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  

	8.	General Provisions 

  

	8.1	Notices 

  
 Any and all notices or other instruments or papers to be given or sent under or in connection with this Data Room Escrow Agreement shall be in writing,
shall specifically refer to this Data Room Escrow Agreement and shall be delivered by personal delivery, by registered mail (return receipt required), an internationally recognized courier (such as Federal Express, DHL or UPS) or by telefax to the
following addresses: 
  

			
	if to Sellers:	  	 Dr. Heinz Schärer
 Homburger
 Weinbergstrasse 56|58
 8006 Zürich, Switzerland
 fax: +41 43 222 15 00

			
		
	if to Buyer:	  	 Smith & Nephew International B.V.
 c/o Smith &
Nephew plc
 15 Adam Street
 London WC2N 6LA
 Attention: Company Secretary
 fax: +44 207 960 2357

		
	with a copy to	  	 Freshfields Bruckhaus Deringer
 65 Fleet
Street
 London EC4Y 1HS
 United Kingdom
 Attention: Ben Spiers
 fax: +44 207 108 7155

		
	if to Escrow Agent:	  	 * and
 *
 Zurich
 fax: *

		
	with a copy to	  	Sellers/Buyer

  
 or such other
addresses as any of the Parties may notify to the other Parties in accordance with the above. All notices under this Data Room Escrow Agreement shall be effective upon receipt or if transmitted by facsimile, when sent. The Parties are obliged to
provide for a valid facsimile number at all times. 
  
 A copy of
any notice given under this Data Room Escrow Agreement by one Party to another shall also be sent to the other Parties as set forth in this Article 8.1 for information purposes. 
  

	8.2	Entire Agreement 

  
 This Data Room Escrow Agreement contains the entire agreement among the Parties with respect to the specific subject matter covered hereby. It may not be
modified or discharged, nor may any of its terms be waived, except by a written amendment signed by all Parties. 
  

	8.3	Severability 

  
 Should any provision of this Data Room Escrow Agreement be prohibited or ineffective or otherwise unenforceable, in whole or in part for whatever reason,
such provision shall cease to have effect without prejudicing the validity of the other provisions herein. The Parties or the court having jurisdiction hereupon will replace such provision with another provision so that, to the extent possible, the
economic balance of this Data Room Escrow Agreement will be preserved. 
  

	8.4	Assignment 

  
 This Data Room Escrow Agreement shall be binding upon and inure to the benefit of the Parties. It is agreed, however, that no Party may assign any of its
rights or obligations hereunder without the written 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 61 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  
 
consent of the other Parties; provided, however, that Buyer may assign this Data Room Escrow Agreement or any of its rights hereunder to any of its
Affiliates without the other Parties’ consent so long as Buyer continues to be bound by all of its obligations under this Data Room Escrow Agreement, and further provided that Buyer informs the other Parties about such assignment in accordance
with Section 7.1. above and complies with any and all documentation requirements of the Data Room Escrow Agent. 
  

	8.5	Amendments and Waivers 

  
 This Data Room Escrow Agreement may only be modified or amended by a document signed by all Parties. Any provision contained in this Data Room Escrow
Agreement may only be waived by a document signed by the party waiving such provision. 
  

	8.6	Representative of Sellers 

  
 Each Seller hereby empowers Dr. Heinz Schärer as his|its duly authorized representative and general attorney in fact under this Data Room Escrow
Agreement with the right of substitution. Accordingly, the Data Room Escrow Agent may rely on any notices or instructions, if given on behalf of any of the Sellers by Dr. Heinz Schärer or, as the case may be, his substitute, such
authorizations to remain valid until revoked in writing by any Seller. Sellers shall within 20 (twenty) days following receipt of such revocation by the Data Room Escrow Agent appoint a new representative in replacement of Dr. Heinz
Schärer, otherwise the Data Room Escrow Agent shall only accept joint instructions by all the Sellers. 
  

	8.7	Entry Into Force 

  
 This Data Room Escrow Agreement enters into force upon signing by all Parties. 
  

	9.	Governing Law and Jurisdiction 

  

	9.1	Governing Law 

  
 This Data Room Escrow Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. 
  

	9.2	Jurisdiction 

  
 Any dispute, controversy or claim arising out of, or in connection with, this Data Room Escrow Agreement, including any dispute relating to its
conclusion, binding effect, amendment and termination, shall be resolved exclusively by the Commercial Court of Zurich (Handelsgericht des Kantons Zürich). 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 62 | 100 

 Data Room Escrow Agreement regarding Plus Orthopedics Holding AG 
  

					
	Hyos Invest Holding AG	 	 	  	 
			
	  

	 	 	  	 
	By: Carolina Müller-Möhl	 	 	  	 
			
	  

	 	 	  	  

	Dr. Ulrich Sigg	 	 	  	Dr. Robert Riedweg
			
	Active Investor AG	 	 	  	 
			
	  

	 	 	  	  

	By: Michael Theurillat	 	 	  	By: Martin Staub
			
	Smith & Nephew International B.V.	 	 	  	 
			
	  

	 	 	  	 
	By:	 	 	  	 
			
	  

	 	 	  	  

	*	 	 	  	*

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 63 | 100 

 Exhibit 1 
  
 Data Room Indices 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 64 | 100 

 Annex 4.2.1(a) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 4.2.1(a) 
  
 Governmental Approvals and Merger Control Laws 
  

			
	 Jurisdiction

	  	 Authority

	Germany	  	German Federal Cartel Office
	Greece	  	Competition Commission
	Turkey	  	Turkish Competition Authority
	China	  	MOFCOM (if approval prior to Closing is required)

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 65 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 5.1 
  
 Sellers’ Representations and Warranties 
  
 Subject to the limitations set forth in the Agreement, Sellers hereby
represent and warrant to Buyer as of the date of this Agreement and as of the Closing Date the following matters. Where any statement in the following representations and warranties is qualified by the expression «to the best of Sellers’
knowledge» or any similar expression, the Sellers shall be deemed to have knowledge of anything of which Sellers and|or any of the Key Persons have actual knowledge having made reasonable enquiry of the competent persons at the top management
level of the PO Companies. 
  

	1.	Ownership and Qualification 

  

	 	(a)	Sellers are the sole legal and beneficial owner of the Shares, free and clear of any Liens. There are no outstanding options, warrants, calls, rights or commitments, or any other
agreements of any character relating to the sale, issuance or voting of, or the granting of rights to acquire, any of the Shares or other securities of the Company. The certificates pursuant to Article 4.3.2(a) are the only existing
certificates regarding the Shares. 

  

	 	(b)	The Shares are validly issued and fully paid in. 

  

	 	(c)	All of the shares in each PO Company (other than those not owned directly or indirectly by the Company) are legally and beneficially owned by the Company (directly or indirectly)
free and clear of any Liens. There are no outstanding options, warrants, calls, rights or commitments, or any other agreements of any character relating to the sale, issuance or voting of, or the granting of rights to acquire, any such shares or
other securities of such companies. 

  

	 	(d)	All of the shares in each PO Company are validly issued and fully paid in. 

  

	 	(e)	The PO Companies are duly incorporated, organized and validly existing under the laws of their respective place of incorporation and have the full corporate power and authority to
own or use their assets and properties and to conduct their business as the same is presently being conducted. The share capital of each PO Company is set forth in Annex B. The share capital of each PO Company has not been repaid in
whole or in part. 

  

	 	(f)	The information in Annex B is true and correct. 

  

	2.	Due Authorization 

  

	 	(a)	Seller 1 and Seller 4 are corporations duly organized and validly existing under the Swiss laws and have the full corporate power, authority and necessary governmental
approvals to own or use their assets and properties and to conduct their business as the same is presently being conducted. 

  

	 	(b)	Each of Sellers has the absolute and unrestricted right, power, authority and capacity to execute this Agreement and to perform its respective obligations under this Agreement. This
Agreement constitutes legal, valid, and binding obligation of Sellers, enforceable against Sellers in accordance with its terms. 

  

	 	(c)	There exist no limitations under applicable law and the constituting documents, if any, of any of the Sellers, or any contracts by which any of the Seller is bound that would
prevent the Sellers from entering into or performing its obligations under this Agreement. 

  

	 	(d)	No authorizations, permits or consents are required from any governmental or administrative authority, or any third party (including without limitation any shareholders or creditors
of Sellers) for the consummation of the transactions contemplated by this Agreement other than as set forth in this Agreement. 

  

	 	(e)	There are no actions, suits or proceedings pending against Sellers or any of Sellers’ Affiliates before any court or administrative board, agency or commission which involve a
claim by a governmental or regulatory authority, or by a third party, which would operate to hinder or substantially impair the consummation of the transactions contemplated by this Agreement. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 66 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
Sellers are not aware of any actions, suits or proceedings in accordance with the preceding sentence which have been threatened in writing to be filed or
instituted against Sellers or any of Sellers’ Affiliates. 

  

	3.	Financial Statements and Events Subsequent Thereto 

  

	 	(a)	The consolidated financial statements of the Group as at December 31, 2006 as set forth in Annex 5.1.3 were prepared in accordance with IFRS as such standards are
applied pursuant to the Plus Orthopedics IFRS Accounting Manual Version 2.0 | October 2005 as disclosed in the Disclosure Information and based thereon and subject thereto fairly represent the financial position of the Group as at
December 31, 2006 and the results of the operations for the financial period then ended. 

  

	 	(b)	Since January 1, 2007, the Group has carried out its business in the ordinary course and as to investments and capital expenditure in line with the 2007 budget as approved by
the competent corporate body of the Group and contained in the Disclosure Information. 

  

	4.	Taxes 

  

	 	(a)	All Tax returns required to be filed prior to Closing by or with respect to Taxes payable or reimbursable by the Group have been timely filed. All such tax returns (a) have
been prepared in the manner required by applicable law, (b) are true, complete and not misleading in all material respects, and (c) accurately reflect the liability for Taxes of the Group in all material respects. 

 

	 	(b)	Each PO Company is and has at all times been resident for Tax purposes in its country of incorporation and is and has not at any time been treated as resident in any other
jurisdiction for any Tax purpose (including any double taxation treaty). 

  

	 	(c)	With respect to income or profits and gains taxes, the PO Companies are finally assessed by the competent tax authorities up to, and including, the business years as set forth in
Annex 5.1.4(c). 

  

	5.	Assets 

  

	 	(a)	The Group has good title to or the valid right to use all assets as reflected in the Consolidated Financial Statement and needed for the continued conduct of its business as the
same is currently being conducted; all such assets are in good working order (fair wear and tear excepted), have been properly maintained, are safe to operate in accordance with their current practice in their current condition and are not subject
to any Liens (or agreements to create Liens). None of the PO Companies has entered into any off balance sheet borrowing arrangement (including factoring arrangements). 

  

	 	(b)	The plant, machinery, vehicles and all other equipment owned or used in connection with the business of the Group are in reasonable repair and condition and good working order and
have been regularly and properly maintained. 

  

	 	(c)	The buildings, plants, structures, and equipment of the Group are structurally sound, are in good operating condition and repair, and are adequate for the uses to which they are
being put, and none of such buildings, plants, structures, or equipment is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost. The building, plants, structures, and
equipment of the Group are sufficient for the continued conduct of the Group’s businesses after the Closing in substantially the same manner as conducted prior to the Closing. 

  

	 	(d)	The operation of the manufacturing sites conducted by the PO Companies complies in all material respects with applicable laws and regulations, and the PO Companies are duly
authorized to operate such manufacturing sites pursuant to applicable laws and regulations. 

  

	6.	Inventory 

  
 All inventory including consignment stock of the Group consists of a quality and quantity usable and salable in the ordinary course of business, except
for obsolete items and items of below-standard 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 67 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 
quality, all of which have been written off or written down in accordance with IFRS in the Final Closing Accounts, as the case may be. All inventories not
written off have been valued at the lower of cost or net realizable value. The quantities of each item of inventory (whether raw materials, work-in-process, or finished goods) are not excessive, but are reasonable in the present circumstances of the
Group. 
  

	7.	Accounts Receivables and Payables 

  
 The trade accounts receivable and trade accounts payable as shown in the Consolidated Financial Statement and the Final Closing Accounts have payment
terms that are in line with normal industry levels in the respective countries and are maintained in the ordinary course of business of the Group. All accounts receivable are valid receivables and result from transactions in the ordinary course of
business or products delivered or services rendered in line with normal industry standards in the respective countries where such business is conducted. As of the date hereof, no written notice has been received from any account debtor that any
material amount of such accounts receivable are subject to any pending or threatened set-off, discount or counterclaim of any kind, other than consistent with past practice pursuant to the Group reserve methodologies. 
  

	8.	Intellectual Property Rights 

  

	 	(a)	All patents, trade names and trade marks registered in the name of one of the PO Companies are listed in Annex 5.1.8 (the Intellectual Property Rights). None of
the Intellectual Property Rights is subject to any Lien. 

  

	 	(b)	The Group is the legal and beneficial owner of, or has adequate license to use, all the know-how and all patents, trade names, trade marks, copyrights and other intellectual
property rights (including all applications for the protection thereof) used for the conduct of the Group’s business as it is being conducted at the Closing Date. 

  

	 	(c)	No claims have been made, or threatened in writing, challenging the use, validity, subsistence or enforceability of the Intellectual Property Rights and other intellectual property
rights owned by any of the PO Companies. All registration fees for the Intellectual Property Rights are paid. 

  

	 	(d)	To the best of Sellers’ knowledge, there has been no infringement of any of the Intellectual Property Rights or other intellectual property rights owned by any of the PO
Companies by any third party. To the best of Sellers’ knowledge, none of the PO Companies has been in conflict with, or infringed, any third party intellectual property rights. None of the PO Companies has been threatened in writing in
connection with any infringement. 

  

	9.	Product Registrations 

  

	 	(a)	Products developed, manufactured, supplied, marketed and|or sold by the Group, which would require registration or other regulatory approvals according to applicable laws and
regulations, are duly registered or approved and such registrations or approvals are complete, accurate and up to date in all material respects. The PO Companies have the sole rights under such product registrations and marketing rights and such
registrations and rights are in full force and effect. 

  

	 	(b)	All products developed, manufactured, supplied, marketed and|or sold by the Group are developed, manufactured, supplied, marketed and|or sold in all material respects in accordance
with the specifications and standards contained in relevant product registration documentations of the Group and in accordance with applicable laws and regulations, including, but not limited to GMP. 

  

	10.	Employment 

  

	 	(a)	No employee of any of the PO Companies has a contractual notice period longer than 6 (six) months nor is there a contractual termination compensation payable for termination on due
notice, which would exceed the equivalent of 6 (six) months’ salary. There are no material 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 68 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	 	 
salary increases resolved but not yet implemented. There are no employment or benefit agreements or plans entitling an employee to severance or other
payments due upon a change of control of the Group. 

  

	 	(b)	There are no current disputes of any of the PO Companies with governmental or self-regulatory authority, any works council or other employee representatives.

  

	 	(c)	Since January 1, 2007, through the date of this Agreement, none of the Key Persons has given or has been given notice of termination of his employment (if any) nor have in
respect of such Key Persons rescission proceedings been started or has the employment agreement been rescinded. 

  

	11.	Material Contracts 

  

	 	(a)	The Disclosure Information contains, lists or refers to all material contracts (the Material Contracts) of the Group, which: 

  

	 	(i)	contain any agreement by the Group prohibiting or materially limiting the right to compete in any material line of business presently conducted by the Group;

  

	 	(ii)	contain any agreement or series of agreements which provide for an annual aggregate payment obligation (Zahlungsverpflichtung) of the Group of an amount exceeding CHF *;

  

	 	(iii)	contain any agreement that involves performance of services or delivery of goods to one or more of the PO Companies of an amount or value exceeding CHF * per annum;

  

	 	(v)	contain any provision which provides for material adverse consequences to one or more of the PO Companies in case of a change of control of the Group; 

  

	 	(vi)	relate to the acquisition or disposal by a PO Company after January 1, 2004 of a company or business for a consideration in excess of CHF *; 

  

	 	(vii)	contain an outstanding obligation in respect of unpaid purchase price (whether or not contingent) of an amount exceeding CHF * upon acquisition of a company or business which
is not reflected in the Consolidated Financial Statements; 

  

	 	(viii)	relate to a joint-venture, alliances or other form of cooperation agreements with third parties providing for an annual aggregate payment obligation of the Group in excess of CHF *;

  

	 	(ix)	are not terminable on less than 12 (twelve) months’ notice without payment obligation triggered by such termination exceeding CHF *; or 

  

	 	(x)	relate to the ownership of shares or equivalent interests in each PO Company providing for any rights or obligations existing or outstanding as of the date hereof.

  

	 	(b)	As of the date hereof, the Material Contracts are, to Sellers’ best knowledge, valid and enforceable, and the Group has performed all material obligations arising out of such
contracts and no notice of termination has been received or given. The counterparties have performed all material obligations arising out of such contracts and to the best of Sellers’ knowledge no grounds for early termination exist.

  

	12.	Insurance 

  

	 	(a)	The Group has obtained reasonable insurance coverage and in line with average industrial standards and as required by law. All premiums due on all insurance contracts (the
Policies) entered into in favor of the Group have been duly paid and, to the best of Sellers’ knowledge, all the Policies are valid and in force. 

  

	 	(b)	There is no material claim outstanding under any of the Policies (or under any policies previously held by the Group); all material claims have been settled in full. Since
January 1, 2004 there have been no material claims as to which insurance coverage has been denied. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 69 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	13.	Litigation 

  
 There are no judgments, decrees or orders outstanding or unsatisfied, and there are no actions, suits or proceedings (Litigation) pending or
threatened in writing against any of the PO Companies by or before any court, arbitral tribunal, administrative board, agency or commission which involve a claim by a governmental or regulatory authority, or by a third party or employee, against any
of the PO Companies of an amount in dispute exceeding CHF *. To the Sellers’ best knowledge, there are no facts or circumstances from which it may be expected that any Litigation involving an amount in dispute exceeding CHF * may arise.

  

	14.	Absence of Certain Changes 

  
 Except for matters that would be permitted in accordance with Article 7 of the Agreement if they occurred after the date of this Agreement, there has
not occurred since January 1, 2007: 
  

	 	(a)	a Material Adverse Effect; 

  

	 	(b)	any matter set forth in Article 7.3 occurring outside the ordinary course of business or outside the 2007 budget as approved by the competent corporate body of the Group and
contained in the Disclosure Information and other than a matter set forth in paragraph (m) of Article 7.3. 

  

	15.	Subsidies 

  
 The Group is not subject to any arrangement for receipt or repayment of any grant, subsidy or financial assistance in excess of CHF * from any
government department or other similar entity that is not reflected in the Consolidated Financial Statements. The execution and consummation of this Agreement does not and will not result in any grant, subsidy or financial assistance from any
government department or other similar entity becoming repayable or accelerated. 
  

	16.	Compliance 

  
 The Group (i) has substantially (itself and in its dealings with third parties) complied with all applicable laws and regulations, and no material
action, suit or proceeding by any third party or any governmental or administrative authority is pending or threatened in writing against the Group alleging any failure to comply with any applicable laws or regulations, and (ii) has obtained
and been in substantial compliance with all of the terms and conditions of all Permits required under any applicable laws. 
  

	17.	Environmental 

  
 The Group does and has: 
  

	 	(a)	complied in all material respects with applicable laws and regulations concerning air, water or land and any other matter classified as an environmental matter under any such laws
and regulations (the Environmental Laws); 

  

	 	(b)	obtained and complied in all material respects with the terms and conditions of any and all licenses, consents, Permits or other authorizations made or issued pursuant to or
required by any Environmental Laws, all of which such licenses, consents, Permits or other authorizations are at the date hereof in full force and effect, and to Sellers’ best knowledge, no circumstance exists which will result in a material
modification, supervision, revocation or non-renewal of such licenses, consents, Permits or other authorizations, and 

  

	 	(c)	to the Sellers’ best knowledge, there is no material civil, criminal or administrative action, claim, investigation or other proceeding or suit active, pending or threatened in
writing against the Group or any of its officers or directors based on Environmental Laws. 

  

	18.	Product Liability 

  
 The Group has not manufactured, sold or supplied products which do not comply in any material respect with representations and warranties expressly or
implicitly made by the Group. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 70 | 100 

 Annex 5.1 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  

	19.	Benefit Plans 

  

	 	(a)	Particulars of all material agreements or arrangements for the payment of pensions, allowances, lump sums or other similar benefits on retirement or death or during periods of
sickness or disablement for the benefit of any current or former director, officer or employee of the Group or their dependants (the Benefit Plans) are set up in compliance with applicable laws and regulations. The Group has no material
obligation to provide or contribute to the provision of any Benefit Plan for or in respect of any of the current or former directors, officers or employees of the PO Companies nor has any proposal been announced or agreement been reached to
establish or contribute to any arrangement providing any such benefits. 

  

	 	(b)	All Benefit Plans are fully funded, as determined pursuant to IAS 19 on a PBO (protected benefit obligation) basis and applicable actuarial principles. All amounts due to be paid to
or in respect of the Benefit Plans by any PO Company on or before the date of this Agreement (including, for the avoidance of doubt, any costs incurred under the Benefit Plans with the previous provider Winterthur Columna, any and all costs incurred
by lack of compliance with applicable laws or regulations have been duly paid in full on the due dates for such payments and all those payments which fall due on or before the Closing Date will have been duly paid on or before the Closing Date.

  

	 	(c)	Other than the Benefit Plans, the Group does not provide or contribute to and is not liable to provide or contribute to the provision of benefits for or in respect of any of its
current or former directors, officers or employees or their dependants. 

  

	20.	Broker’s Fees 

  
 None of the PO Companies has an obligation to pay a broker’s, finder’s or transaction fee or commission in connection with the transactions
contemplated by this Agreement. 
  

	21.	Disclosure 

  
 The Disclosure Information was produced in good faith by Sellers for the purpose of assisting the Buyer in its due diligence investigation and contain all
information (including, for the avoidance of doubt, all information relating to the minority shareholders) which Sellers in good faith believe to be material for a reasonable buyer in evaluating the Group. The Disclosure Information is true,
accurate, complete and not misleading in all material respects. 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 71 | 100 

 Annex 5.1.3 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 5.1.3 
  
 Consolidated Financial Statements* 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 72 | 100 

 Annex 5.1.4(c) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 5.1.4(c) 
  
 Tax Assessment * 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 73 | 100 

 Annex 5.1.8 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 5.1.8 
  
 PO Intellectual Property Rights 
  
 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-011-
	 	Patent	 	M/PLU-011-EP/ES	 	* (indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment)	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Nov-1993	 	94901810.5	 	 	 	23-May-1997	 	0621767	 	16-Nov-2013	 	15	 	30-Nov-2007	 	1
																
	 M/PLU-011-
	 	Patent	 	M/PLU-011-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Nov-1993	 	9401810.5	 	 	 	23-May-1997	 	0621767	 	16-Nov-2013	 	15	 	30-Nov-2007	 	1
																
	 M/PLU-011-
	 	Patent	 	M/PLU-011-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Nov-1993	 	94901810.5	 	 	 	23-May-1997	 	0621767	 	16-Nov-2013	 	 	 	 	 	1
																
	 M/PLU-011-
	 	Patent	 	M/PLU-011-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Nov-1993	 	94901810.5	 	 	 	23-May-1997	 	0621767	 	16-Nov-2013	 	15	 	30-Nov-2007	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	59209018.3-08	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	31-Dec-2017	 	10	 	31-Dec-2006	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-US	 	*	 	 	 	*	 	In Kraft	 	07-Dec-1993	 	08/164,731	 	 	 	10-Oct-1995	 	5,456,717	 	07-Dec-2013	 	12	 	10-Apr-2007	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	59208975.4-08	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 74 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	31-Dec-2017	 	10	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-JP	 	*	 	 	 	*	 	In Kraft	 	24-Nov-1993	 	5-317314	 	 	 	12-Dec-2003	 	3502648	 	24-Nov-2013	 	4	 	12-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-US	 	*	 	 	 	*	 	In Kraft	 	07-Dec-1993	 	166,388	 	 	 	22-Aug-1995	 	5,443,520	 	07-Dec-2013	 	12	 	22-Feb-2007	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1994	 	94906208.7	 	 	 	09-Oct-1997	 	0634912	 	02-Feb-2014	 	5	 	28-Feb-1998	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1994	 	94906208.7	 	 	 	09-Oct-1997	 	0634912	 	02-Feb-2014	 	 	 	 	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1994	 	94906208.7	 	 	 	09-Oct-1997	 	0634912	 	02-Feb-2014	 	5	 	28-Feb-1998	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1994	 	94906208.7	 	 	 	09-Oct-1997	 	0634912	 	02-Feb-2014	 	 	 	 	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-PC/JP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	02-Feb-1994	 	6-517629	 	 	 	 	 	 	 	02-Feb-2014	 	 	 	 	 	1
																
	 M/PLU-023-
	 	Patent	 	M/PLU-023-PC/US	 	*	 	 	 	*	 	In Kraft	 	02-Feb-1994	 	08/318,894	 	 	 	08-Oct-1996	 	5,562,660	 	02-Feb-2014	 	 	 	 	 	1
																
	 M/PLU-026-
	 	Patent	 	M/PLU-026-DE	 	*	 	 	 	*	 	In Kraft	 	07-Dec-1993	 	P4341677.2-35	 	 	 	30-Jan-1995	 	4341677	 	07-Dec-2013	 	14	 	31-Dec-2006	 	1
																
	 M/PLU-027-
	 	Patent	 	M/PLU-027-PC/US	 	*	 	 	 	*	 	In Kraft	 	16-Feb-1994	 	08/318759	 	 	 	30-Jul-1996	 	5,540,686	 	16-Feb-2014	 	 	 	 	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	94917609.3	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/CH1	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	96109520.5	 	 	 	 	 	0736286	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	 	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	 	 	 	 	17-Jul-1997	 	59403882.0-08	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/DE1	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	96109520.5	 	 	 	 	 	59410300.2-08	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	94917609.3	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	94917609.3	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 75 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/FR1	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	96109520.5	 	 	 	 	 	0736286	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/GB1	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	96109520.5	 	 	 	 	 	0736286	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	94917609.3	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/IT1	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	96109520.5	 	 	 	 	 	0736286	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-PC/US	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	08/564,045	 	 	 	03-Feb-1998	 	5,713,902	 	03-Feb-2015	 	12	 	03-Aug-2009	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-PC/UST2	 	*	 	 	 	*	 	In Kraft	 	07-Nov-1997	 	08/966,077	 	 	 	27-Jul-1999	 	5,928,235	 	07-Nov-2017	 	8	 	27-Jan-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-UST2/M	 	*	 	 	 	*	 	In Kraft	 	07-Nov-1997	 	09/552,451	 	 	 	01-May-2001	 	6,224,601	 	07-Nov-2017	 	8	 	01-Nov-2008	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-UST2/T	 	*	 	 	 	*	 	In Kraft	 	07-Nov-1997	 	09/271,065	 	 	 	17-Jul-2001	 	6,261,290	 	07-Nov-2017	 	8	 	17-Jan-2009	 	1
																
	 M/PLU-033-
	 	Patent	 	M/PLU-033-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	16-Dec-1994	 	07-517753	 	 	 	 	 	 	 	16-Dec-2014	 	 	 	 	 	1
																
	 M/PLU-033-
	 	Patent	 	M/PLU-033-PC/US	 	*	 	 	 	*	 	In Kraft	 	16-Dec-1994	 	08/513,954	 	 	 	26-May-1998	 	5,755,802	 	26-May-2015	 	 	 	 	 	1
																
	 M/PLU-034-
	 	Patent	 	M/PLU-034-DE	 	*	 	 	 	*	 	In Kraft	 	23-Nov-1993	 	P4339895.2-35	 	 	 	20-Sep-1994	 	4339895	 	23-Nov-2013	 	15	 	30-Nov-2007	 	1
																
	 M/PLU-035-
	 	Patent	 	M/PLU-035-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	23-Feb-1995	 	 	 	 	 	25-Jun-1998	 	0746276	 	23-Feb-2015	 	13	 	28-Feb-2007	 	1
																
	 M/PLU-035-
	 	Patent	 	M/PLU-035-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	23-Feb-1995	 	 	 	 	 	25-Jun-1998	 	59503076.9-08	 	23-Feb-2015	 	13	 	28-Feb-2007	 	1
																
	 M/PLU-042-
	 	Patent	 	M/PLU-042-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	11-Aug-1996	 	08/745252	 	 	 	 	 	 	 	11-Aug-2016	 	 	 	 	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	96916131.4	 	 	 	08-Nov-2001	 	0827386	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	 	 	 	 	08-Nov-2001	 	0827386	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	 	 	 	 	08-Nov-2001	 	59608508.7-08	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	96916131.4	 	 	 	08-Nov-2001	 	0827386	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	96916131.4	 	 	 	08-Nov-2001	 	0827386	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-045-
	 	Patent	 	M/PLU-045-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-May-1996	 	96916131.4	 	 	 	08-Nov-2001	 	0827386	 	20-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-051-
	 	Patent	 	M/PLU-051-DE/I	 	*	 	 	 	*	 	In Kraft	 	06-Sep-1996	 	19636309.8-09	 	 	 	18-Dec-1997	 	19636309	 	06-Sep-2016	 	11	 	30-Sep-2006	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-DE	 	*	 	 	 	*	 	In Kraft	 	21-Feb-1996	 	19606462.7-09	 	 	 	05-May-1997	 	19606462	 	21-Feb-2016	 	12	 	28-Feb-2007	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 76 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP	 	*	 	 	 	*	 	Offengelegt	 	14-Feb-1997	 	97102432.8-2310	 	0791343	 	 	 	 	 	14-Feb-2017	 	 	 	 	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/CH	 	*	 	 	 	*	 	In Kraft	 	14-Feb-1997	 	97102432.8	 	 	 	08-Feb-2003	 	0791343	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102432.8	 	 	 	 	 	59707180.2-08	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/ES	 	*	 	 	 	*	 	In Kraft	 	14-Feb-1997	 	97102432.8	 	 	 	08-Feb-2003	 	0791343	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/FR	 	*	 	 	 	*	 	In Kraft	 	14-Feb-1997	 	97102432.8	 	 	 	08-Feb-2003	 	0791343	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/GB	 	*	 	 	 	*	 	In Kraft	 	14-Feb-1997	 	97102432.8	 	 	 	08-Feb-2003	 	0791343	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102432.8	 	 	 	 	 	 	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-057-
	 	Patent	 	M/PLU-057-US	 	*	 	 	 	*	 	In Kraft	 	21-Feb-1997	 	08/803,989	 	 	 	21-Sep-1999	 	5,954,770	 	21-Feb-2017	 	8	 	21-Mar-2007	 	1
																
	 M/PLU-058-
	 	Patent	 	M/PLU-058-CH	 	*	 	 	 	*	 	In Kraft	 	07-Mar-1997	 	0554/97	 	 	 	15-Jan-2002	 	692023	 	07-Mar-2017	 	11	 	31-Mar-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-DE/I	 	*	 	 	 	*	 	In Kraft	 	07-May-1996	 	19618321.9-35	 	 	 	29-Aug-2000	 	19618321.9-35	 	07-May-2016	 	12	 	31-May-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	 	 	 	 	30-Aug-2001	 	59704823.1-08	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/LU	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	28-Feb-2022	 	6	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/SE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-US	 	*	 	 	 	*	 	In Kraft	 	21-Feb-1997	 	08/804,374	 	 	 	26-May-1998	 	5,755,804	 	21-Feb-2017	 	12	 	26-Nov-2009	 	1
																
	 M/PLU-063-
	 	Patent	 	M/PLU-063-DE	 	*	 	 	 	*	 	In Kraft	 	26-Aug-1996	 	19634484.0-35	 	 	 	02-Oct-1997	 	196 34 484	 	26-Aug-2016	 	12	 	31-Aug-2007	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 77 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-063-
	 	Patent	 	M/PLU-063-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	19-Jun-1997	 	97929225.7	 	 	 	 	 	 	 	19-Jun-2017	 	11	 	30-Jun-2007	 	1
																
	 M/PLU-063-
	 	Patent	 	M/PLU-063-EP/DE	 	*	 	 	 	*	 	In Kraft	 	19-Jun-1997	 	97929225.7	 	 	 	 	 	59710667.3-08	 	19-Jun-2017	 	11	 	30-Jun-2007	 	1
																
	 M/PLU-063-
	 	Patent	 	M/PLU-063-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	19-Jun-1997	 	97929225.7	 	 	 	 	 	 	 	19-Jun-2017	 	11	 	30-Jun-2007	 	1
																
	 M/PLU-063-
	 	Patent	 	M/PLU-063-PC/US	 	*	 	 	 	*	 	In Kraft	 	19-Jun-1997	 	09/254,117	 	 	 	19-Dec-2000	 	6,162,227	 	19-Jun-2017	 	8	 	19-Jun-2008	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/BE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	59708451.3-08	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-PC/JP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	11-Sep-1997	 	10-513265	 	 	 	 	 	 	 	11-Sep-2017	 	 	 	 	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-PC/US	 	*	 	 	 	*	 	In Kraft	 	11-Sep-1997	 	09/254,853	 	 	 	10-Jul-2001	 	6,258,127	 	11-Sep-2017	 	8	 	10-Jan-2009	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-DE	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1997	 	19716879.5-09	 	 	 	17-Dec-1998	 	19716879	 	22-Apr-2017	 	11	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-EP/CH	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1998	 	98924169.0-2310	 	 	 	01-Sep-2004	 	0975287	 	22-Apr-2018	 	10	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	22-Apr-1998	 	98924169.0-2310	 	 	 	 	 	59811900.0-08	 	22-Apr-2018	 	10	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-EP/FR	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1998	 	98924169.0-2310	 	 	 	01-Sep-2004	 	0975287	 	22-Apr-2018	 	10	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-EP/GB	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1998	 	98924169.0-2310	 	 	 	01-Sep-2004	 	0975287	 	22-Apr-2018	 	10	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-EP/IT	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1998	 	98924169.0-2310	 	 	 	01-Sep-2004	 	0975287	 	22-Apr-2018	 	10	 	30-Apr-2007	 	1
																
	 M/PLU-066-
	 	Patent	 	M/PLU-066-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	22-Apr-1998	 	 	 	 	 	 	 	 	 	22-Apr-2018	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 78 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-066-
	 	Patent	 	M/PLU-066-PC/US	 	*	 	 	 	*	 	In Kraft	 	22-Apr-1998	 	09/403,645	 	 	 	02-Apr-2002	 	6,364,911	 	22-Apr-2018	 	8	 	02-Oct-2009	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-DE	 	*	 	 	 	*	 	Offengelegt	 	14-Nov-1996	 	19647155.9-09	 	 	 	13-May-1998	 	19647155.9-09	 	14-Nov-2016	 	11	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	 	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	59711888.4-08	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/FI	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	 	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	 	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	0942692	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	 	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/SE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	0942692	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-PC/US	 	*	 	 	 	*	 	In Kraft	 	14-Nov-1997	 	09/308,457	 	 	 	26-Dec-2000	 	6,165,221	 	14-Nov-2017	 	8	 	26-Jun-2008	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-DE/I	 	*	 	 	 	*	 	In Kraft	 	20-Jan-1997	 	19701778.9-09	 	 	 	05-Aug-1998	 	19701778	 	20-Jan-2017	 	11	 	31-Jan-2007	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	0944368	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	59709285.0-08	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	0944368	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	0944368	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	0944368	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-PC/US	 	*	 	 	 	*	 	In Kraft	 	21-Nov-1997	 	09/308,762	 	 	 	25-Mar-2003	 	 	 	21-Nov-2017	 	8	 	25-Sep-2010	 	1
																
	 M/PLU-089-
	 	Patent	 	M/PLU-089-DE/I	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	05-Sep-1997	 	19738968.6-35	 	 	 	 	 	 	 	05-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-089-
	 	Patent	 	M/PLU-089-PC/US	 	*	 	 	 	*	 	In Kraft	 	31-Jul-1998	 	09/485,043	 	 	 	18-Sep-2001	 	6,290,700	 	31-Jul-2018	 	8	 	18-Mar-2009	 	1
																
	 M/PLU-097-
	 	Patent	 	M/PLU-097-PC/EP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	07-Apr-2000	 	00925184.4-2310	 	 	 	 	 	 	 	07-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-097-
	 	Patent	 	M/PLU-097-PC/US	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	07-Apr-2000	 	09/958463	 	 	 	 	 	 	 	07-Apr-2020	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 79 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	 Publication No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-098-
	 	Patent	 	M/PLU-098-DE/I	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	23-Jun-1999	 	19928791.0-35	 	 	 	 	 	 	 	23-Jun-2019	 	 	 	 	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/BE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/CH	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	12-Apr-2000	 	00107892.2	 	 	 	 	 	50011481.1-08	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/ES	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/GR	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/IE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/IT	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/NL	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	2	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-EP/SE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107892.2-2310	 	 	 	02-Nov-2005	 	1044665	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-US	 	*	 	 	 	*	 	In Kraft	 	13-Apr-2000	 	 	 	 	 	01-Apr-2003	 	6,540,788	 	13-Apr-2020	 	8	 	01-Oct-2010	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-US/CIP1	 	*	 	 	 	*	 	Anmeldung eingereicht	 	12-May-2006	 	11/433,067	 	US 2006/0276904 A1	 	 	 	 	 	12-May-2026	 	 	 	 	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-US/CON1	 	*	 	 	 	*	 	Offengelegt	 	12-May-2006	 	11/432,914	 	US 2006/0206212 A1	 	 	 	 	 	12-May-2026	 	 	 	 	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-US/T1	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-Jan-2003	 	10/355,385	 	 	 	 	 	 	 	30-Jan-2023	 	 	 	 	 	1
																
	 M/PLU-098-
	 	Patent	 	M/PLU-098-US/T2	 	*	 	 	 	*	 	In Kraft	 	23-Jan-2003	 	10/355,383	 	 	 	26-Oct-2004	 	6,808,539	 	23-Jan-2023	 	4	 	26-Apr-2008	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/BE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/CH	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	12-Apr-2000	 	00107891.4-2310	 	 	 	 	 	50006921.2-08	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/ES	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/FR	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/GB	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/GR	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/IE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 80 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/IT	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/NL	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	3	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/SE	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-US	 	*	 	 	 	*	 	In Kraft	 	13-Apr-2000	 	09/548,576	 	 	 	02-Sep-2003	 	6,613,094	 	13-Apr-2020	 	4	 	02-Mar-2007	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-US/A	 	*	 	 	 	*	 	In Kraft	 	13-Apr-2000	 	10/652,714	 	 	 	28-Feb-2006	 	7,004,973	 	13-Apr-2020	 	4	 	28-Aug-2009	 	1
																
	 M/PLU-102-
	 	Patent	 	M/PLU-102-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	28-Feb-2000	 	00104098.9-2310	 	 	 	 	 	1033117	 	28-Feb-2020	 	8	 	28-Feb-2007	 	1
																
	 M/PLU-102-
	 	Patent	 	M/PLU-102-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	28-Feb-2000	 	00104098.9-2310	 	 	 	 	 	50006919.0-08	 	28-Feb-2020	 	8	 	28-Feb-2007	 	1
																
	 M/PLU-102-
	 	Patent	 	M/PLU-102-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	28-Feb-2000	 	00104098.9-2310	 	 	 	 	 	1033117	 	28-Feb-2020	 	8	 	28-Feb-2007	 	1
																
	 M/PLU-102-
	 	Patent	 	M/PLU-102-US/A	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	09-Jul-2003	 	10/616,102	 	US-2004-0059426-A1	 	 	 	 	 	09-Jul-2023	 	 	 	 	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-DE	 	*	 	 	 	*	 	In Kraft	 	23-Jun-1999	 	19928709.0-09	 	 	 	03-Feb-2005	 	19928709.0-09	 	23-Jun-2019	 	9	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/BE	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/CH	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	50005006.6-08	 	 	 	 	 	 	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/ES	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/FR	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/GB	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	 	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/GR	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	31-Mar-2004	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/IE	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/IT	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/NL	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/SE	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-US	 	*	 	 	 	*	 	In Kraft	 	22-Jun-2000	 	09/599,663	 	 	 	20-Aug-2002	 	6,436,147	 	22-Jun-2020	 	8	 	20-Feb-2010	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/BE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	50008819.5-08	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/ES	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 81 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/IE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	3	 	31-May-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-PC/CN	 	*	 	 	 	*	 	In Kraft	 	17-Oct-2000	 	00817189.0	 	CN 1409624A	 	24-Dec-2004	 	WO 01/28462	 	17-Oct-2020	 	7	 	17-Oct-2006	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	17-Oct-2000	 	PCT/EP00/10235	 	 	 	 	 	2001-531059	 	17-Oct-2020	 	 	 	 	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-PC/US	 	*	 	 	 	*	 	In Kraft	 	17-Oct-2000	 	 	 	 	 	03-Aug-2004	 	6,770,098	 	17-Oct-2020	 	4	 	03-Feb-2008	 	1
																
	 M/PLU-120-
	 	Patent	 	M/PLU-120-DE	 	*	 	 	 	*	 	Offengelegt	 	04-May-2000	 	10021697.8-35	 	 	 	 	 	 	 	04-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-120-
	 	Patent	 	M/PLU-120-EP/CH	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2001	 	01109193.1-1526	 	 	 	 	 	1151732	 	12-Apr-2021	 	7	 	30-Apr-2007	 	1
																
	 M/PLU-120-
	 	Patent	 	M/PLU-120-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	12-Apr-2001	 	01109193.1-1526	 	 	 	 	 	50110429.1-08	 	12-Apr-2021	 	7	 	30-Apr-2007	 	1
																
	 M/PLU-120-
	 	Patent	 	M/PLU-120-EP/FR	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2001	 	01109193.1-1526	 	 	 	 	 	1151732	 	12-Apr-2021	 	7	 	30-Apr-2007	 	1
																
	 M/PLU-120-
	 	Patent	 	M/PLU-120-EP/GB	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2001	 	01109193.1-1526	 	 	 	 	 	1151732	 	12-Apr-2021	 	7	 	30-Apr-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/CH	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	17-May-2001	 	01984556.9-1265	 	1313400	 	 	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	17-May-2001	 	01984556.9-1265	 	1313400	 	 	 	50108254.9-08	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/ES	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/FR	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/GB	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/IT	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/NL	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	2	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-PC/CN	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	17-May-2001	 	01816529.X	 	 	 	 	 	 	 	 	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 82 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	17-May-2001	 	2002-522776	 	 	 	 	 	 	 	17-May-2021	 	 	 	 	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-PC/US	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	10/363,488	 	 	 	16-Aug-2005	 	6,928,742	 	17-May-2021	 	4	 	16-Feb-2009	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-US/CON	 	*	 	 	 	*	 	Anmeldung eingereicht	 	16-Aug-2005	 	11/205,761	 	US 2006-0089657 A1	 	 	 	 	 	16-Aug-2025	 	 	 	 	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-DE	 	*	 	 	 	*	 	In Kraft	 	05-Feb-2001	 	10105085.2-09	 	 	 	27-Nov-2001	 	10105085	 	05-Feb-2021	 	7	 	28-Feb-2007	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	31-Jan-2002	 	02718071.0	 	 	 	 	 	 	 	31-Jan-2022	 	 	 	 	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	31-Jan-2002	 	02718071.0	 	1358053	 	 	 	 	 	31-Jan-2022	 	 	 	 	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	31-Jan-2002	 	02718071.0	 	 	 	 	 	 	 	31-Jan-2022	 	 	 	 	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-PC/EP	 	*	 	 	 	*	 	Mitteilung 51 (4) erhalten	 	31-Jan-2002	 	02718071.0	 	1358053	 	 	 	 	 	31-Jan-2022	 	6	 	31-Jan-2007	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-PC/JP	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	31-Jan-2002	 	2002-562537	 	 	 	 	 	 	 	31-Jan-2022	 	 	 	 	 	1
																
	 M/PLU-133-
	 	Patent	 	M/PLU-133-PC/US	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	31-Jan-2002	 	10/468,673	 	US 2004-0132852-A1	 	 	 	 	 	31-Jan-2022	 	 	 	 	 	1
																
	 M/PLU-138-
	 	Patent	 	M/PLU-138-DE	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	28-Aug-2001	 	10141976.7-54	 	 	 	 	 	 	 	28-Aug-2021	 	7	 	31-Aug-2007	 	1
																
	 M/PLU-144-
	 	Patent	 	M/PLU-144-DE/I	 	*	 	 	 	*	 	Anmeldung eingereicht	 	18-Feb-2003	 	10306793.0	 	 	 	 	 	 	 	18-Feb-2023	 	5	 	28-Feb-2007	 	1
																
	 M/PLU-144-
	 	Patent	 	M/PLU-144-PC/EP	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	29-Apr-2003	 	03752717.3	 	1507472	 	 	 	 	 	29-Apr-2023	 	5	 	30-Apr-2007	 	1
																
	 M/PLU-144-
	 	Patent	 	M/PLU-144-PC/JP	 	*	 	 	 	*	 	Prüfung beantragt	 	29-Apr-2003	 	P2004-504878	 	 	 	 	 	 	 	29-Apr-2023	 	 	 	 	 	1
																
	 M/PLU-144-
	 	Patent	 	M/PLU-144-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	29-Apr-2003	 	10/994188	 	 	 	 	 	 	 	29-Apr-2023	 	 	 	 	 	1
																
	 M/PLU-146-
	 	Patent	 	M/PLU-146-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	21-May-2002	 	10222416.1	 	 	 	 	 	 	 	21-May-2022	 	 	 	 	 	1
																
	 M/PLU-146-
	 	Patent	 	M/PLU-146-PC/EP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	18-Feb-2003	 	03752711.6-2318	 	1507488	 	 	 	 	 	18-Feb-2023	 	5	 	28-Feb-2007	 	1
																
	 M/PLU-146-
	 	Patent	 	M/PLU-146-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	18-Feb-2003	 	10/994,186	 	 	 	 	 	 	 	18-Feb-2023	 	 	 	 	 	1
																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-DE/I	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	16-Sep-2002	 	10243101.9-45	 	 	 	 	 	 	 	16-Sep-2022	 	5	 	30-Sep-2006	 	1
																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-PC/CN	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	27-May-2003	 	03815104.9	 	CN1665551A	 	 	 	 	 	 	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 83 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-PC/EP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	27-May-2003	 	03732486.0-2107	 	1515758	 	 	 	 	 	27-May-2023	 	5	 	31-May-2007	 	1
																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-PC/JP	 	*	 	 	 	*	 	Prüfung beantragt	 	27-May-2003	 	2004-516563	 	 	 	 	 	 	 	27-May-2023	 	 	 	 	 	1
																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-PC/US	 	*	 	 	 	*	 	Offengelegt	 	27-May-2003	 	10/519,338	 	US 2006/0100716 A1	 	 	 	 	 	27-May-2023	 	 	 	 	 	1
																
	 M/PLU-149-
	 	Patent	 	M/PLU-149-PC/ZA	 	*	 	 	 	*	 	In Kraft	 	27-May-2003	 	2004/9778	 	 	 	31-May-2006	 	2004/09778	 	27-May-2023	 	5	 	27-May-2007	 	1
																
	 M/PLU-150-
	 	Patent	 	M/PLU-150-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	29-Oct-2002	 	10250390.7	 	 	 	 	 	 	 	29-Oct-2022	 	6	 	31-Oct-2007	 	1
																
	 M/PLU-154-
	 	Patent	 	M/PLU-154-DE	 	*	 	 	 	*	 	In Kraft	 	22-Sep-2003	 	10343826.2-09	 	 	 	09-Feb-2006	 	10343826	 	22-Sep-2023	 	4	 	30-Sep-2006	 	1
																
	 M/PLU-154-
	 	Patent	 	M/PLU-154-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	15-Sep-2004	 	04765254.0	 	1667596	 	 	 	 	 	15-Sep-2024	 	3	 	30-Sep-2006	 	1
																
	 M/PLU-154-
	 	Patent	 	M/PLU-154-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	15-Sep-2004	 	10/573,144	 	 	 	 	 	 	 	15-Sep-2024	 	 	 	 	 	1
																
	 M/PLU-165-
	 	Patent	 	M/PLU-165-DE/I	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	25-May-2004	 	102004025612.8-35	 	 	 	 	 	 	 	25-May-2024	 	4	 	31-May-2007	 	1
																
	 M/PLU-165-
	 	Patent	 	M/PLU-165-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	20-Apr-2005	 	05735803.8-2318	 	1742583	 	 	 	 	 	20-Apr-2025	 	4	 	30-Apr-2008	 	1
																
	 M/PLU-165-
	 	Patent	 	M/PLU-165-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	20-Apr-2005	 	11/568,178	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-169-
	 	Patent	 	M/PLU-169-DE/I	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	31-Aug-2004	 	102004042183.8-35	 	 	 	 	 	 	 	31-Aug-2024	 	4	 	31-Aug-2007	 	1
																
	 M/PLU-169-
	 	Patent	 	M/PLU-169-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-May-2005	 	05754311.8	 	 	 	 	 	 	 	30-May-2025	 	4	 	31-May-2008	 	1
																
	 M/PLU-169-
	 	Patent	 	M/PLU-169-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-May-2005	 	11/571,226	 	 	 	 	 	 	 	30-May-2025	 	 	 	 	 	1
																
	 M/PLU-176-
	 	Patent	 	M/PLU-176-EP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	23-Dec-2004	 	04030665.6-2310	 	1674051	 	 	 	 	 	23-Dec-2024	 	4	 	31-Dec-2007	 	1
																
	 M/PLU-176-
	 	Patent	 	M/PLU-176-PC	 	*	 	 	 	*	 	Offengelegt	 	22-Dec-2005	 	PCT/EP2005/013905	 	WO 2006/066936	 	 	 	 	 	22-Dec-2025	 	2	 	22-Dec-2007	 	1
																
	 M/PLU-177-
	 	Patent	 	M/PLU-177-DE	 	*	 	 	 	*	 	Recherche abgeschlossen	 	09-Sep-2004	 	102004043700.9	 	 	 	 	 	 	 	09-Sep-2024	 	3	 	30-Sep-2006	 	1
																
	 M/PLU-177-
	 	Patent	 	M/PLU-177-EP	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	17-Aug-2005	 	05017885.4-2310	 	1642552	 	 	 	 	 	17-Aug-2025	 	3	 	31-Aug-2007	 	1
																
	 M/PLU-177-
	 	Patent	 	M/PLU-177-US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	09-Sep-2005	 	11/222,678	 	 	 	 	 	 	 	09-Sep-2025	 	 	 	 	 	1
																
	 M/PLU-179-
	 	Patent	 	M/PLU-179-DE	 	*	 	 	 	*	 	Recherche abgeschlossen	 	05-Nov-2004	 	102004053606.6	 	 	 	 	 	 	 	05-Nov-2024	 	3	 	30-Nov-2006	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 84 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-179-
	 	Patent	 	M/PLU-179-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	04-Nov-2005	 	05823121.8	 	 	 	 	 	 	 	04-Nov-2025	 	4	 	30-Nov-2008	 	1
																
	 M/PLU-179-
	 	Patent	 	M/PLU-179-US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	07-Nov-2005	 	11/269,125	 	US 2006/0111787 A1	 	 	 	 	 	07-Nov-2025	 	 	 	 	 	1
																
	 M/PLU-183-
	 	Patent	 	M/PLU-183-DE/I	 	*	 	 	 	*	 	Recherche abgeschlossen	 	05-Apr-2005	 	102005015598.7	 	 	 	 	 	 	 	05-Apr-2025	 	3	 	30-Apr-2007	 	1
																
	 M/PLU-188-
	 	Patent	 	M/PLU-188-DE	 	*	 	 	 	*	 	Anmeldung noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-190-
	 	Patent	 	M/PLU-190-DE	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	18-Oct-2005	 	102005049851.5-35	 	 	 	 	 	 	 	18-Oct-2025	 	3	 	31-Oct-2007	 	1
																
	 M/PLU-190-
	 	Patent	 	M/PLU-190-PC	 	*	 	 	 	*	 	Anmeldung eingereicht	 	18-Oct-2006	 	PCT/EP2006/010052	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-191-
	 	Patent	 	M/PLU-191-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	02-Nov-2005	 	102005052354.4	 	 	 	 	 	 	 	02-Nov-2025	 	3	 	30-Nov-2007	 	1
																
	 M/PLU-191-
	 	Patent	 	M/PLU-191-PC	 	*	 	 	 	*	 	Anmeldung eingereicht	 	12-Oct-2006	 	PCT/EP2006/009886	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-192-
	 	Patent	 	M/PLU-192-US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	26-Jul-2006	 	11/460,098	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-193-
	 	Patent	 	M/PLU-193-DE/I	 	*	 	 	 	*	 	Recherche abgeschlossen	 	12-Oct-2005	 	102005048873.0	 	 	 	 	 	 	 	20-Sep-2025	 	3	 	30-Sep-2007	 	1
																
	 M/PLU-193-
	 	Patent	 	M/PLU-193-PC	 	*	 	 	 	*	 	Recherchenergebnis erhalten	 	08-Aug-2006	 	PCT/EP2006/007842	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-194-
	 	Patent	 	M/PLU-194-PC/I	 	*	 	 	 	*	 	Anmeldung eingereicht	 	10-Mar-2006	 	PCT/EP2006/002239	 	 	 	 	 	 	 	10-Mar-2026	 	 	 	 	 	1
																
	 M/PLU-198-
	 	Patent	 	M/PLU-198-DE	 	*	 	 	 	*	 	Noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-199-
	 	Patent	 	M/PLU-199-DE	 	*	 	 	 	*	 	Recherche beantragt	 	13-Apr-2006	 	102006017473.9	 	 	 	 	 	 	 	13-Apr-2026	 	3	 	30-Apr-2008	 	1
																
	 M/PLU-200-
	 	Patent	 	M/PLU-200-DE	 	*	 	 	 	*	 	In Kraft	 	22-Dec-2003	 	10360390.5	 	 	 	27-Oct-2005	 	10360390.5-09	 	22-Dec-2023	 	4	 	31-Dec-2006	 	1
																
	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/AU	 	*	 	 	 	*	 	Anmeldung eingereicht	 	13-Dec-2004	 	2004308073	 	 	 	 	 	 	 	13-Dec-2024	 	6	 	13-Dec-2009	 	1
																
	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/CN	 	*	 	 	 	*	 	Prüfung beantragt	 	13-Dec-2004	 	200480038580.8	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	13-Dec-2004	 	04803788.1	 	1699386	 	 	 	 	 	13-Dec-2024	 	4	 	31-Dec-2007	 	1
																
	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/IN	 	*	 	 	 	*	 	Anmeldung eingereicht	 	13-Dec-2004	 	2242/CHENP/2006	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	13-Dec-2004	 	2006-544297	 	 	 	 	 	 	 	13-Dec-2024	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 85 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-201-
	 	Patent	 	M/PLU-201-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	13-Dec-2004	 	10/596,752	 	 	 	 	 	 	 	13-Dec-2024	 	 	 	 	 	1
																
	 M/PLU-202-
	 	Patent	 	M/PLU-202-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	03-May-2000	 	10021387.1-35	 	 	 	12-Sep-2002	 	10021387	 	03-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-203-
	 	Patent	 	M/PLU-203-DE	 	*	 	 	 	*	 	Recherche abgeschlossen	 	31-Jul-2006	 	102006035602.0	 	 	 	 	 	 	 	31-Jul-2026	 	3	 	31-Jul-2008	 	1
																
	 M/PLU-204-
	 	Patent	 	M/PLU-204-DE	 	*	 	 	 	*	 	Recherche abgeschlossen	 	23-Jun-2006	 	102006028995.1	 	 	 	 	 	 	 	23-Jun-2026	 	3	 	30-Jun-2008	 	1
																
	 M/PLU-210-
	 	Patent	 	M/PLU-210-DE/I	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-Aug-2006	 	102006040501.3	 	 	 	 	 	 	 	30-Aug-2026	 	3	 	31-Aug-2008	 	1
																
	 M/PLU-214-
	 	Patent	 	M/PLU-214-PC	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-Oct-2006	 	PCT/EP2006/010423	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-216-
	 	Patent	 	M/PLU-216-DE	 	*	 	 	 	*	 	Recherche beantragt	 	29-Dec-2006	 	102006062618.4	 	 	 	 	 	 	 	29-Dec-2026	 	3	 	31-Dec-2008	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	24-Jan-2003	 	03701707.6	 	1448360	 	14-Dec-2005	 	1448360	 	24-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	24-Jan-2003	 	03701707.6	 	1448360	 	 	 	1448360	 	24-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	24-Jan-2003	 	03701707.6	 	1448360	 	14-Dec-2005	 	1448360	 	24-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-PC/AU	 	*	 	 	 	*	 	Prüfung beantragt	 	24-Jan-2003	 	2003202796	 	 	 	 	 	 	 	24-Jan-2023	 	6	 	24-Jan-2008	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-PC/CN	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	24-Jan-2003	 	03802937.5	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	24-Jan-2003	 	2003-563802	 	 	 	 	 	 	 	24-Jan-2023	 	 	 	 	 	1
																
	 M/PLU-217-
	 	Patent	 	M/PLU-217-PC/US	 	*	 	 	 	*	 	Anmeldung eingereicht	 	24-Jan-2003	 	10/501,936	 	 	 	 	 	 	 	24-Jan-2023	 	 	 	 	 	1
																
	 M/PLU-219-
	 	Patent	 	M/PLU-219-EP	 	*	 	 	 	*	 	Noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-220-
	 	Patent	 	M/PLU-220-DE	 	*	 	 	 	*	 	Noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-222-
	 	Patent	 	M/PLU-222-DE	 	*	 	 	 	*	 	Noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-223-
	 	Patent	 	M/PLU-223-DE	 	*	 	 	 	*	 	Noch nicht eingereicht	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/END-013-
	 	Patent	 	M/END-013-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Dec-1994	 	95905074.1	 	 	 	03-Aug-2000	 	0732903	 	16-Dec-2014	 	13	 	31-Dec-2006	 	1
																
	 M/END-013-
	 	Patent	 	M/END-013-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	16-Dec-1994	 	95905074.1	 	 	 	03-Aug-2000	 	69425902.0-08	 	16-Dec-2014	 	13	 	31-Dec-2006	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 86 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

																
	 M/END-013-
	 	Patent	 	M/END-013-PC/US	 	*	 	 	 	*	 	In Kraft	 	16-Dec-1994	 	08/652,568	 	 	 	09-May-2000	 	6,059,833	 	09-May-2017	 	8	 	09-Nov-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-DE/I	 	*	 	 	 	*	 	In Kraft	 	03-Feb-1997	 	19703987.1-35	 	 	 	12-Feb-1998	 	19703987	 	03-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-EP/DE	 	*	 	 	 	*	 	In Kraft	 	02-Feb-1998	 	98908039.5	 	 	 	 	 	59808459.2-08	 	02-Feb-2018	 	10	 	28-Feb-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1998	 	98908039.5	 	 	 	 	 	0957784	 	02-Feb-2018	 	10	 	28-Feb-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1998	 	98908039.5	 	 	 	 	 	0957784	 	02-Feb-2018	 	10	 	28-Feb-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1998	 	98908039.5	 	 	 	 	 	0957784	 	02-Feb-2018	 	10	 	28-Feb-2007	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	02-Feb-1998	 	10-532549	 	 	 	 	 	 	 	02-Feb-2018	 	 	 	 	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-PC/US	 	*	 	 	 	*	 	In Kraft	 	02-Feb-1998	 	09/355,717	 	 	 	24-Oct-2000	 	6,136,037	 	02-Feb-2018	 	8	 	24-Apr-2008	 	1
																
	 M/END-031-
	 	Patent	 	M/END-031-DE	 	*	 	 	 	*	 	Prüfung im Gange	 	14-Feb-1997	 	19705733.0	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/BE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	59806747.7-08	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/DK	 	*	 	 	 	*	 	In Kraft	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/ES	 	*	 	 	 	*	 	In Kraft	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/GR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/IE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	98941383,6	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/SE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-PC/JP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	20-Jul-1998	 	2000-503795	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
	 M/END-032-
	 	Patent	 	M/END-032-PC/US	 	*	 	 	 	*	 	In Kraft	 	20-Jul-1998	 	09/463,476	 	 	 	04-Dec-2001	 	6,325,829	 	20-Jul-2018	 	8	 	04-Jun-2009	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 87 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/END-034-
	 	Patent	 	M/END-034-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	01-Dec-1999	 	99123862.7-2310	 	 	 	 	 	1018317	 	01-Dec-2019	 	8	 	31-Dec-2006	 	1
																
	 M/END-034-
	 	Patent	 	M/END-034-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	01-Dec-1999	 	99123862.7-2310	 	 	 	 	 	59912618.3-08	 	01-Dec-2019	 	8	 	31-Dec-2006	 	1
																
	 M/END-034-
	 	Patent	 	M/END-034-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	01-Dec-1999	 	99123862.7-2310	 	 	 	 	 	1018317	 	01-Dec-2019	 	8	 	31-Dec-2006	 	1
																
	 M/END-034-
	 	Patent	 	M/END-034-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	01-Dec-1999	 	99123862.7-2310	 	 	 	 	 	1018317	 	01-Dec-2019	 	8	 	31-Dec-2006	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-DE	 	*	 	 	 	*	 	In Kraft	 	07-Jan-2002	 	10200263.0-35	 	 	 	25-Jan-2007	 	10200263	 	07-Jan-2022	 	6	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/CH	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	 	 	 	 	1325718	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/DE	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	1325718	 	 	 	50301206.8-08	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/FR	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	 	 	 	 	1325718	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/GB	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	 	 	 	 	1325718	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/IT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	 	 	 	 	1325718	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/NL	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	 	 	21-Sep-2005	 	1325718	 	07-Jan-2023	 	1	 	31-Jan-2007	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-US	 	*	 	 	 	*	 	In Kraft	 	07-Jan-2003	 	10/337,922	 	 	 	05-Sep-2006	 	7,101,401	 	07-Jan-2023	 	4	 	05-Mar-2010	 	1
																
	 M/ITP-013-
	 	Patent	 	M/ITP-013-DE	 	*	 	 	 	*	 	In Kraft	 	10-Jan-2002	 	10200690.3-09	 	 	 	03-Mar-2005	 	10200690	 	10-Jan-2022	 	6	 	31-Jan-2007	 	1
																
	 M/ITP-013-
	 	Patent	 	M/ITP-013-PC/EP	 	*	 	 	 	*	 	Anmeldung eingereicht	 	03-Jan-2003	 	03702385.0-2310	 	1463466	 	 	 	 	 	03-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/ITP-013-
	 	Patent	 	M/ITP-013-PC/US	 	*	 	 	 	*	 	Offengelegt	 	03-Jan-2003	 	10/501,004	 	US 2005/0107799 A1	 	 	 	 	 	03-Jan-2023	 	 	 	 	 	1
																
	 M/ITP-014-
	 	Patent	 	M/ITP-014-DE	 	*	 	 	 	*	 	Recherche abgeschlossen	 	01-Jul-2003	 	10329673.5	 	 	 	 	 	 	 	01-Jul-2023	 	4	 	31-Jul-2006	 	1
																
	 M/ITP-014-
	 	Patent	 	M/ITP-014-EP	 	*	 	 	 	*	 	Prüfungsbescheid erhalten	 	18-Jun-2004	 	04014381.0	 	1506750	 	 	 	 	 	18-Jun-2024	 	4	 	30-Jun-2007	 	1
																
	 M/ITP-015-
	 	Patent	 	M/ITP-015-DE/I	 	*	 	 	 	*	 	Anmeldung eingereicht	 	03-Apr-2003	 	10315259.8	 	 	 	 	 	 	 	03-Apr-2023	 	5	 	30-Apr-2007	 	1
																
	 M/ITP-015-
	 	Patent	 	M/ITP-015-EP	 	*	 	 	 	*	 	Beantworung PRA-Bescheid eingereicht	 	03-Feb-2004	 	04002342.6	 	1444956	 	 	 	 	 	03-Feb-2024	 	4	 	28-Feb-2007	 	1
																
	 M/ITP-019-
	 	Patent	 	M/ITP-019-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	05-Jul-2005	 	102005031402.3	 	 	 	 	 	 	 	05-Jul-2025	 	3	 	31-Jul-2007	 	1
																
	 M/ITP-019-
	 	Patent	 	M/ITP-019-PC	 	*	 	 	 	*	 	Offengelegt	 	15-May-2006	 	PCT/EP2006/004568	 	WO 2007/003243	 	 	 	 	 	15-May-2026	 	 	 	 	 	1

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 88 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/ITP-020-
	 	Patent	 	M/ITP-020-DE	 	*	 	 	 	*	 	Anmeldung eingereicht	 	30-Aug-2005	 	102005041062.6	 	 	 	 	 	 	 	30-Aug-2025	 	3	 	31-Aug-2007	 	1
																
	 M/ITP-020-
	 	Patent	 	M/ITP-020-PC	 	*	 	 	 	*	 	Recherchenergebnis erhalten	 	08-Aug-2006	 	PCT/EP2006/007841	 	 	 	 	 	 	 	 	 	 	 	 	 	1
																
	 M/PLU-012-
	 	Patent	 	M/PLU-012-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120835.1	 	 	 	02-Oct-1997	 	0601223	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-013-
	 	Patent	 	M/PLU-013-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Dec-1992	 	92120836.9	 	 	 	04-Sep-1997	 	0601224	 	07-Dec-2012	 	15	 	31-Dec-2006	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	94917609.3	 	 	 	17-Jul-1997	 	0701419	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-029-
	 	Patent	 	M/PLU-029-EP/AT1	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	10-May-1994	 	96109520.5	 	 	 	 	 	0736286	 	10-May-2014	 	14	 	31-May-2007	 	1
																
	 M/PLU-059-
	 	Patent	 	M/PLU-059-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Feb-1997	 	97102433.6	 	 	 	30-Aug-2001	 	0791344	 	14-Feb-2017	 	11	 	28-Feb-2007	 	1
																
	 M/PLU-064-
	 	Patent	 	M/PLU-064-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	11-Sep-1997	 	 	 	 	 	 	 	 	 	11-Sep-2017	 	10	 	30-Sep-2006	 	1
																
	 M/PLU-068-
	 	Patent	 	M/PLU-068-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	14-Nov-1997	 	97950194.7-2310	 	 	 	 	 	 	 	14-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-075-
	 	Patent	 	M/PLU-075-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	21-Nov-1997	 	97952792.6	 	 	 	 	 	0944368	 	21-Nov-2017	 	10	 	30-Nov-2006	 	1
																
	 M/PLU-099-
	 	Patent	 	M/PLU-099-EP/AT	 	*	 	 	 	*	 	In Kraft	 	12-Apr-2000	 	00107891.4-2310	 	 	 	30-Jun-2004	 	1044664	 	12-Apr-2020	 	8	 	30-Apr-2007	 	1
																
	 M/PLU-111-
	 	Patent	 	M/PLU-111-EP/AT	 	*	 	 	 	*	 	In Kraft	 	09-Jun-2000	 	00112385.0	 	 	 	 	 	 	 	09-Jun-2020	 	8	 	30-Jun-2007	 	1
																
	 M/PLU-115-
	 	Patent	 	M/PLU-115-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	18-May-2000	 	00110627.7-2310	 	 	 	 	 	1093776	 	18-May-2020	 	8	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/AT	 	*	 	 	 	*	 	In Kraft	 	17-May-2001	 	01984556.9-1265	 	1313400	 	30-Nov-2005	 	1313400	 	17-May-2021	 	7	 	31-May-2007	 	1
																
	 M/PLU-129-
	 	Patent	 	M/PLU-129-EP/LI	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	17-May-2001	 	01984556.9-1265	 	1313400	 	 	 	 	 	17-May-2021	 	 	 	 	 	1
																
	 M/END-030-
	 	Patent	 	M/END-030-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	02-Feb-1998	 	98908039.5	 	 	 	 	 	0957784	 	02-Feb-2018	 	10	 	28-Feb-2007	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	9	 	31-Jul-2006	 	1
																
	 M/END-032-
	 	Patent	 	M/END-032-EP7/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	20-Jul-1998	 	 	 	 	 	 	 	 	 	20-Jul-2018	 	 	 	 	 	1
																
	 M/END-034-
	 	Patent	 	M/END-034-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	01-Dec-1999	 	99123862.7-2310	 	 	 	 	 	1018317	 	01-Dec-2019	 	8	 	31-Dec-2006	 	1
																
	 M/ITP-011-
	 	Patent	 	M/ITP-011-EP/AT	 	*	 	 	 	*	 	EP Nationale Phase in Bearbeitung	 	07-Jan-2003	 	03000062.4	 	E304827	 	 	 	1325718	 	07-Jan-2023	 	5	 	31-Jan-2007	 	1
																
	 M/PLU-029-
	 	Utility
Model	 	M/PLU-029-EP/G	 	*	 	 	 	*	 	In Kraft	 	10-May-1994	 	G9421911.7	 	 	 	23-Jan-1997	 	G9421911.7	 	 	 	 	 	 	 	2

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 89 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-058-
	 	Utility Model	 	M/PLU-058-DE/G	 	*	 	 	 	*	 	In Kraft	 	04-Mar-1997	 	29703947.4	 	 	 	05-Jun-1997	 	29703947.4	 	04-Mar-2007	 	 	 	 	 	2
																
	 M/PLU-102-
	 	Utility Model	 	M/PLU-102-DE/I	 	*	 	 	 	*	 	In Kraft	 	16-Apr-1999	 	29906909.5	 	 	 	30-Sep-1999	 	29906909.5	 	16-Apr-2009	 	9	 	30-Apr-2007	 	2
																
	 M/PLU-104-
	 	Utility Model	 	M/PLU-104-DE	 	*	 	 	 	*	 	In Kraft	 	02-Mar-1999	 	29903768.1	 	 	 	09-Sep-1999	 	29903768.1	 	02-Mar-2009	 	9	 	31-Mar-2007	 	2
																
	 M/PLU-105-
	 	Utility Model	 	M/PLU-105-DE	 	*	 	 	 	*	 	In Kraft	 	02-Mar-1999	 	29903767.3	 	 	 	27-May-1999	 	29903767.3	 	02-Mar-2009	 	9	 	31-Mar-2007	 	2
																
	 M/PLU-111-
	 	Utility Model	 	M/PLU-111-DE/G	 	*	 	 	 	*	 	In Kraft	 	23-Jun-1999	 	29924628.0	 	 	 	06-May-2004	 	29924628.0	 	23-Jun-2009	 	9	 	30-Jun-2007	 	2
																
	 M/PLU-192-
	 	Utility Model	 	M/PLU-192-DE/G	 	*	 	 	 	*	 	In Kraft	 	16-Nov-2005	 	202005020876.0	 	 	 	05-Oct-2006	 	202005020876.0	 	16-Nov-2015	 	4	 	30-Nov-2008	 	2
																
	 M/ITP-012-
	 	Utility Model	 	M/ITP-012-DE/G	 	*	 	 	 	*	 	In Kraft	 	04-Jan-2002	 	20220481.2	 	 	 	04-Sep-2003	 	20220481.2	 	04-Jan-2012	 	7	 	31-Jan-2008	 	2
																
	 M/PLU-025-
	 	Trademark	 	M/PLU-025-CH	 	*	 	10	 	*	 	eingetragen	 	14-Oct-1998	 	08443/1998	 	 	 	02-Mar-1999	 	459241	 	 	 	 	 	14-Oct-2008	 	3
																
	 M/PLU-025-
	 	Trademark	 	M/PLU-025-IRM	 	*	 	10	 	*	 	anhängig	 	04-Mar-1999	 	711362	 	 	 	04-Mar-1999	 	711362	 	 	 	 	 	04-Mar-2009	 	3
																
	 M/PLU-043-
	 	Trademark	 	M/PLU-043-CA	 	*	 	10	 	*	 	eingetragen	 	31-Jan-1996	 	802,898	 	 	 	28-Jun-2002	 	TMA564,162	 	 	 	 	 	28-Jun-2017	 	3
																
	 M/PLU-043-
	 	Trademark	 	M/PLU-043-CH	 	*	 	10	 	*	 	eingetragen	 	01-Jun-1994	 	3700/1994.1	 	 	 	09-Nov-1994	 	412553	 	 	 	 	 	01-Jun-2014	 	3
																
	 M/PLU-043-
	 	Trademark	 	M/PLU-043-GB	 	*	 	10	 	*	 	eingetragen	 	08-Jun-1994	 	1,574,617	 	 	 	08-Jun-1994	 	1,574,617	 	 	 	 	 	08-Jun-2011	 	3
																
	 M/PLU-043-
	 	Trademark	 	M/PLU-043-IRM	 	*	 	10	 	*	 	anhängig	 	26-Sep-1994	 	626571	 	 	 	26-Sep-1994	 	626571	 	 	 	 	 	26-Sep-2014	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-CH	 	*	 	10	 	*	 	eingetragen	 	17-Jun-1994	 	4179/1994.0	 	 	 	17-Jun-1994	 	425921	 	 	 	 	 	17-Jun-2014	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-EM	 	*	 	10	 	*	 	eingetragen	 	01-Apr-1997	 	504688	 	 	 	05-Jan-2000	 	504688	 	 	 	 	 	01-Apr-2007	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-IRM	 	*	 	10	 	*	 	anhängig	 	15-Sep-1997	 	681301	 	 	 	15-Sep-1997	 	681301	 	 	 	 	 	15-Sep-2007	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-JP	 	*	 	10	 	*	 	Offengelegt	 	25-Mar-1997	 	31209/1997	 	 	 	02-Jul-1999	 	4288730	 	 	 	 	 	02-Jul-2009	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-KR	 	*	 	10	 	*	 	eingetragen	 	02-May-1997	 	97-20106	 	 	 	06-Jul-1998	 	408089	 	 	 	 	 	06-Jul-2008	 	3
																
	 M/PLU-046-
	 	Trademark	 	M/PLU-046-US	 	*	 	10	 	*	 	eingetragen	 	22-Apr-1997	 	75/279,282	 	 	 	04-Apr-2000	 	2338976	 	 	 	 	 	04-Apr-2010	 	3
																
	 M/PLU-047-
	 	Trademark	 	M/PLU-047-CH	 	*	 	10	 	*	 	eingetragen	 	17-Jun-1994	 	4178/1994.8	 	 	 	17-Jun-1994	 	425920	 	 	 	 	 	17-Jun-2014	 	3
																
	 M/PLU-048-
	 	Trademark	 	M/PLU-048-CH	 	*	 	10	 	*	 	eingetragen	 	28-Jan-1993	 	400085	 	 	 	18-May-1993	 	400085	 	 	 	 	 	28-Jan-2013	 	3
																
	 M/PLU-048-
	 	Trademark	 	M/PLU-048-IRM	 	*	 	10	 	*	 	anhängig	 	08-Mar-1993	 	599542	 	 	 	08-Mar-1993	 	599542	 	 	 	 	 	08-Mar-2013	 	3
																
	 M/PLU-050-
	 	Trademark	 	M/PLU-050-JP	 	*	 	10	 	*	 	eingetragen	 	02-Feb-1995	 	8500/95	 	 	 	11-Dec-1998	 	4219455	 	 	 	 	 	11-Dec-2008	 	3
																
	 M/PLU-052-
	 	Trademark	 	M/PLU-052-CH/I	 	*	 	05	 	*	 	eingetragen	 	28-Jan-2000	 	00915/2000	 	 	 	20-Jul-2000	 	474388	 	 	 	 	 	28-Jan-2010	 	3
																
	 M/PLU-052-
	 	Trademark	 	M/PLU-052-JP	 	*	 	10	 	*	 	eingetragen	 	23-Jun-1995	 	62475/1995	 	 	 	04-Dec-1998	 	4217325	 	 	 	 	 	04-Dec-2008	 	3
																
	 M/PLU-052-
	 	Trademark	 	M/PLU-052-NO	 	*	 	01,05	 	*	 	eingetragen	 	19-Jul-1995	 	95 4553	 	 	 	18-Jul-1996	 	175715	 	 	 	 	 	 	 	3
																
	 M/PLU-052-
	 	Trademark	 	M/PLU-052-US	 	*	 	01,05	 	*	 	anhängig	 	11-Aug-1995	 	74/717,615	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-053-
	 	Trademark	 	M/PLU-053-CH	 	*	 	10	 	*	 	eingetragen	 	23-Jun-1995	 	8452/1995.7	 	 	 	23-Jun-1995	 	420069	 	 	 	 	 	 	 	3
																
	 M/PLU-053-
	 	Trademark	 	M/PLU-053-IRM	 	*	 	10	 	*	 	anhängig	 	15-Dec-1995	 	649959	 	 	 	15-Dec-1995	 	649959	 	 	 	 	 	15-Dec-2015	 	3
																
	 M/PLU-053-
	 	Trademark	 	M/PLU-053-JP	 	*	 	10	 	*	 	eingetragen	 	26-Jun-1995	 	62992/1995	 	 	 	13-Feb-1998	 	4114033	 	 	 	 	 	13-Feb-2008	 	3
																
	 M/PLU-053-
	 	Trademark	 	M/PLU-053-NO	 	*	 	10	 	*	 	eingetragen	 	19-Jul-1995	 	95 4552	 	 	 	18-Jul-1996	 	175714	 	 	 	 	 	 	 	3
																
	 M/PLU-053-
	 	Trademark	 	M/PLU-053-SE	 	*	 	10	 	*	 	eingetragen	 	30-Jun-1995	 	95-07645	 	 	 	24-Oct-1997	 	325280	 	 	 	 	 	24-Oct-2007	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 90 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-053-
	 	Trademark	 	M/PLU-053-US	 	*	 	10	 	*	 	eingetragen	 	01-Aug-1995	 	74/709,229	 	 	 	08-Jan-2002	 	2526359	 	 	 	 	 	08-Jan-2012	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-CH	 	*	 	10	 	*	 	eingetragen	 	21-May-1996	 	10451/1995.4	 	 	 	20-Aug-1996	 	426 291	 	 	 	 	 	21-May-2016	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-DK	 	*	 	10	 	*	 	eingetragen	 	21-Sep-1995	 	VA 07.080 1995	 	 	 	15-Dec-1995	 	VR 08.480 1995	 	 	 	 	 	15-Dec-2015	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-GB	 	*	 	10	 	*	 	eingetragen	 	14-Sep-1995	 	2033839	 	 	 	14-Sep-1995	 	2033839	 	 	 	 	 	14-Sep-2015	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-GR	 	*	 	10	 	*	 	eingetragen	 	19-Sep-1995	 	126201	 	 	 	17-Dec-1998	 	126201	 	 	 	 	 	19-Sep-2015	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-IRM	 	*	 	10	 	*	 	eingetragen	 	05-Jun-1996	 	665433	 	 	 	05-Jun-1996	 	665433	 	 	 	 	 	05-Jun-2016	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-JP	 	*	 	10	 	*	 	eingetragen	 	18-Sep-1995	 	94861/1995	 	 	 	30-Jan-1998	 	4108687	 	 	 	 	 	30-Jan-2008	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-SE	 	*	 	10	 	*	 	eingetragen	 	15-Sep-1995	 	95-10464	 	 	 	12-Jul-1996	 	315015	 	 	 	 	 	12-Jul-2016	 	3
																
	 M/PLU-056-
	 	Trademark	 	M/PLU-056-US	 	*	 	10	 	*	 	eingetragen	 	20-Nov-1995	 	75/022,449	 	 	 	01-Sep-1998	 	2,186,233	 	 	 	 	 	01-Sep-2008	 	3
																
	 M/PLU-060-
	 	Trademark	 	M/PLU-060-JP	 	*	 	10	 	*	 	eingetragen	 	15-Feb-1996	 	8-13583	 	 	 	11-Dec-1998	 	4218939	 	 	 	 	 	11-Dec-2008	 	3
																
	 M/PLU-060-
	 	Trademark	 	M/PLU-060-SG	 	*	 	10	 	*	 	Prüfungsbescheid erhalten	 	18-Jul-1996	 	7375/96	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-060-
	 	Trademark	 	M/PLU-060-US	 	*	 	10	 	*	 	anhängig	 	12-Jun-1996	 	75/117866	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-061-
	 	Trademark	 	M/PLU-061-CH	 	*	 	10	 	*	 	eingetragen	 	09-Feb-1996	 	00866/1996	 	 	 	19-Feb-1997	 	435429	 	 	 	 	 	09-Feb-2016	 	3
																
	 M/PLU-061-
	 	Trademark	 	M/PLU-061-EM	 	*	 	10	 	*	 	eingetragen	 	01-Apr-1996	 	168906	 	 	 	29-Mar-1999	 	168906	 	 	 	 	 	01-Apr-2016	 	3
																
	 M/PLU-061-
	 	Trademark	 	M/PLU-061-SG	 	*	 	10	 	*	 	Anmeldung eingereicht	 	18-Jul-1996	 	7374	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-069-
	 	Trademark	 	M/PLU-069-US	 	*	 	10	 	*	 	anhängig	 	04-Sep-1996	 	75/160296	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-070-
	 	Trademark	 	M/PLU-070-CH	 	*	 	10	 	*	 	eingetragen	 	15-Jul-1996	 	05168/1996	 	 	 	15-Jul-1996	 	435004	 	 	 	 	 	15-Jul-2016	 	3
																
	 M/PLU-070-
	 	Trademark	 	M/PLU-070-IRM	 	*	 	10	 	*	 	anhängig	 	14-Jan-1997	 	668959	 	 	 	14-Jan-1997	 	668959	 	 	 	 	 	 	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-CA	 	*	 	10	 	*	 	eingetragen	 	08-Oct-1996	 	825,354	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-CL	 	*	 	10	 	*	 	eingetragen	 	04-Aug-1997	 	385.894	 	 	 	06-Apr-2001	 	593.934	 	 	 	 	 	06-Apr-2011	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-EM	 	*	 	10	 	*	 	eingetragen	 	08-Oct-1996	 	562843	 	 	 	09-Nov-1998	 	562843	 	 	 	 	 	31-Oct-2006	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-IRM	 	*	 	10	 	*	 	anhängig	 	22-Jun-1998	 	695460	 	 	 	22-Jun-1998	 	695460	 	 	 	 	 	22-Jun-2008	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-JP	 	*	 	10	 	*	 	eingetragen	 	18-Mar-1997	 	28320/1997	 	 	 	05-Feb-1999	 	4237214	 	 	 	 	 	05-Feb-2009	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-MX	 	*	 	10	 	*	 	eingetragen	 	18-Jun-1997	 	298614	 	 	 	26-Nov-1997	 	564616	 	 	 	 	 	18-Jun-2007	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-NO	 	*	 	10	 	*	 	eingetragen	 	17-Mar-1997	 	972209	 	 	 	23-Dec-1997	 	187694	 	 	 	 	 	23-Dec-2007	 	3
																
	 M/PLU-076-
	 	Trademark	 	M/PLU-076-SG	 	*	 	10	 	*	 	eingetragen	 	28-Oct-1996	 	11720/96	 	 	 	28-Oct-1996	 	T96/11720J	 	 	 	 	 	28-Oct-2016	 	3
																
	 M/PLU-081-
	 	Trademark	 	M/PLU-081-US/I	 	*	 	10	 	*	 	eingetragen	 	18-Nov-1997	 	75/392,195	 	 	 	02-Oct-2001	 	2,494,600	 	 	 	 	 	02-Oct-2011	 	3
																
	 M/PLU-084-
	 	Trademark	 	M/PLU-084-CH	 	*	 	10	 	*	 	eingetragen	 	16-May-1997	 	03888/1997	 	 	 	13-Nov-1997	 	446859	 	 	 	 	 	16-May-2007	 	3
																
	 M/PLU-085-
	 	Trademark	 	M/PLU-085-CH	 	*	 	01,05,10	 	*	 	eingetragen	 	11-Apr-1997	 	02912/1997	 	 	 	12-Nov-1998	 	456212	 	 	 	 	 	11-Apr-2007	 	3
																
	 M/PLU-085-
	 	Trademark	 	M/PLU-085-EM	 	*	 	01,05,10	 	*	 	eingetragen	 	01-Apr-1997	 	504647	 	 	 	25-Nov-1999	 	504647	 	 	 	 	 	01-Apr-2007	 	3
																
	 M/PLU-085-
	 	Trademark	 	M/PLU-085-JP	 	*	 	01,10	 	*	 	eingetragen	 	16-Apr-1997	 	106418/1997	 	 	 	19-Mar-1999	 	4251284	 	 	 	 	 	19-Mar-2009	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 91 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-086-
	 	Trademark	 	M/PLU-086-CH	 	*	 	10	 	*	 	anhängig	 	13-Aug-1998	 	06646/1998	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-086-
	 	Trademark	 	M/PLU-086-EM	 	*	 	10	 	*	 	eingetragen	 	05-Mar-1999	 	1097583	 	 	 	12-Apr-2000	 	1097583	 	 	 	 	 	05-Mar-2009	 	3
																
	 M/PLU-086-
	 	Trademark	 	M/PLU-086-GR	 	*	 	10	 	*	 	eingetragen	 	09-Apr-1997	 	132840	 	 	 	17-Mar-1999	 	132840	 	 	 	 	 	10-Apr-2007	 	3
																
	 M/PLU-086-
	 	Trademark	 	M/PLU-086-IRM	 	*	 	10	 	*	 	anhängig	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-086-
	 	Trademark	 	M/PLU-086-JP	 	*	 	10	 	*	 	eingetragen	 	02-Apr-1997	 	101426/1997	 	 	 	10-Dec-1999	 	4342034	 	 	 	 	 	10-Dec-2009	 	3
																
	 M/PLU-086-
	 	Trademark	 	M/PLU-086-SE	 	*	 	10	 	*	 	eingetragen	 	02-Apr-1997	 	97-03287	 	 	 	11-Dec-1998	 	329401	 	 	 	 	 	11-Dec-2008	 	3
																
	 M/PLU-087-
	 	Trademark	 	M/PLU-087-IRM	 	*	 	10	 	*	 	anhängig	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-088-
	 	Trademark	 	M/PLU-088-FR	 	*	 	10	 	*	 	eingetragen	 	18-Dec-1996	 	 	 	 	 	18-Dec-1996	 	96 656082	 	 	 	 	 	31-Dec-2006	 	3
																
	 M/PLU-088-
	 	Trademark	 	M/PLU-088-GB	 	*	 	10	 	*	 	eingetragen	 	17-Jun-1997	 	2136128	 	 	 	17-Jun-1997	 	2136128	 	 	 	 	 	17-Jun-2007	 	3
																
	 M/PLU-088-
	 	Trademark	 	M/PLU-088-GR	 	*	 	10	 	*	 	Offengelegt	 	06-Jun-1997	 	133445	 	 	 	18-May-1999	 	133445	 	 	 	 	 	07-Jun-2007	 	3
																
	 M/PLU-088-
	 	Trademark	 	M/PLU-088-IRM	 	*	 	10	 	*	 	eingetragen	 	29-May-1997	 	674159	 	 	 	29-May-1997	 	674159	 	 	 	 	 	29-May-2007	 	3
																
	 M/PLU-088-
	 	Trademark	 	M/PLU-088-JP	 	*	 	10	 	*	 	eingetragen	 	30-Apr-1997	 	111615/1997	 	 	 	23-Apr-1999	 	4265590	 	 	 	 	 	23-Apr-2009	 	3
																
	 M/PLU-090-
	 	Trademark	 	M/PLU-090-CH	 	*	 	10	 	*	 	eingetragen	 	08-Oct-1997	 	 	 	 	 	07-Apr-1998	 	450661	 	 	 	 	 	08-Oct-2007	 	3
																
	 M/PLU-090-
	 	Trademark	 	M/PLU-090-EM	 	*	 	10	 	*	 	eingetragen	 	07-Oct-1997	 	647016	 	 	 	18-Mar-1999	 	647016	 	 	 	 	 	07-Oct-2007	 	3
																
	 M/PLU-091-
	 	Trademark	 	M/PLU-091-CH	 	*	 	10	 	*	 	eingetragen	 	10-Jun-1998	 	04620/1998	 	 	 	10-Dec-1998	 	456946	 	 	 	 	 	 	 	3
																
	 M/PLU-091-
	 	Trademark	 	M/PLU-091-EM	 	*	 	10	 	*	 	eingetragen	 	16-Jun-1998	 	851352	 	 	 	17-Aug-1999	 	851352	 	 	 	 	 	16-Jun-2008	 	3
																
	 M/PLU-091-
	 	Trademark	 	M/PLU-091-US	 	*	 	10	 	*	 	eingetragen	 	27-Aug-1998	 	75/544245	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-093-
	 	Trademark	 	M/PLU-093-CH	 	*	 	10	 	*	 	Anmeldung eingereicht	 	31-Aug-1998	 	07126/1998	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-093-
	 	Trademark	 	M/PLU-093-EM	 	*	 	10	 	*	 	eingetragen	 	03-Sep-1998	 	920652	 	 	 	10-Jan-2001	 	920652	 	 	 	 	 	03-Sep-2008	 	3
																
	 M/PLU-093-
	 	Trademark	 	M/PLU-093-US	 	*	 	10	 	*	 	eingetragen	 	17-Nov-1999	 	75/851688	 	 	 	 	 	2,737,179	 	 	 	 	 	 	 	3
																
	 M/PLU-094-
	 	Trademark	 	M/PLU-094-EM	 	*	 	10,16,41,42	 	*	 	eingetragen	 	08-Jan-1999	 	1037878	 	 	 	21-Feb-2000	 	1037878	 	 	 	 	 	08-Jan-2009	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-CA	 	*	 	10	 	*	 	eingetragen	 	28-Jan-1999	 	1003348	 	 	 	04-Jan-2001	 	TMA539,129	 	 	 	 	 	04-Jan-2016	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-CH	 	*	 	10	 	*	 	Offengelegt	 	28-Oct-1998	 	08867/1998	 	 	 	17-Mar-1999	 	459649	 	 	 	 	 	28-Oct-2008	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-EM	 	*	 	10	 	*	 	eingetragen	 	11-Dec-1998	 	1015577	 	 	 	16-Feb-2000	 	1015577	 	 	 	 	 	11-Dec-2008	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-IRM	 	*	 	10	 	*	 	anhängig	 	19-Mar-1999	 	712597	 	 	 	19-Mar-1999	 	712597	 	 	 	 	 	19-Mar-2009	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-JP	 	*	 	10	 	*	 	eingetragen	 	25-Mar-1999	 	11-26563	 	 	 	16-Mar-2001	 	4460594	 	 	 	 	 	16-Mar-2011	 	3
																
	 M/PLU-096-
	 	Trademark	 	M/PLU-096-US	 	*	 	10	 	*	 	eingetragen	 	08-Mar-1999	 	75/654551	 	 	 	22-Oct-2002	 	2,637,879	 	 	 	 	 	22-Oct-2012	 	3
																
	 M/PLU-103-
	 	Trademark	 	M/PLU-103-CH	 	*	 	10	 	*	 	eingetragen	 	03-Mar-1999	 	01940/1999	 	 	 	03-Aug-1999	 	463663	 	 	 	 	 	03-Mar-2009	 	3
																
	 M/PLU-103-
	 	Trademark	 	M/PLU-103-DE	 	*	 	10	 	*	 	eingetragen	 	18-Feb-1999	 	39909263.3	 	 	 	25-May-1999	 	39909263	 	 	 	 	 	28-Feb-2009	 	3
																
	 M/PLU-103-
	 	Trademark	 	M/PLU-103-EM	 	*	 	10	 	*	 	eingetragen	 	05-Oct-1999	 	1334283	 	 	 	16-Nov-2000	 	1334283	 	 	 	 	 	05-Oct-2009	 	3
																
	 M/PLU-103-
	 	Trademark	 	M/PLU-103-IRM	 	*	 	10	 	*	 	anhängig	 	01-Oct-1999	 	722 447	 	 	 	01-Oct-1999	 	722 447	 	 	 	 	 	01-Oct-2009	 	3
																
	 M/PLU-106-
	 	Trademark	 	M/PLU-106-CH	 	*	 	10	 	*	 	eingetragen	 	03-Mar-1999	 	01906/1999	 	 	 	29-Jul-1999	 	463539	 	 	 	 	 	03-Mar-2009	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 92 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local
Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	     Publication No.    

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-107-
	 	Trademark	 	M/PLU-107-CH	 	*	 	10	 	*	 	eingetragen	 	03-Mar-1999	 	01905/1999	 	 	 	29-Jul-1999	 	463538	 	 	 	 	 	03-Mar-2009	 	3
																
	 M/PLU-107-
	 	Trademark	 	M/PLU-107-EM	 	*	 	10	 	*	 	eingetragen	 	04-Mar-1999	 	1094903	 	 	 	12-Apr-2000	 	1094903	 	 	 	 	 	04-Mar-2009	 	3
																
	 M/PLU-108-
	 	Trademark	 	M/PLU-108-CH	 	*	 	10	 	*	 	eingetragen	 	07-Apr-1999	 	03043/1999	 	 	 	02-Sep-1999	 	464567	 	 	 	 	 	07-Apr-2009	 	3
																
	 M/PLU-108-
	 	Trademark	 	M/PLU-108-EM	 	*	 	10	 	*	 	Offengelegt	 	08-Apr-1999	 	1131960	 	 	 	13-Jul-2000	 	1131960	 	 	 	 	 	08-Apr-2009	 	3
																
	 M/PLU-114-
	 	Trademark	 	M/PLU-114-CH	 	*	 	10	 	*	 	eingetragen	 	26-Aug-1999	 	07669/1999	 	 	 	12-Jan-2000	 	468400	 	 	 	 	 	26-Aug-2009	 	3
																
	 M/PLU-114-
	 	Trademark	 	M/PLU-114-EM	 	*	 	10	 	*	 	eingetragen	 	03-Sep-1999	 	1297902	 	 	 	23-Oct-2000	 	1297902	 	 	 	 	 	03-Sep-2009	 	3
																
	 M/PLU-117-
	 	Trademark	 	M/PLU-117-EM	 	*	 	10	 	*	 	eingetragen	 	28-Oct-1999	 	1362862	 	 	 	22-Jan-2001	 	1362862	 	 	 	 	 	28-Oct-2009	 	3
																
	 M/PLU-119-
	 	Trademark	 	M/PLU-119-CH	 	*	 	10	 	*	 	eingetragen	 	26-Oct-1999	 	09691/1999	 	 	 	26-Apr-2000	 	471599	 	 	 	 	 	26-Oct-2009	 	3
																
	 M/PLU-119-
	 	Trademark	 	M/PLU-119-EM	 	*	 	10	 	*	 	eingetragen	 	02-Nov-1999	 	1368455	 	 	 	12-Jan-2001	 	1368455	 	 	 	 	 	02-Nov-2009	 	3
																
	 M/PLU-119-
	 	Trademark	 	M/PLU-119-IRM	 	*	 	10	 	*	 	anhängig	 	26-Apr-2000	 	736414	 	 	 	26-Apr-2000	 	736414	 	 	 	 	 	26-Apr-2010	 	3
																
	 M/PLU-121-
	 	Trademark	 	M/PLU-121-EM	 	*	 	10	 	*	 	eingetragen	 	21-Dec-1999	 	1432947	 	 	 	06-Mar-2001	 	1432947	 	 	 	 	 	21-Dec-2009	 	3
																
	 M/PLU-125-
	 	Trademark	 	M/PLU-125-CH	 	*	 	10,16,41,42	 	*	 	eingetragen	 	25-May-2000	 	06290/2000	 	 	 	10-Nov-2000	 	478265	 	 	 	 	 	25-May-2010	 	3
																
	 M/PLU-125-
	 	Trademark	 	M/PLU-125-EM	 	*	 	10,16,41,42	 	*	 	eingetragen	 	23-May-2000	 	1671767	 	 	 	24-Jul-2001	 	1671767	 	 	 	 	 	23-May-2010	 	3
																
	 M/PLU-141-
	 	Trademark	 	M/PLU-141-CH	 	*	 	01,10	 	*	 	eingetragen	 	02-May-2001	 	04383/2001	 	 	 	08-Oct-2001	 	490141	 	 	 	 	 	02-May-2011	 	3
																
	 M/PLU-141-
	 	Trademark	 	M/PLU-141-EM	 	*	 	01,10	 	*	 	eingetragen	 	27-Apr-2001	 	2195725	 	 	 	 	 	 	 	 	 	 	 	27-Apr-2011	 	3
																
	 M/PLU-141-
	 	Trademark	 	M/PLU-141-JP	 	*	 	01,10	 	*	 	eingetragen	 	21-May-2001	 	2001-45583	 	 	 	22-Nov-2002	 	4622977	 	 	 	 	 	 	 	3
																
	 M/PLU-142-
	 	Trademark	 	M/PLU-142-CH	 	*	 	10	 	*	 	eingetragen	 	07-May-2001	 	04526/2001	 	 	 	07-Nov-2001	 	491677	 	 	 	 	 	07-May-2011	 	3
																
	 M/PLU-142-
	 	Trademark	 	M/PLU-142-EM	 	*	 	10	 	*	 	eingetragen	 	16-May-2001	 	2220747	 	 	 	20-Aug-2002	 	2220747	 	 	 	 	 	16-May-2011	 	3
																
	 M/PLU-142-
	 	Trademark	 	M/PLU-142-IRM	 	*	 	10	 	*	 	eingetragen	 	07-May-2001	 	 	 	 	 	03-Jan-2002	 	776029	 	 	 	 	 	03-Jan-2012	 	3
																
	 M/PLU-142-
	 	Trademark	 	M/PLU-142-JP	 	*	 	10	 	*	 	eingetragen	 	21-May-2001	 	2001-45584	 	 	 	25-Oct-2002	 	4615613	 	 	 	 	 	25-Oct-2012	 	3
																
	 M/PLU-143-
	 	Trademark	 	M/PLU-143-CH	 	*	 	01,10	 	*	 	eingetragen	 	13-Jul-2001	 	 	 	 	 	23-Jan-2002	 	493960	 	 	 	 	 	13-Jul-2011	 	3
																
	 M/PLU-143-
	 	Trademark	 	M/PLU-143-EM	 	*	 	01,10	 	*	 	eingetragen	 	16-Jul-2001	 	2301752	 	 	 	19-Sep-2003	 	2301752	 	 	 	 	 	16-Jul-2011	 	3
																
	 M/PLU-143-
	 	Trademark	 	M/PLU-143-JP	 	*	 	01,10	 	*	 	eingetragen	 	11-Sep-2001	 	2001-82245	 	 	 	15-Nov-2002	 	4621211	 	 	 	 	 	15-Nov-2012	 	3
																
	 M/PLU-143-
	 	Trademark	 	M/PLU-143-US/I	 	*	 	01,10	 	*	 	Instruktionen im PRA Verfahren erhalten	 	20-Sep-2005	 	78/716,636	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-145-
	 	Trademark	 	M/PLU-145-CH	 	*	 	10	 	*	 	eingetragen	 	25-Sep-2001	 	09382/2001	 	 	 	26-Feb-2002	 	495132	 	 	 	 	 	25-Sep-2011	 	3
																
	 M/PLU-145-
	 	Trademark	 	M/PLU-145-EM	 	*	 	10	 	*	 	eingetragen	 	24-Sep-2001	 	2385839	 	 	 	22-Sep-2003	 	2385839	 	 	 	 	 	24-Sep-2011	 	3
																
	 M/PLU-145-
	 	Trademark	 	M/PLU-145-IRM	 	*	 	10	 	*	 	eingetragen	 	10-Oct-2002	 	790367	 	 	 	10-Oct-2002	 	790367	 	 	 	 	 	10-Oct-2012	 	3
																
	 M/PLU-145-
	 	Trademark	 	M/PLU-145-JP	 	*	 	10	 	*	 	eingetragen	 	28-Sep-2001	 	2001-87836	 	 	 	22-Nov-2002	 	4623012	 	 	 	 	 	22-Nov-2012	 	3
																
	 M/PLU-145-
	 	Trademark	 	M/PLU-145-US	 	*	 	10	 	*	 	eingetragen	 	24-Sep-2001	 	76/316,310	 	 	 	13-Jul-2004	 	2,863,198	 	 	 	 	 	13-Jul-2014	 	3
																
	 M/PLU-155-
	 	Trademark	 	M/PLU-155-US	 	*	 	[44]	 	*	 	Beantworung PRA-Bescheid eingereicht	 	01-Aug-2003	 	78/282,282	 	 	 	 	 	 	 	 	 	 	 	 	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 93 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-157-
	 	Trademark	 	M/PLU-157-CH	 	*	 	10	 	*	 	eingetragen	 	09-Mar-1992	 	 	 	 	 	04-Jun-1992	 	393233	 	 	 	 	 	09-Mar-2012	 	3
																
	 M/PLU-157-
	 	Trademark	 	M/PLU-157-IRM	 	*	 	10	 	*	 	eingetragen	 	04-Jun-1992	 	 	 	 	 	04-Jun-1992	 	588061	 	 	 	 	 	04-Jun-2012	 	3
																
	 M/PLU-158-
	 	Trademark	 	M/PLU-158-CH	 	*	 	10	 	*	 	eingetragen	 	09-Mar-1992	 	 	 	 	 	20-May-1992	 	392558	 	 	 	 	 	09-Mar-2012	 	3
																
	 M/PLU-158-
	 	Trademark	 	M/PLU-158-IRM	 	*	 	10	 	*	 	eingetragen	 	20-May-1992	 	 	 	 	 	20-May-1992	 	586944	 	 	 	 	 	20-May-2012	 	3
																
	 M/PLU-159-
	 	Trademark	 	M/PLU-159-CH	 	*	 	10	 	*	 	eingetragen	 	09-Mar-1992	 	 	 	 	 	20-May-1992	 	392557	 	 	 	 	 	09-Mar-2012	 	3
																
	 M/PLU-159-
	 	Trademark	 	M/PLU-159-IRM	 	*	 	10	 	*	 	eingetragen	 	20-May-1992	 	 	 	 	 	20-May-1992	 	586943	 	 	 	 	 	20-May-2012	 	3
																
	 M/PLU-160-
	 	Trademark	 	M/PLU-160-CH	 	*	 	10	 	*	 	eingetragen	 	09-Mar-1992	 	 	 	 	 	20-May-1992	 	392556	 	 	 	 	 	09-Mar-2012	 	3
																
	 M/PLU-160-
	 	Trademark	 	M/PLU-160-IRM	 	*	 	10	 	*	 	eingetragen	 	20-May-1992	 	 	 	 	 	20-May-1992	 	586942	 	 	 	 	 	20-May-2012	 	3
																
	 M/PLU-161-
	 	Trademark	 	M/PLU-161-CH	 	*	 	10	 	*	 	eingetragen	 	10-Jun-1992	 	 	 	 	 	04-Aug-1992	 	394984	 	 	 	 	 	10-Jun-2012	 	3
																
	 M/PLU-161-
	 	Trademark	 	M/PLU-161-IRM	 	*	 	10	 	*	 	eingetragen	 	04-Aug-1992	 	 	 	 	 	04-Aug-1992	 	590344	 	 	 	 	 	04-Aug-2012	 	3
																
	 M/PLU-162-
	 	Trademark	 	M/PLU-162-CH	 	*	 	10	 	*	 	eingetragen	 	09-Mar-1992	 	 	 	 	 	20-May-1992	 	392554	 	 	 	 	 	09-Mar-2012	 	3
																
	 M/PLU-162-
	 	Trademark	 	M/PLU-162-IRM	 	*	 	10	 	*	 	eingetragen	 	20-May-1992	 	 	 	 	 	20-May-1992	 	586941	 	 	 	 	 	20-May-2012	 	3
																
	 M/PLU-167-
	 	Trademark	 	M/PLU-167-CH	 	*	 	10	 	*	 	eingetragen	 	03-May-2004	 	01601/2004	 	 	 	08-Oct-2004	 	526546	 	 	 	 	 	03-May-2014	 	3
																
	 M/PLU-167-
	 	Trademark	 	M/PLU-167-EM	 	*	 	10	 	*	 	eingetragen	 	22-Apr-2004	 	3789351	 	 	 	07-Jul-2005	 	3789351	 	 	 	 	 	22-Apr-2014	 	3
																
	 M/PLU-170-
	 	Trademark	 	M/PLU-170-EM	 	*	 	10	 	*	 	eingetragen	 	06-Jul-2004	 	3916665	 	 	 	19-Sep-2005	 	3916665	 	 	 	 	 	06-Jul-2014	 	3
																
	 M/PLU-171-
	 	Trademark	 	M/PLU-171-CH	 	*	 	10	 	*	 	eingetragen	 	28-Jun-2004	 	02289/2004	 	 	 	30-Sep-2004	 	526349	 	 	 	 	 	28-Jun-2014	 	3
																
	 M/PLU-174-
	 	Trademark	 	M/PLU-174-CH	 	*	 	10	 	*	 	eingetragen	 	05-Aug-2004	 	02781/2004	 	 	 	04-Nov-2004	 	526978	 	 	 	 	 	05-Aug-2014	 	3
																
	 M/PLU-174-
	 	Trademark	 	M/PLU-174-US	 	*	 	[44]	 	*	 	eingetragen	 	05-Aug-2004	 	78/462,596	 	 	 	07-Nov-2006	 	3,169,563	 	 	 	 	 	07-Nov-2016	 	3
																
	 M/PLU-180-
	 	Trademark	 	M/PLU-180-CH	 	*	 	10	 	*	 	eingetragen	 	09-Nov-2004	 	03801/2004	 	 	 	27-Apr-2005	 	532995	 	 	 	 	 	09-Nov-2014	 	3
																
	 M/PLU-180-
	 	Trademark	 	M/PLU-180-IRM	 	*	 	10	 	*	 	eingetragen	 	12-Dec-2005	 	 	 	 	 	12-Dec-2005	 	873065	 	 	 	 	 	12-Dec-2015	 	3
																
	 M/PLU-180-
	 	Trademark	 	M/PLU-180-IRM/US	 	*	 	26,39,44	 	*	 	eingetragen	 	12-Dec-2005	 	 	 	 	 	31-Oct-2006	 	3,165,503	 	 	 	 	 	31-Oct-2016	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-CH	 	*	 	10,42	 	*	 	eingetragen	 	02-Dec-2004	 	528741	 	 	 	 	 	 	 	 	 	 	 	02-Dec-2014	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-IN	 	*	 	10	 	*	 	Beantworung PRA-Bescheid eingereicht	 	28-Mar-2005	 	1347403	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-IRM	 	*	 	10,42	 	*	 	Avis de Refus	 	10-May-2005	 	 	 	 	 	10-May-2005	 	853476	 	 	 	 	 	10-May-2015	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-IRM/US	 	*	 	[26],[39],
[44],[100],
[101]	 	*	 	eingetragen	 	12-May-2005	 	 	 	 	 	31-Oct-2006	 	3,165,407	 	 	 	 	 	31-Oct-2016	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-MY	 	*	 	10	 	*	 	Beantworung PRA-Bescheid eingereicht	 	07-Apr-2005	 	2005/05166	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-NZ	 	*	 	10	 	*	 	eingetragen	 	29-Mar-2005	 	727364	 	 	 	29-Sep-2005	 	727364	 	 	 	 	 	02-Dec-2014	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-ZA	 	*	 	10	 	*	 	Beantworung PRA-Bescheid eingereicht	 	24-Mar-2005	 	2005/05712	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-182-
	 	Trademark	 	M/PLU-182-CH	 	*	 	10,42	 	*	 	eingetragen	 	02-Dec-2004	 	528742	 	 	 	14-Dec-2004	 	528742	 	 	 	 	 	02-Dec-2014	 	3
																
	 M/PLU-182-
	 	Trademark	 	M/PLU-182-IRM	 	*	 	10,42	 	*	 	eingetragen	 	12-May-2005	 	 	 	 	 	12-May-2005	 	853477	 	 	 	 	 	12-May-2015	 	3
																
	 M/PLU-182-
	 	Trademark	 	M/PLU-182-IRM/US	 	*	 	[26],[39],
[44],[100],
[101]	 	*	 	eingetragen	 	12-May-2005	 	79/012,155	 	 	 	01-Aug-2006	 	3,123,837	 	 	 	 	 	01-Aug-2016	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 94 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/PLU-184-
	 	Trademark	 	M/PLU-184-CH	 	*	 	16,41,42,09	 	*	 	eingetragen	 	18-Mar-2005	 	00764/2005	 	 	 	02-Jun-2005	 	534107	 	 	 	 	 	18-Mar-2015	 	3
																
	 M/PLU-184-
	 	Trademark	 	M/PLU-184-IRM	 	*	 	09,41,42	 	*	 	eingetragen	 	15-Jul-2005	 	860486	 	 	 	15-Jul-2005	 	860486	 	 	 	 	 	15-Jul-2015	 	3
																
	 M/PLU-184-
	 	Trademark	 	M/PLU-184-IRM/US	 	*	 	[02],[05],
[21],[22],
[23],[26],
[29],[36],
[37],[38],
[50],[100],
[101],[107]	 	*	 	eingetragen	 	15-Jul-2005	 	 	 	 	 	31-Oct-2006	 	3,165,433	 	 	 	 	 	31-Oct-2016	 	3
																
	 M/PLU-196-
	 	Trademark	 	M/PLU-196-CH	 	*	 	10	 	*	 	eingetragen	 	16-Jun-2005	 	 	 	 	 	14-Nov-2005	 	539780	 	 	 	 	 	16-Jun-2015	 	3
																
	 M/PLU-196-
	 	Trademark	 	M/PLU-196-IRM	 	*	 	10	 	*	 	Anmeldung eingereicht	 	02-Dec-2005	 	01527/2005	 	 	 	02-Dec-2005	 	874271	 	 	 	 	 	02-Dec-2015	 	3
																
	 M/PLU-197-
	 	Trademark	 	M/PLU-197-CH	 	*	 	10	 	*	 	Anmeldung eingereicht	 	15-Dec-2005	 	545252	 	 	 	 	 	545252	 	 	 	 	 	15-Dec-2015	 	3
																
	 M/PLU-197-
	 	Trademark	 	M/PLU-197-US	 	*	 	[44]	 	*	 	Anmeldung eingereicht	 	15-Dec-2005	 	78/774,610	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/PLU-211-
	 	Trademark	 	M/PLU-211-CH	 	*	 	10	 	*	 	eingetragen	 	12-Dec-2005	 	02973/2005	 	544316	 	 	 	544316	 	 	 	 	 	12-Dec-2015	 	3
																
	 M/PLU-211-
	 	Trademark	 	M/PLU-211-MAT	 	*	 	10	 	*	 	eingetragen	 	18-Apr-2006	 	883358	 	 	 	18-Apr-2006	 	883358	 	 	 	 	 	 	 	3
																
	 M/PLU-215-
	 	Trademark	 	M/PLU-215-CH	 	*	 	09,10,42	 	*	 	eingetragen	 	17-Jul-2002	 	 	 	 	 	24-Oct-2002	 	504507	 	 	 	 	 	17-Jul-2012	 	3
																
	 M/PLU-224-
	 	Trademark	 	M/PLU-224-CH	 	*	 	10	 	*	 	eingetragen	 	23-Oct-2006	 	0212/2006	 	 	 	30-Jan-2007	 	554202	 	 	 	 	 	23-Oct-2016	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-DE	 	*	 	10	 	*	 	eingetragen	 	20-Jul-1989	 	E28829/10WZ	 	 	 	29-Jul-1998	 	2105018	 	 	 	 	 	31-Jul-2009	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-DK	 	*	 	10	 	*	 	eingetragen	 	20-Jul-1994	 	VA05.055-1994	 	 	 	14-Oct-1994	 	VR06.936-1994	 	 	 	 	 	14-Oct-2014	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-GB	 	*	 	10	 	*	 	eingetragen	 	17-Jan-1990	 	1411045	 	 	 	05-Jun-1992	 	1411045	 	 	 	 	 	20-Jul-2016	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-GR	 	*	 	10	 	*	 	eingetragen	 	14-Oct-1994	 	121277	 	 	 	17-Sep-1997	 	121277	 	 	 	 	 	14-Oct-2014	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-IRM	 	*	 	10	 	*	 	anhängig	 	 	 	A962/90	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-JP	 	*	 	10	 	*	 	eingetragen	 	13-Jun-1994	 	6-57288	 	 	 	24-Feb-1997	 	3258440	 	 	 	 	 	24-Feb-2007	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-NO	 	*	 	10	 	*	 	eingetragen	 	27-Jun-1994	 	94.3588	 	 	 	05-Oct-1995	 	169742	 	 	 	 	 	05-Oct-2015	 	3
																
	 M/END-016-
	 	Trademark	 	M/END-016-US/I	 	*	 	10	 	*	 	eingetragen	 	16-Nov-1999	 	75/850649	 	 	 	26-Dec-2000	 	2415623	 	 	 	 	 	26-Dec-2010	 	3
																
	 M/END-018-
	 	Trademark	 	M/END-018-CH	 	*	 	10	 	*	 	eingetragen	 	21-Mar-1995	 	418194	 	 	 	21-Mar-1995	 	418194	 	 	 	 	 	 	 	3
																
	 M/END-018-
	 	Trademark	 	M/END-018-IRM	 	*	 	10	 	*	 	eingetragen	 	15-Aug-1995	 	641205	 	 	 	15-Aug-1995	 	641205	 	 	 	 	 	15-Aug-2015	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-CH	 	*	 	10	 	*	 	eingetragen	 	21-Mar-1995	 	418202	 	 	 	21-Mar-1995	 	418202	 	 	 	 	 	 	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-GB	 	*	 	10	 	*	 	eingetragen	 	22-Mar-1995	 	2015035	 	 	 	22-Mar-1995	 	2015035	 	 	 	 	 	22-Mar-2015	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-GR	 	*	 	10	 	*	 	eingetragen	 	12-Apr-1995	 	123.905	 	 	 	17-Dec-1997	 	123.905	 	 	 	 	 	12-Apr-2015	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-IRM	 	*	 	10	 	*	 	eingetragen	 	15-Aug-1995	 	641206	 	 	 	15-Aug-1995	 	641206	 	 	 	 	 	15-Aug-2015	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-JP	 	*	 	10	 	*	 	eingetragen	 	24-Mar-1995	 	27805/1995	 	 	 	24-Dec-1999	 	4347371	 	 	 	 	 	24-Dec-2009	 	3
																
	 M/END-019-
	 	Trademark	 	M/END-019-NO	 	*	 	10	 	*	 	eingetragen	 	23-Mar-1995	 	95 1915	 	 	 	08-Aug-1996	 	176125	 	 	 	 	 	08-Aug-2016	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-CH	 	*	 	10	 	*	 	eingetragen	 	09-Feb-1996	 	00867/1996	 	 	 	19-Feb-1997	 	435430	 	 	 	 	 	09-Feb-2016	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-EM	 	*	 	10	 	*	 	eingetragen	 	01-Apr-1996	 	168831	 	 	 	26-Jun-1998	 	168831	 	 	 	 	 	01-Apr-2016	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-JP	 	*	 	10	 	*	 	eingetragen	 	15-Feb-1996	 	13585/1996	 	 	 	21-May-1999	 	4274483	 	 	 	 	 	21-May-2009	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-NO	 	*	 	10	 	*	 	eingetragen	 	13-Feb-1996	 	960955	 	 	 	29-May-1997	 	182255	 	 	 	 	 	29-May-2007	 	3

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 95 | 100 

 Schutzrechte der Fa. PLUS ORTHOPEDICS AG 
  

																															
	 Aktenzeichen

	 	Property
Type

	 	           Case Ref.          

	 	 Title

	 	Local Classes

	 	 Country

	 	     Case Status    

	 	   Application  
Date

	 	 Application
No.

	 	 Publication
No.

	 	     Registered    
Date

	 	 Registration
No.

	 	   Expiry Date  

	 	Annuity

	 	 Next Renewal
Date

	 	Index

	 M/END-026-
	 	Trademark	 	M/END-026-SG	 	*	 	10	 	*	 	Prüfungsbescheid erhalten	 	18-Jul-1996	 	7376/96	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-US	 	*	 	10	 	*	 	eingetragen	 	12-Jun-1996	 	75/117865	 	 	 	24-Mar-1998	 	2146713	 	 	 	 	 	24-Mar-2008	 	3
																
	 M/PLU-025-
	 	Trademark	 	M/PLU-025-AT	 	*	 	10	 	*	 	eingetragen	 	11-Mar-1992	 	AM 1174/92	 	 	 	12-Jun-1992	 	142432	 	 	 	 	 	12-Jun-2012	 	3
																
	 M/PLU-060-
	 	Trademark	 	M/PLU-060-LI	 	*	 	10	 	*	 	eingetragen	 	18-Apr-1996	 	9874	 	 	 	09-Oct-1996	 	9874	 	 	 	 	 	18-Apr-2016	 	3
																
	 M/PLU-061-
	 	Trademark	 	M/PLU-061-LI	 	*	 	10	 	*	 	eingetragen	 	18-Apr-1996	 	9875	 	 	 	09-Oct-1996	 	9875	 	 	 	 	 	18-Apr-2016	 	3
																
	 M/PLU-090-
	 	Trademark	 	M/PLU-090-LI	 	*	 	10	 	*	 	eingetragen	 	12-Feb-1998	 	10647	 	 	 	10-Jun-1998	 	10647	 	 	 	 	 	12-Feb-2008	 	3
																
	 M/PLU-091-
	 	Trademark	 	M/PLU-091-LI	 	*	 	10	 	*	 	eingetragen	 	17-Jun-1998	 	 	 	 	 	15-Sep-1998	 	10769	 	 	 	 	 	17-Jun-2008	 	3
																
	 M/PLU-103-
	 	Trademark	 	M/PLU-103-AT	 	*	 	10	 	*	 	eingetragen	 	06-Jul-1999	 	AM4058/99	 	 	 	30-Nov-1999	 	185381	 	 	 	 	 	30-Nov-2009	 	3
																
	 M/PLU-108-
	 	Trademark	 	M/PLU-108-LI	 	*	 	10	 	*	 	eingetragen	 	20-Sep-1999	 	11316	 	 	 	15-Dec-1999	 	11316	 	 	 	 	 	20-Sep-2009	 	3
																
	 M/PLU-181-
	 	Trademark	 	M/PLU-181-TH	 	*	 	10	 	*	 	Beantworung PRA-Bescheid eingereicht	 	01-Apr-2005	 	586277	 	 	 	 	 	 	 	 	 	 	 	 	 	3
																
	 M/END-026-
	 	Trademark	 	M/END-026-LI	 	*	 	10	 	*	 	eingetragen	 	18-Apr-1996	 	9873	 	 	 	09-Oct-1996	 	9873	 	 	 	 	 	18-Apr-2016	 	3
																
	 M/PLU-018-
	 	Design	 	M/PLU-018-INT	 	*	 	 	 	*	 	eingetragen	 	16-Nov-1992	 	DM/024434	 	 	 	15-Feb-1993	 	DM/024 434	 	 	 	 	 	 	 	4
																
	 M/PLU-019-
	 	Design	 	M/PLU-019-INT	 	*	 	 	 	*	 	eingetragen	 	16-Nov-1992	 	DM/024435	 	 	 	15-Feb-1993	 	DM/024435	 	 	 	 	 	 	 	4
																
	 M/PLU-040-
	 	Design	 	M/PLU-040-INT	 	*	 	 	 	*	 	eingetragen	 	28-Feb-1994	 	DM/028828	 	 	 	13-May-1994	 	DM/028 828	 	 	 	 	 	 	 	4
																
	 M/PLU-051-
	 	Design	 	M/PLU-051-INT	 	*	 	 	 	*	 	eingetragen	 	09-Sep-1996	 	006314	 	 	 	09-Sep-1996	 	DM/037477	 	 	 	16	 	09-Sep-2011	 	4
																
	 M/PLU-116-
	 	Design	 	M/PLU-116-INT	 	*	 	 	 	*	 	eingetragen	 	01-Dec-1999	 	DM/050361	 	 	 	01-Dec-1999	 	DM/050361	 	 	 	11	 	01-Dec-2009	 	4

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 96 | 100 

 BREVETS ORTHO-ID 
  

													
	 NOM

	 	 N° Dépót & Date

	 	 N° Publication &
Date

	 	Délivré

	 	 Déposant (s)

	 	Inventeurs

	 	 Paiement Annuité

	 POLARCUP
	 	 N° 9812121
 du 24/9/98
	 	FR 2 783 703
du 9/2/01	 	9.2.01	 	OID & Gpe Giles	 	*	 	 Géré Par
 Cabinet Conseil

	 	 	 PCT/FR00/00688
 du
20/3/00
	 	 WO 01/70141 A1
du 27/9/01
	 	 	OID & Gpe Giles	 	 	Germain & Moreau
							
	 TRIPLE ARTICULATION
	 	 N° 03 01651
 du 12/2/03
	 	FR 2 850 861
du 13/6/04	 	30.09.2005	 	OID & Gpe Giles	 	*	 	Payé le 6/2/06
	 	 	 PCT/FR04/02110
 du
9/8/04
	 	 	 	 	OID & Gpe Giles	 	 
							
	 POLARCROSS
	 	N° 02 08828
du 12/7/02	 	FR 2 842 096
du 16/1/2004	 	 	 	OID	 	*	 	Probléme
							
	 CERAMIQUE
	 	N° 02 16186
du 3/12/02	 	FR 2 847 801
du 4/6/04	 	 	 	OID	 	*	 	Payé ie 5/10/05
							
	 TD STEM
	 	N° 05.11344
du 8/11/05	 	 	 	 	 	OID	 	*	 	 Géré Par
 Cabinet Consell

							
	 CLOU HUMERAL
	 	N° 03 08372
du 9/7/03	 	 	 	 	 	OID	 	*	 	Payé le 5/10/05
							
	 THORACO
	 	N° 03 07313
du 18/6/03	 	 	 	 	 	OID	 	*	 	Payé le 5/10/05

  
 BREVETS ORTHO-ID 
  

											
	 NOM

	 	 N° Dépót & Date

	 	 N° Publication & Date

	 	 Délivré

	 	 Déposant(s)

	 	Inventeurs

	 POLARCUP
	 	N° 9812121
du 24/9/98	 	 FR 2 783 703
 du 9/2/01
	 	9/2/01	 	 OID &
 Gpe Giles
	 	*
	 	 	PCT/FR00/00688
du 20/3/00	 	 WO 01/70141
 A1
 du 27/9/01
	 	 	 	 OID &
 Gpe Giles
	 
						
	 TRIPLE ARTICULATION
	 	N° 03 01651
du 12/2/03	 	     FR 2 850 861    
 du 13/8/04
	 	30/09/2005	 	 OID &
 Gpe Giles
	 	*
	 	 	PCT/FR04/02110
du 9/8/04	 	 	 	 	 	 OID &
 Gpe Giles
	 
						
	 POLARCROSS
	 	N° 02 08828
du 12/7/02	 	FR 2 842 096   du 16/1/2004	 	 	 	OID	 	*
						
	 CERAMIQUE
	 	N° 02 15186
du 3/12/02	 	 FR 2 847 801
 du 4/8/04
	 	 	 	OID	 	*
						
	 TD STEM
	 	N° 05.11344
du 8/11/05	 	 	 	 	 	OID	 	*

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 97 | 100 

 Annex 5.2 to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 5.2 
  
 Buyer’s Representations and Warranties 
  
 Subject to the limitations set forth in the Agreement, Buyer hereby
represents and warrants to Sellers as of the date of this Agreement and as of the Closing Date the following matters. 
  

	 	(1)	Buyer is a corporation duly organized and validly existing under the laws of its place of incorporation and has the full corporate power, authority and necessary governmental
approvals to own or use its assets and properties and to conduct its business as the same is presently being conducted. 

  

	 	(2)	Buyer has the absolute and unrestricted right, power, authority and capacity and has received all the necessary approvals from its corporate bodies to execute this Agreement and to
perform its respective obligations under this Agreement. There exist no limitations under applicable law and the constituting documents of Buyer, or any contracts by which Buyer is bound that would prevent Buyer from entering into or performing its
obligations under this Agreement. 

  

	 	(3)	No authorizations, permits or consents are required from any governmental or administrative authority, or any third party (including without limitation any shareholders or creditors
of Buyer) for the consummation of the transactions contemplated by this Agreement other than as set forth in this Agreement. 

  

	 	(4)	There are no actions, suits or proceedings pending against Buyer or any of Buyer’s Affiliates before any court or administrative board, agency or commission which involve a
claim by a governmental or regulatory authority, or by a third party, which would operate to hinder or substantially impair the consummation of the transactions contemplated by this Agreement. Buyer is not aware of any actions, suits or proceedings
in accordance with the preceding sentence which have been threatened in writing to be filed or instituted against Buyer or any of Buyer’s Affiliates. 

  

	 	(5)	Buyer has procured that it will on the Closing Date have the necessary funds at its disposal to finance the transactions contemplated by this Agreement. 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 98 | 100 

 Annex 6.1.4(d)(i) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 6.1.4(d)(ii) 
  
 Dataroom Indices * 
  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 99 | 100 

 Annex 6.1.4(d)(iii) to the Share Purchase Agreement regarding Plus Orthopedics Holding AG 
  
 Annex 6.1.4(d)(iii) 
  
 Disclosure Letter 
  
 Dear Sir or Madam: 
  
 On behalf of Sellers, we hereby deliver to you this Disclosure Letter
referred to in Article 6.1.4(d)(iii) of the Share Purchase Agreement of even date hereof between us regarding the sale and purchase of the shares in Plus Orthopedics Holding AG (the SPA). 
  
 Words and expressions defined in the SPA shall, unless the context otherwise
requires, have the same meaning in this Disclosure Letter. 
  
 For the purposes of the SPA, we hereby disclose to you the information and documents set forth in this Disclosure Letter and the annexes hereto. We wish to record the following preliminary matters in relation to this Disclosure Letter:

  

	 	(a)	The disclosures contained in this Disclosure Letter are not to be taken as any admission by us that any of the matters calls for disclosure within the terms of the SPA.

  

	 	(b)	The disclosure of any matter or document by this Disclosure Letter shall not, other than as expressly provided for in the SPA, imply any representation, warranty, undertaking or
indemnity as to the same. 

  

	 	(c)	You have confirmed to us that, as of the date hereof, you are not aware that any of the representations and warranties given by us in Article 5.1 and Annex 5.1 of the SPA
is untrue or inaccurate and therefore breached (other than as Fairly Disclosed). 

  
 In addition to the information Fairly Disclosed to you pursuant to Article 6.1.4(d)(i) and (ii) of the SPA, we hereby Fairly Disclose to you
pursuant to Article 6.1.4(d)(iii) of the SPA all matters that are Fairly Disclosed in Exhibit 1 hereto. 
  
 Sincerely yours, 
  

							
	 	 	Hyos Invest Holding AG	 	 	 	 
				
	 	 	  

	 	 	 	 
	 	 	Carolina Müller-Möhl	 	 	 	 
				
	 	 	Dr. Ulrich Sigg	 	 	 	 
				
	 	 	  

	 	 	 	 
				
	 	 	  
 Dr. Robert Riedweg
	 	 	 	 
				
	 	 	  

	 	 	 	 
				
	 	 	  
 Active Investor AG
	 	 	 	 
				
	 	 	  

	 	 	 	  

	 	 	Michael Theurillat	 	 	 	Martin Staub
				
	 	 	Buyer acknowledges receipt of this letter:	 	 	 	 
				
	 	 	Smith & Nephew International B.V.	 	 	 	 
				
	 	 	  

	 	 	 	 
	 	 	By:	 	 	 	 

  

	*	Indicates omission of material, which has been separately filed, pursuant to a request for confidential treatment. 

  

 100 | 100

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]